



**AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND,
2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED
PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED
SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT LOW
RISK OF PROGRESSING TO SEVERE ILLNESS**

Study Intervention Number: PF-07321332
Study Intervention Name: nirmatrelvir
US IND Number: CCI
EudraCT Number: 2021-002857-28
ClinicalTrials.gov ID: NCT05011513
Protocol Number: C4671002
Phase: 2/3
Brief Title: A Phase 2/3 Efficacy and Safety Study of PF-07321332/Ritonavir in Nonhospitalized Low-Risk Adult Participants With COVID-19

This document and accompanying materials contain confidential information belonging to Pfizer. Except as otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer must be promptly notified.

Document History

Document	Version Date
Amendment 6	09 June 2022
Amendment 5	21 January 2022
Amendment 4	23 November 2021
Protocol Amendment Change Letter	27 September 2021
Protocol Amendment Change Letter	31 August 2021
Protocol Amendment Change Letter	13 August 2021
Amendment 3	03 August 2021
Protocol Amendment Change Letter	22 July 2021
Amendment 2	19 July 2021
Amendment 1	02 July 2021
Original protocol	18 June 2021

This amendment incorporates all revisions to date, including amendments made at the request of country health authorities and IRBs/ECs and any protocol administrative clarification letter.

Amendment 6 (09 June 2022)

Overall Rationale for the Amendment:

Study C4671002 enrolled participants who had risk factors for severe COVID-19 illness and who were vaccinated against the SARS-CoV-2 virus as well as participants who did not have risk factors for severe COVID-19 illness and who were not vaccinated. Data from this study are required to support regulatory submissions, thereby necessitating an interim analysis utilizing the 19 December 2021 dataset. This dataset had not been analyzed previously because the protocol was amended to increase the sample size and extend enrollment to assess the potential benefit of participants at low risk of progression to severe COVID-19 in the clinically relevant endpoint of COVID-19 related hospitalization or death from any cause (Protocol Amendment 5, 21 January 2022). This third interim analysis (100% planned enrollment through Protocol Amendment 4) did not include any data from participants who entered the study under Protocol Amendment 5. Finally, this amendment defines the second interim analysis (80% of planned enrollment through Protocol Amendment 4) that was

conducted following the first interim analysis (45% planned enrollment through Protocol Amendment 4).

In addition, hypertension was added as a potential risk and hemodynamic and inflammatory effects, TSH and T4 (free) elevations were removed as potential risks.

Protocol Amendment Summary of Changes Table

Section # and Name	Description of Change	Brief Rationale	Substantial or Nonsubstantial
Section 9.4. Interim Analyses Section 1.1. Synopsis Section 4.1. Overall Design	At the conclusion of the first interim analysis (45% planned enrollment through Protocol Amendment 4), the E-DMC requested an additional second interim analysis (80% planned enrollment through Protocol Amendment 4). A third interim analysis (100% planned enrollment through Protocol Amendment 4) is being added to support regulatory filings utilizing the dataset from 19 December 2021. Clarified other sections of the protocol to differentiate the interim analyses conducted.	This dataset includes participants who had risk factors for severe COVID-19 illness and who were vaccinated against the SARS-CoV-2 virus as well as participants who did not have risk factors for severe COVID-19 illness and who were not vaccinated. The data were never released nor analyzed previously.	Substantial
Section 2.3.1. Risk Assessment	Added hypertension as a potential risk and removed hemodynamic and inflammatory effects, and TSH and T4 (free) elevations as potential risks.	Program level decision related to emerging safety data.	Substantial
Section 1.2. Schema	Corrected spelling in the study schema.	Correction to typo	Nonsubstantial
Section 2.2. Background	Updated the indication for use of remdesivir and added reference. Updated the EUA status of PF-07321332/ritonavir and molnupiravir. Added clarification regarding reproductive studies conducted with molnupiravir.	For investigator awareness	Nonsubstantial
Section 5.2. .Exclusion Criteria	Included molnupiravir in Exclusion Criterion #15 which had been omitted in the previous amendment.	To bring into alignment with Section 6.8 of the protocol.	Nonsubstantial

TABLE OF CONTENTS

LIST OF TABLES	9
1. PROTOCOL SUMMARY	10
1.1. Synopsis	10
1.2. Schema	15
1.3. Schedule of Activities	16
2. INTRODUCTION	24
2.1. Study Rationale	24
2.2. Background	24
2.2.1. Nonclinical Studies of PF-07321332	25
2.2.2. Clinical Overview	26
2.3. Benefit/Risk Assessment	27
2.3.1. Risk Assessment	28
2.3.2. Benefit Assessment	30
2.3.3. Overall Benefit/Risk Conclusion	30
3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS	31
4. STUDY DESIGN	32
4.1. Overall Design	32
4.2. Scientific Rationale for Study Design	34
4.2.1. Diversity of Study Population	35
4.2.2. Choice of Contraception/Barrier Requirements	35
CCI	
4.3. Justification for Dose	35
4.4. End of Study Definition	36
5. STUDY POPULATION	36
5.1. Inclusion Criteria	36
5.2. Exclusion Criteria	37
5.3. Lifestyle Considerations	40
5.3.1. Contraception	40
5.4. Screen Failures	40
5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Administration of Study Intervention	40

6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY	41
6.1. Study Intervention(s) Administered	41
6.1.1. Administration	42
6.2. Preparation, Handling, Storage, and Accountability	43
6.2.1. Preparation and Dispensing	44
6.3. Measures to Minimize Bias: Randomization and Blinding.....	44
6.3.1. Allocation to Study Intervention	44
6.3.2. Blinding of the Sponsor	45
6.3.3. Breaking the Blind	45
6.4. Study Intervention Compliance.....	45
6.5. Dose Modification.....	46
6.6. Continued Access to Study Intervention After the End of the Study.....	46
6.7. Treatment of Overdose.....	46
6.8. Concomitant Therapy.....	47
6.8.1. Rescue Medicine.....	47
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL.....	48
7.1. Discontinuation of Study Intervention	48
7.1.1. Potential Cases of Decreased eGFR	48
7.2. Participant Discontinuation/Withdrawal From the Study	49
7.2.1. Withdrawal of Consent	49
7.3. Lost to Follow-Up	50
8. STUDY ASSESSMENTS AND PROCEDURES.....	50
8.1. Efficacy Assessments.....	51
8.1.1. Participant Diary.....	51
8.1.2. COVID-19-Related Medical Visit Details.....	51
8.1.3. Daily Signs and Symptoms of COVID-19	52
8.1.4. Oxygen Support Details.....	52
8.1.5. PRO Assessments	52
8.1.5.1. WPAI Questionnaire	52
8.1.5.2. EQ-5D-5L Scale.....	53
8.1.5.3. Global Impression Questions	53

8.1.6. Exit Interview	53
8.2. Safety Assessments	53
8.2.1. Medical History	53
8.2.2. Height and Weight.....	54
8.2.3. Targeted Physical Examinations.....	54
8.2.4. Vital Signs	54
8.2.5. Clinical Safety Laboratory Assessments	54
8.2.6. Pregnancy Testing	55
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting	55
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.....	56
8.3.1.1. Reporting SAEs to Pfizer Safety	57
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF	57
8.3.2. Method of Detecting AEs and SAEs	57
8.3.3. Follow-Up of AEs and SAEs.....	57
8.3.4. Regulatory Reporting Requirements for SAEs.....	57
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and Occupational Exposure	58
8.3.5.1. Exposure During Pregnancy.....	58
8.3.5.2. Exposure During Breastfeeding	59
8.3.5.3. Occupational Exposure	60
8.3.6. Cardiovascular and Death Events	60
8.3.7. Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs or SAEs.....	60
8.3.8. Adverse Events of Special Interest	60
8.3.8.1. Lack of Efficacy	61
8.3.9. Medical Device Deficiencies	61
8.3.10. Medication Errors	61
8.4. Pharmacokinetics	62
8.5. Genetics	63
8.5.1. Specified Genetics	63
CCI	
8.6. Biomarkers	63
8.6.1. Specified Gene Expression (RNA) Research	63

CCI CCI	
8.6.3. Specified Metabolomic Research	64
8.6.4. Viral Load Assessments	64
CCI	
8.7. Immunogenicity Assessments	64
8.8. Health Economics	64
9. STATISTICAL CONSIDERATIONS	64
9.1. Statistical Hypotheses	65
9.1.1. Estimands.....	65
9.1.1.1. Primary Estimand/Co-Primary Estimands	65
9.1.1.2. Secondary Estimands	66
9.2. Analysis Sets	67
9.3. Statistical Analyses	67
9.3.1. General Considerations.....	68
9.3.2. Primary Endpoint(s)/Estimand(s) Analysis	68
9.3.2.1. Supplemental Analyses	69
9.3.3. Secondary Endpoint(s)/Estimand(s) Analysis	70
CCI	
9.3.5. Other Safety Analyses	71
9.3.5.1. Laboratory Test Results	72
9.3.5.2. Physical Examination and Vital Signs	72
9.3.5.3. Persistent Symptoms of COVID-19.....	72
9.3.6. Other Analyse(s).....	72
9.3.6.1. PK Analyses	72
9.4. Interim Analyses	72
9.5. Sample Size Determination.....	74
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS	75
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations	75
10.1.1. Regulatory and Ethical Considerations	75
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP.....	75
10.1.2. Financial Disclosure	76

10.1.3. Informed Consent Process	76
10.1.4. Data Protection	77
10.1.5. Committees Structure	77
10.1.5.1. Data Monitoring Committee	77
10.1.6. Dissemination of Clinical Study Data	78
10.1.7. Data Quality Assurance	79
10.1.8. Source Documents	81
10.1.9. Study and Site Start and Closure	81
10.1.10. Publication Policy	82
10.1.11. Sponsor’s Qualified Medical Personnel	83
10.2. Appendix 2: Clinical Laboratory Tests	84
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-Up, and Reporting	85
10.3.1. Definition of AE	85
10.3.2. Definition of an SAE	86
10.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During the Active Collection Period.....	87
10.3.4. Reporting of SAEs.....	91
10.4. Appendix 4: Contraceptive and Barrier Guidance	92
10.4.1. Male Participant Reproductive Inclusion Criteria	92
10.4.2. Female Participant Reproductive Inclusion Criteria.....	92
10.4.3. Woman of Childbearing Potential	93
10.4.4. Contraception Methods.....	94
CCI	
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow Up Assessments and Study Intervention Rechallenge Guidelines	97
10.7. Appendix 7: ECG Findings of Potential Clinical Concern (No Longer Applicable)	99
10.8. Appendix 8: Prohibited Concomitant Medications That May Result in DDI.....	100
10.9. Appendix 9: Signs and Symptoms Attributable to COVID-19	109
10.10. Appendix 10: Country-Specific Requirements	110
10.10.1. France	110
10.10.2. Japan	110

10.11. Appendix 11: Protocol Amendment History.....112
10.12. Appendix 12: Abbreviations121
11. REFERENCES125

LIST OF TABLES

Table 1 Protocol-Required Safety Laboratory Assessments84
Table 2. Signs and Symptoms Attributable to COVID-19109

1. PROTOCOL SUMMARY

1.1. Synopsis

An Interventional Efficacy and Safety, Phase 2/3, Double-Blind, 2-Arm Study to Investigate Orally Administered PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants with COVID-19 who are at Low Risk of Progressing to Severe Illness.

Brief Title: A Phase 2/3 Efficacy and Safety Study of PF-07321332/Ritonavir in Nonhospitalized Low-Risk Adult Participants With COVID-19.

Rationale: The purpose of this study is to evaluate the efficacy and safety of PF-07321332/ritonavir for the treatment of nonhospitalized, symptomatic, adult participants with COVID-19 who are at low risk of progression to severe illness.

Objectives, Endpoints, and Estimands

Objectives	Endpoints	Estimands
Primary:	Primary:	Primary:
<ul style="list-style-type: none"> To compare the efficacy of PF-07321332/ritonavir to placebo for the treatment of symptomatic COVID-19 in nonhospitalized adult participants with COVID-19 who are at low risk of progression to severe disease. 	<ul style="list-style-type: none"> Time (days) to sustained alleviation of all targeted COVID-19 signs/symptoms through Day 28. 	<ul style="list-style-type: none"> The difference in median time (days) to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease at baseline and were treated ≤ 5 days after COVID-19 symptom onset. This will be estimated irrespective of adherence to randomized treatment.
Secondary:	Secondary:	Secondary:
<ul style="list-style-type: none"> To describe the safety and tolerability of PF-07321332/ritonavir relative to placebo in the treatment of nonhospitalized symptomatic adult participants with COVID-19 who are at low risk of progression to severe disease. 	<ul style="list-style-type: none"> Incidence of TEAEs. Incidence of SAEs and AEs leading to discontinuations. 	<ul style="list-style-type: none"> Not Applicable.
<ul style="list-style-type: none"> To compare PF-07321332/ritonavir versus placebo for COVID-19-related hospitalization and all-cause mortality in nonhospitalized adult participants with COVID-19 who are at low risk of progression to severe disease. 	<ul style="list-style-type: none"> Proportion of participants with COVID-19-related hospitalization or death from any cause through Day 28. 	<ul style="list-style-type: none"> The difference in proportions of patients experiencing COVID-19-related hospitalization or death from any cause through Day 28 in nonhospitalized adult patients with COVID-19

Objectives	Endpoints	Estimands
	<ul style="list-style-type: none"> • Proportion of participants with death (all cause) through Week 24. 	<p>who are at low risk of progression to severe disease and were treated ≤ 5 days after COVID-19 symptom onset. This will be estimated without regard to adherence to randomized treatment.</p> <ul style="list-style-type: none"> • Not Applicable
<ul style="list-style-type: none"> • To compare PF-07321332/ritonavir versus placebo for COVID-19-related medical visits in nonhospitalized adult participants with COVID-19 who are at low risk of progression to severe disease. 	<ul style="list-style-type: none"> • Number of COVID-19 related medical visits through Day 28. • Number of days in hospital and ICU stay in participants with COVID-19-related hospitalization through Day 28. 	<ul style="list-style-type: none"> • The difference in the estimated rate of the number of COVID-19-related medical visits through Day 28 in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease and were treated ≤ 5 days after COVID-19 symptom onset. This will be estimated without regard to adherence to randomized treatment. • The difference in the estimated rate of number of days in hospital and ICU stay in patients with COVID-19-related hospitalization through Day 28 in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease and were treated ≤ 5 days after COVID-19 symptom onset. This will be estimated without regard to adherence to randomized treatment.
<ul style="list-style-type: none"> • To compare PF-07321332/ritonavir to placebo for the duration and severity of signs and symptoms in nonhospitalized symptomatic adult participants with COVID-19 who are at low risk of progression to severe disease. 	<ul style="list-style-type: none"> • Proportion of participants with severe signs/symptoms attributed to COVID-19 through Day 28. • Time (days) to sustained resolution of all targeted COVID-19 signs/symptom through Day 28. • Duration of each targeted COVID-19 sign/symptom. • Progression to a worsening status in 1 or more self-reported COVID-19-associated symptoms through Day 28. • Proportion of participants with a resting peripheral oxygen saturation $\geq 95\%$ at Days 1 and 5. 	<ul style="list-style-type: none"> • Not Applicable.

Objectives	Endpoints	Estimands
<ul style="list-style-type: none">To determine the PK of PF-07321332 in nonhospitalized adult participants with COVID-19 who are at low risk of progression to severe disease.	<ul style="list-style-type: none">PF-07321332 PK in plasma and whole blood (if feasible).	<ul style="list-style-type: none">Not Applicable.
<ul style="list-style-type: none">To describe the viral load in nasal samples over time in nonhospitalized adult participants with COVID-19 who are at low risk of progression to severe disease.	<ul style="list-style-type: none">Viral titers measured via RT-PCR in NP/nasal swabs over time.	<ul style="list-style-type: none">Not Applicable.

Overall Design

Brief Summary

This Phase 2/3, randomized, double-blind, placebo-controlled study in nonhospitalized symptomatic adult participants with COVID-19 who are at low risk of progressing to severe illness will determine the efficacy, safety, and tolerability of PF-07321332/ritonavir compared with placebo. Eligible participants with a confirmed diagnosis of SARS-CoV-2 infection will be randomized (1:1) to receive PF-07321332/ritonavir or placebo orally q12h for 5 days (10 doses total). Randomization will be stratified by geographic region, by vaccination status and by COVID-19 symptom onset (≤ 3 days vs > 3 to 5 days).

Number of Participants

Approximately 1980 participants will be randomly assigned to study intervention.

Note: "Enrolled" means a participant's, or his or her legally authorized representative's, agreement to participate in a clinical study following completion of the informed consent process and screening. A participant will be considered enrolled if the informed consent is not withdrawn prior to participating in any study activity after screening. Potential participants who are screened for the purpose of determining eligibility for the study, but do not participate in the study, are not considered enrolled, unless otherwise specified by the protocol.

Intervention Groups and Duration

Participants will be screened within 48 hours before randomization. Eligible participants will receive PF-07321332 plus ritonavir or placebo orally q12h for 5 days. The total study duration is up to 24 weeks, with study intervention through Day 5 or Day 6, efficacy assessments through Day 28, a safety follow-up period through Day 34, and long-term follow-up at Weeks 12 and 24.

Data Monitoring Committee or Other Independent Oversight Committee: Yes

An independent E-DMC will review unblinded data to ensure the safety of participants throughout the duration of the study, as specified in the E-DMC Charter. In addition to up to weekly reviews of safety, the E-DMC will review the following:

- Sentinel cohort safety review: The E-DMC will review unblinded safety data after approximately the first 100 randomized participants have completed through Day 10. Whether enrollment is paused for this review will depend on the successful completion of the Study C4671005 sentinel cohort (after approximately the first 60 randomized participants have completed through Day 10). If the C4671005 sentinel cohort safety review has successfully completed and no clinically significant safety signals have been identified prior to enrollment of the first 100 participants in this Study C4671002, the study will continue without pause. Otherwise, enrollment of Study C4671002 will be paused pending the E-DMC review of safety data. After review of the sentinel cohort in this Study C4671002, the frequency of safety reviews may be reduced subsequently based on E-DMC recommendations.
- Proof-of-concept assessment: Viral load data when 25% (approximately 200 participants in the primary analysis set with evaluable data) complete the Day 5 assessments. Enrollment will not be paused during review of these data, but may be paused or stopped following E-DMC review.
- First interim analysis (45% planned enrollment through Protocol Amendment 4): A planned interim analysis for efficacy, futility and sample size reestimation was conducted after approximately 45% of participants completed the Day 28 assessments in the mITT analysis set.
- Second interim analysis (80% planned enrollment through Protocol Amendment 4): At the request of the E-DMC, a second interim analysis was conducted on 80% of enrolled participants without any adjustment to the alpha.

Details of the E-DMC are specified in the E-DMC Charter.

Statistical Methods

The primary endpoint of this study is the time (days) to sustained alleviation of all targeted COVID-19 signs/symptoms through Day 28. Time to sustained alleviation of all targeted COVID-19 signs/symptoms will be summarized graphically using Kaplan-Meier plots for each of the treatment group. Log-rank test will be used to compare the difference in time (days) to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between treatment groups.

The initial estimate of required sample size was based on the primary endpoint, the difference in time to sustained alleviation of all targeted COVID-19 associated signs/symptoms between participants who were treated ≤ 3 days after COVID-19 symptom onset, treated with PF-07321332/ritonavir compared to placebo. The sample size was

calculated based on a 2-sample test-parallel design–log-rank test, assuming a 90% power, 2-sided test at $\alpha=0.05$, approximate accrual rate of 30 participants per day, 2 days difference in the median days to sustained alleviation of all targeted COVID-19-associated symptoms (6 days for PF-07321332/ritonavir and 8 days for placebo ie, a 25% reduction in time to sustained alleviation of all targeted COVID-19 signs/symptoms) based on Lilly-BLAZE-1¹ and assuming a 18% study discontinuation rate, the sample size of approximately 800 participants (approximately 515 events) will provide 90% power to detect that difference.

Allowing for approximately 30% of participants with COVID-19 symptom onset >3 days, a sample size of approximately 1140 participants was to be enrolled for this study.

After the second interim analysis (80% planned enrollment through Protocol Amendment 4), in order to improve estimation precision of the treatment effect in the clinically relevant key secondary endpoint of COVID-19-related hospitalization or death from any cause, the sample size was adjusted to approximately 1880 participants. This adjustment is expected to provide the required total number of 26 COVID-19-related hospitalizations or death from any cause, which will have approximately 90% conditional power (based on the second interim analysis data) such that the nominal 95% CI of the treatment group difference in the event rate does not include 0 when assuming that PF-07321332/ritonavir reduces the event rate by 70% or more relative to placebo.


The sample size increase of 740 participants is based on the assumption of a 1.5% event rate for the targeted enrollment countries. The number of participants is approximately 1880 (1140 enrolled participants plus the increase of 740 participants). Assuming a 5% premature study discontinuation rate, approximately 1980 participants will be enrolled in the study.

A third interim analysis (100% planned enrollment through Protocol Amendment 4) to support regulatory filings was performed utilizing the dataset from 19 December 2021, which includes participants who had risk factors for severe COVID-19 illness and who were vaccinated against the SARS-CoV-2 virus as well as participants who did not have risk factors for severe COVID-19 illness and who were not vaccinated. This dataset was originally prepared to support an analysis based on all participants enrolled prior to Protocol Amendment 5 (21 January 2022). The data were never released nor analyzed previously because the protocol was amended (Protocol Amendment 5) to increase the sample size. Alpha was adjusted for the first interim analysis (45% planned enrollment through Protocol Amendment 4), no further adjustment for alpha was performed in the second interim analysis (80% planned enrollment through Protocol Amendment 4) and no adjustment for alpha was performed in the the third interim analysis (100% planned enrollment through Protocol Amendment 4). At the first interim analysis (45%), the IA met futility criteria and there is no remaining alpha for subsequent hypothesis tests. Thus all further analysis will use nominal p-values for reporting.

The primary estimand is the difference between PF-07321332/ritonavir and placebo in median time (days) to sustained alleviation of all targeted signs and symptoms of COVID-19 through Day 28 in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease at baseline and were treated ≤ 5 days after COVID-19 symptom

onset. This will be estimated irrespective of adherence to randomized treatment. Because the study did not meet the primary endpoint based on the interim analysis at 45%, all hypothesis assessments are done with a nominal alpha.

1.2. Schema



1.3. Schedule of Activities

The SoA table provides an overview of the protocol visits and procedures. Refer to the [STUDY ASSESSMENTS AND PROCEDURES](#) section of the protocol for detailed information on each procedure and assessment required for compliance with the protocol.

The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evaluations or assessments required to protect the well-being of the participant.

Visit Identifier Abbreviations used in this table may be found in Appendix 12 .	Screening	Baseline (Day 1)	Day 3	Day 5	Day 10	Day 14	Day 21	Day 34	LT F/U		ET (prior to Day 34)	Notes
									Week 12	Week 24		
Visit Window	Day -1 to Day 1	0 days	±1 day	±1 day	±1 day	±2 days	±2 days	±3 days	±7 days	±7 days	±5 days	
ELIGIBILITY												
Informed consent	X											• See Section 10.1.3 .
Verify inclusion/exclusion criteria	X											• See Section 5.1 and Section 5.2 .
Demographics and medical history	X											• See Section 8.2.1 .
COVID-19 risk factor assessment	X											• See Appendix 9 .
PHYSICAL EXAMINATION & VITAL SIGNS												
Targeted physical examination	X	X		X		[X]		[X]			[X]	<ul style="list-style-type: none"> Will be completed at all in-person visits and on Days 14 and 34 and ET (prior to Day 34) if conducted in person. In the event that an in-person visit is not feasible at the investigational site, targeted physical examinations may be performed by a licensed HCP at an alternate site approved by the investigator (eg, the participant's home) when feasible. AEs should be assessed by means of a telemedicine visit if not feasible during an in person visit. Previously identified AEs (either by interview, physical exam, or other
Vital signs	X	X	[X]	X		[X]		[X]			[X]	

Visit Identifier Abbreviations used in this table may be found in Appendix 12 .	Screening	Baseline (Day 1)	Day 3	Day 5	Day 10	Day 14	Day 21	Day 34	LT F/U		ET (prior to Day 34)	Notes
									Week 12	Week 24		
Visit Window	Day -1 to Day 1	0 days	±1 day	±1 day	±1 day	±2 days	±2 days	±3 days	±7 days	±7 days	±5 days	
												assessment) should be monitored to the extent possible if telemedicine is used. <ul style="list-style-type: none"> Targeted physical examinations see Section 8.2.3. Vital signs see Section 8.2.4.
Weight, height	X											<ul style="list-style-type: none"> Height may be self reported. See Section 8.2.2.
LABORATORY												
Hematology		X		X		[X]		[X]			[X]	<ul style="list-style-type: none"> Screening visit: Laboratory assessments are not required at screening unless deemed necessary by the investigator to confirm eligibility. If deemed necessary, laboratory assessments at screening will be performed at the local laboratory. The medical laboratory test abnormalities within 6 months prior to screening must be closely assessed. If abnormalities cannot be verified, consider conducting local laboratory testing at screening to confirm eligibility for the study. Baseline laboratory assessments should be collected prior to first dose of study intervention. If post-screening eGFR is <45 mL/min/1.73m², the participant will be instructed to discontinue any remaining study intervention doses as soon as study staff become aware of the eGFR results. If another baseline laboratory result meets protocol Section 5.2 exclusionary values and the participant is still receiving study treatment, contact the Medical Monitor. Laboratory tests at Days 14 and 34 are required only if clinically relevant abnormal laboratory values were present from a sample
Blood chemistry		X		X		[X]		[X]			[X]	
Other laboratory assessments		X		X		[X]		[X]			[X]	

Visit Identifier Abbreviations used in this table may be found in Appendix 12 .	Screening	Baseline (Day 1)	Day 3	Day 5	Day 10	Day 14	Day 21	Day 34	LT F/U		ET (prior to Day 34)	Notes
									Week 12	Week 24		
Visit Window	Day -1 to Day 1	0 days	±1 day	±1 day	±1 day	±2 days	±2 days	±3 days	±7 days	±7 days	±5 days	
												drawn at the previous study visit when laboratory assessments were performed. <ul style="list-style-type: none"> Abnormal laboratory values related to AEs should be followed until resolution. See Section 8.2.5 and Appendix 2.
Pregnancy test	X							X			X	<ul style="list-style-type: none"> A negative urine or serum (β-hCG) pregnancy test must be confirmed at screening for WOCBP only. Pregnancy tests will also be done whenever 1 menstrual cycle is missed during the active treatment period (or when potential pregnancy is otherwise suspected) and at Day 34 or ET visit. See Section 8.2.6.
FSH	X											<ul style="list-style-type: none"> FSH is to be performed locally in female participants <60 years of age at screening who are not using hormonal contraception or hormonal replacement therapy, to confirm postmenopausal status. Female participants aged 50 to 60 years with no menses for 12 months do not need FSH testing to be performed to confirm postmenopausal status. When FSH testing is required to confirm postmenopausal status, a participant may be enrolled in the study prior to the test result being available as long as the FSH test result confirms postmenopausal status prior to dosing See Section 10.4.3 and Appendix 2.
Rapid antigen testing	X											<ul style="list-style-type: none"> Only required if a participant does not have results of a positive SARS-CoV-2 test that was obtained within 5 days prior randomization. Refer to Section 5.1.

Visit Identifier Abbreviations used in this table may be found in Appendix 12 .	Screening	Baseline (Day 1)	Day 3	Day 5	Day 10	Day 14	Day 21	Day 34	LT F/U		ET (prior to Day 34)	Notes
									Week 12	Week 24		
Visit Window	Day -1 to Day 1	0 days	±1 day	±1 day	±1 day	±2 days	±2 days	±3 days	±7 days	±7 days	±5 days	
Viral load assessment		X	X	X	X	X						<ul style="list-style-type: none"> At baseline, an NP swab will be collected by the investigational site staff to confirm SARS-CoV-2 infection by RT-PCR. This test will not be used to determine study eligibility. Subsequent NP or nasal swabs will be collected on Days 1, 3, 5, 10, and 14. <ul style="list-style-type: none"> NP swabs will be collected by an HCP during an in-person visit. Otherwise, a nasal swab will be self-collected by the participant. See Section 8.6.4.
Specified protein research (plasma biomarkers)		X		X		[X]						<ul style="list-style-type: none"> Refer to Section 8.6.2.
CCI [REDACTED]		[REDACTED]		[REDACTED]		[REDACTED]						[REDACTED]
[REDACTED]		[REDACTED]		[REDACTED]		[REDACTED]						[REDACTED]
PK												
PK sample (PF-07321332)		X		X								<ul style="list-style-type: none"> On Day 1, one blood sample for PK will be collected 30 to 90 minutes postdose if feasible. On Day 5, one blood sample for PK will be collected. The preferred time of sample collection is predose up to 2 hours before study intervention administration; if a predose sample collection is not possible, collect this sample at any time during the visit, even after study intervention has been administered. Refer to Section 8.4.

Visit Identifier Abbreviations used in this table may be found in Appendix 12 .	Screening	Baseline (Day 1)	Day 3	Day 5	Day 10	Day 14	Day 21	Day 34	LT F/U		ET (prior to Day 34)	Notes
									Week 12	Week 24		
Visit Window	Day -1 to Day 1	0 days	±1 day	±1 day	±1 day	±2 days	±2 days	±3 days	±7 days	±7 days	±5 days	
Optional PK sampling ([PF-07321332] collected via home health, site visit, or self-collected using Tasso; in a subset of participants, if feasible)			X									<ul style="list-style-type: none"> PK sample(s) will be collected either during in-person visit (a single blood sample collected at any time on either Days 2, 3, or 4) or self-collected by Tasso microsampling device (selected sites) at the following timepoints: <ul style="list-style-type: none"> Day 2 before the evening dose, Day 3 after the morning dose at the following times: 1 sample between 30 to 90 minutes, 1 sample between 2 to 6 hours, and 1 sample 8 to 12 hours after the dose (the last sample should be collected before the evening dose). Refer to Section 8.4.
RANDOMIZATION		X										
STUDY INTERVENTION												
Study intervention administration		Day 1 through Day 5 (10 doses total)										<ul style="list-style-type: none"> If 1 dose was administered on Day 1, study intervention administration should end on Day 6. See Section 6.1
STUDY PROCEDURES & ASSESSMENTS												
Collect/update secondary contacts		X		X	X	X	X	X	X			<ul style="list-style-type: none"> The investigator will capture contact information for at least 2 individuals who the site can contact if the participant is unable to be reached after multiple attempts. At baseline, the investigator will also request contact information for any household members who may be eligible to participate in Study C4671006
Record supplemental oxygen requirements	X	X		X	X	X	X	X			X	<ul style="list-style-type: none"> See Section 8.1.4.

Visit Identifier Abbreviations used in this table may be found in Appendix 12 .	Screening	Baseline (Day 1)	Day 3	Day 5	Day 10	Day 14	Day 21	Day 34	LT F/U		ET (prior to Day 34)	Notes
									Week 12	Week 24		
Visit Window	Day -1 to Day 1	0 days	±1 day	±1 day	±1 day	±2 days	±2 days	±3 days	±7 days	±7 days	±5 days	
Study kit dispensed and participant instructed on its use		X										
Participant-completed study diary (COVID-19 signs and symptoms and global impression questions)		Every day from Day 1 through Day 28										<ul style="list-style-type: none"> See Section 8.1.1 and Section 8.1.5.3. Global impression questions will be answered every day from Day 1 through Day 28 after COVID-19 signs and symptom diary is completed. Global impression questions will only be assessed in participants, as available.
WPAI				X		X			X	X		<ul style="list-style-type: none"> Will be assessed in participants, as available. See Section 8.1.5.1.
EQ-5D-5L		X		X		X		X	X	X		<ul style="list-style-type: none"> Will be assessed in participants, as available. See Section 8.1.5.2.
Exit interview								X				<ul style="list-style-type: none"> Exit interviews will be conducted by telephone and are to occur after the Day 34 visit in a select group of US English-speaking participants (up to 50) at selected sites. See Section 8.1.6.
Staff review of study diary				X	X	X	X	X			X	<ul style="list-style-type: none"> See Section 8.1.1.
Participant-completed study intervention log		Day 1 through Day 5										<ul style="list-style-type: none"> Study intervention log should be completed daily on Days 1 through Day 6 if only 1 dose was administered on Day 1. See Section 6.4.
Record COVID-19-related medical visits				X	X	X	X	X				<ul style="list-style-type: none"> COVID-19 related medical visits a participant has attended since the last assessment will be collected. See Section 8.1.2.
Retrieval of unused study intervention and empty study intervention containers				X		[X]		[X]			X	<ul style="list-style-type: none"> If the Day 5 visit is conducted prior to last dose of study intervention, the study intervention log, empty study intervention containers, and unused study intervention should be returned at the next in-person visit. See Section 6.4.

Visit Identifier Abbreviations used in this table may be found in Appendix 12 .	Screening	Baseline (Day 1)	Day 3	Day 5	Day 10	Day 14	Day 21	Day 34	LT F/U		ET (prior to Day 34)	Notes
									Week 12	Week 24		
Visit Window	Day -1 to Day 1	0 days	±1 day	±1 day	±1 day	±2 days	±2 days	±3 days	±7 days	±7 days	±5 days	
Study intervention accountability				X		[X]		X			X [if needed]	<ul style="list-style-type: none"> Study intervention accountability is only performed at the Day 14 visit if the participant administered treatment after the Day 5 visit was conducted. If the Day 14 visit is not an in-person visit, study intervention accountability will then be performed during the Day 34 visit. See Section 6.4.
Contraception check		X		X	X	X	X	X			X	<ul style="list-style-type: none"> See Section 5.3.1.
Vital status check									X	X	X	
Long-term follow-up telemedicine interview									X	X		<ul style="list-style-type: none"> Staff will ask participants if they are experiencing COVID-19 signs and symptoms and conduct a vital status check.
CONCOMITANT TREATMENT(S)												
Prior/concomitant medications	X	X		X	X	X	X	X			X	<ul style="list-style-type: none"> All prescription and over-the-counter medications including vaccines taken by the participant within 30 days before study entry (considered prior treatment) will be recorded. Concomitant therapies will be collected through the Day 34 visit. Refer to Section 6.8.
Adjunctive therapeutic procedures	X	X		X	X	X	X	X			X	<ul style="list-style-type: none"> Will be collected through the Day 34 visit.
SERIOUS AND NONSERIOUS AE MONITORING	X	X	[X]	X	X	X	X	X			X	<ul style="list-style-type: none"> AEs should be assessed by means of a telemedicine visit if not feasible via an in-person visit. Refer to Section 8.3.

- Site staff should, in discussion with participants, determine the most appropriate location to conduct study visits, whether in-person or remotely by telemedicine. In-person visits should take place at the investigational site. If investigational site in-person visit is not feasible, then alternate venues may include the participant's home or an alternate, noninvestigational site location approved by the investigator. If an in-person visit is held at a location other than the investigational site, in certain situations the assigned HCP performing the visit may be unable to complete all assessments. In these cases, a telemedicine visit should also occur to perform the remaining assessments. Remote visits can be conducted using a telemedicine system approved for use at the site.
- Assessments indicated in brackets [X] will be performed only for in-person visits.

Visit Identifier Abbreviations used in this table may be found in Appendix 12 .	Screening	Baseline (Day 1)	Day 3	Day 5	Day 10	Day 14	Day 21	Day 34	LT F/U		ET (prior to Day 34)	Notes
									Week 12	Week 24		
Visit Window	Day -1 to Day 1	0 days	±1 day	±1 day	±1 day	±2 days	±2 days	±3 days	±7 days	±7 days	±5 days	

- **Screening** procedures may be done from Day -1 to Day 1. In many cases, all screening procedures can be completed in <24 hours. For these participants, screening procedures may be completed on the same calendar day as randomization and Baseline/Day 1 procedures, including first dose of study intervention.
- **Baseline** assessments should be performed before the administration of the first study intervention.
- **Day 1** is the start of dosing.
- **For Study Intervention Administration:** Participants will receive study intervention for 5 days (10 doses total). The first dose will be administered at the Baseline/Day 1 visit during the in person visit, if possible. All subsequent doses (ie, 9) will be self-administered outside the study clinic (eg, at home).
- **Screening, Baseline, and Day 5** visits will be conducted in person (at the investigational site approved by the investigator or a remote location, including a participant’s home).
- **Day 3** will only be conducted in person if a PK sample (not using Tasso) is collected by an HCP or at the discretion of the investigator.
- **Day 3 and Day 5** visits must be conducted on separate calendar days.
- **Day 10, Day 21, Week 12 and Week 24** visits will be conducted by telemedicine system. Telemedicine visits may be conducted in-person at the discretion of the investigator.
- **Day 14** may be conducted in person or by telemedicine system.
- **Day 34** will be conducted in person or by telemedicine system.
- **Early Termination prior to Day 34** visit will be conducted in person or by telemedicine system.

2. INTRODUCTION

PF-07321332, a potent and selective SARS-CoV-2 3CL protease inhibitor, is being investigated as an oral antiviral treatment of COVID-19.

2.1. Study Rationale

The purpose of this study is to evaluate the efficacy and safety of PF-07321332/ritonavir for the treatment of nonhospitalized, symptomatic, adult participants with COVID-19 who are at low risk of progression to severe illness.

2.2. Background

In December 2019, COVID-19 was identified as a new, potentially fatal, respiratory infection caused by the novel coronavirus, SARS-CoV-2. The WHO declared COVID-19 a Public Health Emergency of International Concern² on 30 January 2020 and further characterized the disease outbreak as a pandemic on 11 March 2020.³ As of 12 January 2022, at least 315 million cases have been confirmed worldwide, and at least 5.5 million deaths have occurred.⁴

COVID-19 manifests as a wide range of illness, from asymptomatic infection to severe pneumonia, ARDS, and death. Although most (approximately 80%) cases are asymptomatic or mild,⁵ patients who are hospitalized with COVID-19 may have significant morbidity and mortality,^{6,7} and are at increased risk of developing complications such as severe inflammation associated with elevations in proinflammatory cytokines, ARDS, acute cardiac injury, thromboembolic events, hypercoagulability, and/or kidney injury.⁸⁻¹¹ Moreover, other comorbidities, such as hypertension, obesity, and diabetes, as well as older age and male sex increase the risk for worse outcomes.⁶

Although there are symptomatic and/or supportive treatments for COVID-19, few antiviral drugs are available or in late-stage development to help treat COVID-19 in patients with mild to moderate COVID-19. Existing compounds, such as hydroxychloroquine and lopinavir/ritonavir, have been evaluated as potential treatment options for COVID-19, but have not demonstrated benefit or efficacy beyond SoC.¹²⁻¹⁴ The FDA has approved IV remdesivir,¹⁵ an antiviral drug with activity against SARS-CoV-2, for hospitalized patients with COVID-19 and for the treatment of mild to moderate COVID-19 in high-risk nonhospitalized patients.¹⁶ However, remdesivir monotherapy may not be sufficient in all subsets of patients¹⁷ across the COVID-19 spectrum or has shown modest effects.^{18,19} Favipiravir is currently under investigation for its activity against SARS-CoV-2 due to its broad-spectrum activity against various RNA viruses^{20,21} and has been approved in India and Russia to treat mild to moderate COVID-19.²² Although favipiravir has been generally well tolerated in clinical studies primarily for the treatment of the influenza virus, teratogenic findings in multiple animal species at exposures comparable to those achieved with the dosage regimen to treat influenza have limited its clinical use.²⁰

Three IV-administered mAb based regimens have received EUA for treatment of COVID-19 in the outpatient setting for high risk persons on the basis of observed reductions in hospitalizations and deaths in placebo-controlled randomized controlled trials.²²⁻²⁴

Eligibility for mAbs is limited to persons meeting EUA-defined criteria of being at high risk for progression to severe COVID-19 or hospitalization, may only be administered in settings in which health care providers have immediate access to medications to treat a severe infusion reaction and require patients be monitored during administration and for at least 1 hour after infusion is complete. In addition, as the mAb based regimens primarily target the variable spike protein, there is ongoing risk that the continued emergence of SARS-CoV-2 variants will negatively impact the efficacy of mAb based regimens.

In December 2021, the FDA granted EUA for a 5 day course of treatment for 2 separate oral antiviral agents, PF-07321332 (nirmatrelvir)/ritonavir and molnupiravir, for the treatment of COVID-19 in adult and pediatric patients 12 years of age and older who weigh at least 40 kilograms, with mild to moderate COVID-19 who are at high risk for progressing to severe illness. Molnupiravir is not recommended during pregnancy, as findings from animal reproduction studies showed that molnupiravir may cause fetal harm when administered to pregnant individuals. In January 2022, remdesivir received approval for this same population. This treatment is administered by IV infusion over 3 days for nonhospitalized patients with mild to moderate COVID-19 who are at high risk for progressing to severe illness.

There is thus a high unmet need for antiviral agents that could be used for the treatment of nonhospitalized persons with COVID-19. Such agents, particularly those that target highly conserved viral targets, don't require administration in a healthcare setting, and with a risk/benefit profile supportive of administration to a broad patient population will significantly add to the treatment armamentarium for COVID-19.

The coronavirus 3CL protease is a virally encoded enzyme that is critical to the SARS-CoV-2 replication cycle, analogous to other obligatory virally encoded proteases (eg, HIV Protease, HCV Protease).²⁵ Mutagenesis experiments with other coronaviruses and picornaviruses that are related to SARS-CoV-2 (picornavirus-like supercluster) have demonstrated that the activity of the 3CL protease (or the corresponding picornaviral 3C enzyme) is essential for viral replication. No close human analogs of coronavirus 3CL enzymes are known, suggesting that appropriate 3CL inhibitors may function as selective inhibitors of SARS-CoV-2 and other coronaviruses as therapeutic agents.

PF-07321332, a potent and selective inhibitor of the SARS-CoV-2 3CL protease, is being developed as an oral treatment in patients with COVID-19.

In this study, PF-07321332 will be coadministered with ritonavir. Ritonavir is a strong CYP3A4 inhibitor, and is being coadministered with PF-07321332 to achieve exposures sufficient to suppress viral replication through the entire dosing interval (ie, $C_{trough} > EC_{90}$). Ritonavir is not expected to have any antiviral activity against the SARS-CoV-2 virus.

2.2.1. Nonclinical Studies of PF-07321332

Data from nonclinical studies support the planned clinical trials with PF-07321332; these studies are described in the IB.²⁶

PF-07321332 exhibits a broad-spectrum activity across the Coronaviridae family of 3CL proteases demonstrating its potential for antiviral efficacy.

In vitro, PF-07321332 inhibited SARS-CoV-2 viral-induced cytopathic effect in monkey kidney Vero cell assays. PF-07321332 exhibited antiviral activity against SARS-CoV-2 in dNHBE cells. Furthermore, PF-07321332 inhibited HCoV229E viral-induced cytopathic effect in human MRC-5 cells with no detectable cytotoxicity at the highest compound concentration tested.

Test article-related findings identified in the safety pharmacology studies included changes in locomotor activity and transient higher respiratory rate and minute volume in rats at the high dose, as well as minor and transient hemodynamic changes (increased blood pressure and decreased heart rate) at the high dose in cynomolgus monkeys. The potential effects on safety pharmacology parameters are monitorable in the clinic, and no correlated clinical signs or histopathological findings in the relevant organs were observed in the 14-day or 15-day repeat dose GLP toxicity studies in rats or monkeys. ECG data were also collected in the 15-day GLP monkey study and there were no test article-related changes in ECG parameters (HR, RR-, PR-, QRS-, QT-, QTc-intervals) or ECG morphology in that study.

2.2.2. Clinical Overview

C4671001 (NCT04756531) is an ongoing FIH single and multiple dose escalation study to evaluate the safety, tolerability, and PK of PF-07321332 in healthy adult participants. Preliminary data from this study collected as of 07 April 2021 (SAD) and 14 April 2021 (MAD) in a total of 31 participants who were randomized and treated with PF-07321332 or placebo indicate that the clinical safety profile of PF-07321332 appears to be acceptable at single doses up to 1500 mg alone and up to 750 mg administered with ritonavir (100 mg at -12h, 0h, 12h), and at repeated daily doses administered orally for 10 days of up to 500 mg PF-07321332 BID with 100 mg ritonavir BID.

Preliminary PK data on Day 1, Day 5 and Day 10 following multiple oral administration of PF-07321332/ritonavir 75/100 mg, 250/100 mg, and 500/100 mg BID suggest less than proportional increase in exposures at steady state. Multiple dosing over 10 days achieved steady state on Day 2 with approximately 2-fold accumulation. Day 5 and Day 10 exposure was similar at all doses.

Following single doses of PF-07321332 with and without ritonavir, all AEs were mild and none were considered treatment related. There were no obvious trends in, or association of, TEAEs with dose level of PF-07321332. Following multiple doses, the most commonly observed AEs by SOC were Gastrointestinal Disorders and Nervous System Disorders. Diarrhea was the most common reported AE, occurring in 4 participants across treatment groups. A total of 5 treatment related TEAEs were observed in Part-2:MAD.

Across treatment groups, blood TSH increased in 3 participants, and 2 participants reported dysgeusia. The 3 participants with elevated TSH results did not experience related clinical symptoms and the free T4 results remained within reference range. No SAEs or deaths were reported based on these preliminary safety data as of 07 April 2021 and 14 April 2021.

Current evidence indicates that the clinical safety profile of PF-07321332 is acceptable at single doses up to 1500 mg alone and up to 750 mg administered with ritonavir (100 mg at -12h, 0h, 12h), and at repeated daily doses administered orally for 10 days of up to 500 mg PF-07321332 BID with 100 mg ritonavir BID.

C4671005 (NCT04960202), a Phase 2/3, randomized, double-blind, placebo-controlled study in nonhospitalized symptomatic adult participants with a laboratory-confirmed diagnosis of SARS-CoV-2 infection, included participants 18 years of age and older with at least 1 risk factor for progression to severe disease and with a COVID-19 symptom onset of ≤ 5 days. The study excluded individuals with a history of prior COVID-19 infection or SARS-CoV-2 vaccination before the Day 34 visit. The primary efficacy endpoint was the proportion of participants with COVID-19 related hospitalization or death from any cause through Day 28.

In the analysis of the primary endpoint from all participants enrolled in Study C4671005, an 89% reduction in COVID-19-related hospitalization or death from any cause compared with placebo in participants treated within 3 days of symptom onset was observed. 0.7% of participants who received PF-07321332/ritonavir were hospitalized through Day 28 following randomization (5 of 697 hospitalized with no deaths), compared to 6.5% of participants who received placebo and were hospitalized or died (44 of 682 hospitalized with 9 subsequent deaths) ($p < 0.0001$). In a secondary endpoint, PF-07321332/ritonavir reduced the risk of hospitalization or death for any cause by 88% compared with placebo in participants treated within 5 days of symptom onset; 0.8% of patients who received PF-07321332/ritonavir were hospitalized or died through Day 28 following randomization (8 of 1039 hospitalized with no deaths) compared with 6.3% of patients who received placebo (66 of 1046 hospitalized with 12 subsequent deaths) ($p < 0.0001$). Treatment with PF-07321332/ritonavir was safe and well tolerated.

A prespecified interim analysis of Study C4671002, which included 45% of the trial's planned enrollment, showed that the novel primary endpoint of self-reported, sustained alleviation of all symptoms for 4 consecutive days, as compared to placebo, was not met. The key secondary endpoint of COVID-19-related hospitalization or death from any cause through Day 28 was also examined at the interim analysis, showing 0.6% of those who received PF-07321332/ritonavir were hospitalized following randomization (2 of 333 hospitalized with no deaths), compared to 2.4% of participants who received placebo and were hospitalized (8 of 329 hospitalized with no deaths).

This study, C4671002, is ongoing and participant-level treatment assignment remains blinded.

2.3. Benefit/Risk Assessment

More detailed information about the known and expected benefits and risks and reasonably expected AEs of PF-07321332 may be found in the IB, which is the SRSD for this study. The SRSD for ritonavir is the USPI ²⁷ for NORVIR.

2.3.1. Risk Assessment

Potential Risk of Clinical Significance	Summary of Data/Rationale for Risk	Mitigation Strategy
Study Intervention(s) PF-07321332		
Emesis	Sporadic emesis was observed at ≥ 100 mg/kg/day of PF-07321332 in the 15-day NHP toxicology study.	AEs will be monitored and participants may receive antiemetics.
Hypertension	Transient increases in systolic, diastolic, and mean blood pressure were observed in the preclinical studies. In Study C4671005 (adults at high risk for severe disease), a small imbalance in 9 participants with reported events of hypertension was reported (1% vs <1%).	Vital signs will be monitored per SoA during the study during any in-clinic visits. All AEs will be monitored in the study. Concomitant medications will also be reviewed for potential new AEs and worsening of the condition.
Study Intervention(s): Ritonavir		
Gastrointestinal disturbances (including diarrhea, nausea, vomiting and abdominal pain)	Frequently reported adverse reaction in HIV-positive patients who are HIV-positive at 600 mg BID.	Lower dose of 100 mg twice daily is used in this study. There will be close observation of AEs. In addition to ongoing review of AEs by the sponsor, an E-DMC will review safety data as described in Section 10.1.5.1. Taking study intervention with food may improve tolerability.
Neurological disturbances (eg, paresthesia, including oral paresthesia, dysgeusia and dizziness)	Frequently reported adverse reaction in patients who are HIV-positive at 600 mg BID.	Lower dose used in this study. There will be close observation of AEs. In addition to ongoing review of AEs by the sponsor, an E-DMC will review safety data as described in Section 10.1.5.1.
Rash (most commonly reported as erythematous and maculopapular, followed by pruritic)	Frequently reported adverse reaction in patients who are HIV-positive at 600 mg BID.	Lower dose used in this study. There will be close observation of AEs and monitoring through targeted physical exams. If needed, therapeutic interventions per SoC may be provided.
Fatigue/Asthenia	Frequently reported adverse reaction in patients who are HIV-positive at 600 mg BID.	Lower dose used in this study. There will be close observation of AEs. Fatigue (low energy or tiredness) will be assessed through collection of

Potential Risk of Clinical Significance	Summary of Data/Rationale for Risk	Mitigation Strategy
		daily signs and symptoms and will also be assessed through targeted physical examinations when performed during the study visits.

2.3.2. Benefit Assessment

PF-07321332 has been shown to have SARS-CoV-2 antiviral activity in vitro and is intended to reduce virus titers, thereby reducing the duration and severity of symptoms and the risk of mortality in SARS-CoV-2 infected patients. Efficacy, safety and tolerability of PF-07321332 was demonstrated in the C4671005 study in adults at increased risk of progressing to severe COVID-19 illness. As a result, emergency use authorization has been granted for PF-07321332/ritonavir by the FDA for the treatment of mild to moderate COVID-19 in certain adults and pediatric patients (12 years of age and older) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. As noted in Section 2.2.2, at the 45% interim analysis for Study C4671002, a reduction in the number of hospitalizations or death was noted in participants treated with PF-07321332/ritonavir compared with placebo. On this basis, the potential benefit to individual study participants who receive the study intervention may include a shorter time to clinical recovery, prevention of hospitalization, and a lower probability of progressing to more severe illness or death. The potential benefit of the study is that it may provide a new treatment option for nonhospitalized patients with COVID-19 who are at low risk for progression to severe disease and hospitalization. In the context of the global pandemic public health emergency this treatment could play an important role in alleviating current pressures on health care systems globally.

2.3.3. Overall Benefit/Risk Conclusion

Taking into account the current COVID-19 global pandemic and the high burden of both mortality and morbidity and the potential for future epidemic outbreaks, the lack of readily available outpatient treatment options, and the measures taken to minimize risk to participants in this study, the potential risks identified in association with PF-07321332 are justified by the anticipated benefits that may be afforded to participants with COVID-19. An independent E-DMC will be responsible for monitoring the safety of participants at regularly scheduled intervals throughout the duration of the study and for assessing efficacy, futility and sample size estimation at the time of the interim analysis according to the E-DMC charter.

3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS

Objectives	Endpoints	Estimands
Primary:	Primary:	Primary:
<ul style="list-style-type: none"> To compare the efficacy of PF-07321332/ritonavir to placebo for the treatment of symptomatic COVID-19 in nonhospitalized adult participants with COVID-19 who are at low risk of progression to severe disease. 	<ul style="list-style-type: none"> Time (days) to sustained alleviation of all targeted COVID-19 signs/symptoms through Day 28. 	<ul style="list-style-type: none"> The difference in median time (days) to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease at baseline and were treated ≤ 5 days after COVID-19 symptom onset. This will be estimated irrespective of adherence to randomized treatment.
Secondary:	Secondary:	Secondary:
<ul style="list-style-type: none"> To describe the safety and tolerability of PF-07321332/ritonavir relative to placebo in the treatment of nonhospitalized symptomatic adult participants with COVID-19 who are at low risk of progression to severe disease. 	<ul style="list-style-type: none"> Incidence of TEAEs. Incidence of SAEs and AEs leading to discontinuations. 	<ul style="list-style-type: none"> Not Applicable.
<ul style="list-style-type: none"> To compare PF-07321332/ritonavir versus placebo for COVID-19-related hospitalization and all-cause mortality in nonhospitalized adult participants with COVID-19 who are at low risk of progression to severe disease. 	<ul style="list-style-type: none"> Proportion of participants with COVID-19-related hospitalization or death from any cause through Day 28. Proportion of participants with death (all cause) through Week 24. 	<ul style="list-style-type: none"> The difference in proportions of patients experiencing COVID-19-related hospitalization or death from any cause through Day 28 in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease and were treated ≤ 5 days after COVID-19 symptom onset. This will be estimated without regard to adherence to randomized treatment. Not Applicable
<ul style="list-style-type: none"> To compare PF-07321332/ritonavir versus placebo for COVID-19-related medical visits in nonhospitalized adult participants with COVID-19 who are at low risk of progression to severe disease. 	<ul style="list-style-type: none"> Number of COVID-19-related medical visits through Day 28. 	<ul style="list-style-type: none"> The difference in the estimated rate of the number of COVID-19-related medical visits through Day 28 in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease and were treated ≤ 5 days after COVID-19 symptom onset.

Objectives	Endpoints	Estimands
	<ul style="list-style-type: none"> Number of days in hospital and ICU stay in participants with COVID-19-related hospitalization through Day 28. 	<p>This will be estimated without regard to adherence to randomized treatment.</p> <ul style="list-style-type: none"> The difference in the estimated rate of number of days in hospital and ICU stay in patients with COVID-19-related hospitalization through Day 28 in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease and were treated ≤ 5 days after COVID-19 symptom onset. This will be estimated without regard to adherence to randomized treatment.
<ul style="list-style-type: none"> To compare PF-07321332/ritonavir to placebo for the duration and severity of signs and symptoms in nonhospitalized symptomatic adult participants with COVID-19 who are at low risk of progression to severe disease. 	<ul style="list-style-type: none"> Proportion of participants with severe signs/symptoms attributed to COVID-19 through Day 28. Time (days) to sustained resolution of all targeted COVID-19 signs/symptom through Day 28. Duration of each targeted COVID-19 sign/symptom. Progression to a worsening status in 1 or more self-reported COVID-19-associated symptoms through Day 28. Proportion of participants with a resting peripheral oxygen saturation $\geq 95\%$ at Days 1 and 5. 	<ul style="list-style-type: none"> Not Applicable.
<ul style="list-style-type: none"> To determine the PK of PF-07321332 in nonhospitalized adult participants with COVID-19 who are at low risk of progression to severe disease. 	<ul style="list-style-type: none"> PF-07321332 PK in plasma and whole blood (if feasible). 	<ul style="list-style-type: none"> Not Applicable.
<ul style="list-style-type: none"> To describe the viral load in nasal samples over time in nonhospitalized adult participants with COVID-19 who are at low risk of progression to severe disease. 	<ul style="list-style-type: none"> Viral titers measured via RT-PCR in NP/nasal swabs over time. 	<ul style="list-style-type: none"> Not Applicable.

4. STUDY DESIGN

4.1. Overall Design

This Phase 2/3, randomized, double-blind, placebo-controlled study in approximately 1980 symptomatic low risk participants with COVID-19 who are nonhospitalized will determine the efficacy, safety, and tolerability of PF-07321332/ritonavir compared with placebo. Eligible participants with a confirmed diagnosis of SARS-CoV-2 infection will be

randomized (1:1) to receive PF-07321332/ritonavir or placebo orally q12h for 5 days (10 doses total). Randomization will be stratified by geographic region, by vaccination status and by COVID-19 symptom onset (≤ 3 days vs > 3 to 5 days). Throughout the study period, provision will be made to allow study visits to be conducted at a participant's home or at another nonclinic location approved by the investigator where possible when participants are unwilling or unable to attend a clinic visit.

The total study duration is up to 24 weeks and includes a screening period of no more than 48 hours, administration of study intervention through Day 5 or Day 6, efficacy assessments through Day 28, a safety follow-up period through Day 34, and long-term follow up at Weeks 12 and 24.

An independent E-DMC will review unblinded data for this Study C4671002 to ensure the safety of participants throughout the duration of the study. In addition to up to weekly reviews of safety, the E-DMC will review the following:

- Sentinel cohort safety review: The E-DMC will review unblinded safety data after approximately the first 100 randomized participants have completed through Day 10. Whether enrollment is paused for this review will depend on the successful completion of the Study C4671005 sentinel cohort (after approximately the first 60 randomized participants have completed through Day 10). If the Study C4671005 sentinel cohort safety review has successfully completed and no clinically significant safety signals have been identified prior to enrollment of the first 100 participants in this Study C4671002, the study will continue without pause. Otherwise, enrollment of Study C4671002 will be paused pending the E-DMC review of safety data. After review of the sentinel cohort in this Study C4671002, the frequency of safety reviews may be reduced subsequently based on E-DMC recommendations.
- Proof-of-concept assessment: Viral load data when 25% (approximately 200 participants in the primary analysis set with evaluable data) complete the Day 5 assessments. Enrollment will not be paused during review of these data, but may be paused or stopped following E-DMC review.
- First interim analysis (45% planned enrollment through Protocol Amendment 4): A planned interim analysis for efficacy, futility and sample size reestimation was conducted after approximately 45% of participants completed the Day 28 assessments in the mITT analysis set.
- Second interim analysis (80% planned enrollment through Protocol Amendment 4): At the request of the E-DMC, a second interim analysis was conducted on 80% of enrolled participants without any adjustment to the alpha.

A third interim analysis (100% planned enrollment through Protocol Amendment 4) was performed on all participants enrolled through Protocol Amendment 4 and had completed the Day 34 visit. Data from the study are required to support regulatory submissions thereby necessitating this interim analysis.

Subsequent to the interim analyses above, there will be a final analysis for reporting the results of this study. The final study analysis will be performed after all participants have completed or otherwise withdrawn from the study.

4.2. Scientific Rationale for Study Design

This study evaluates safety and the potential effect of an investigational agent on alleviating/resolving COVID-19-associated symptoms, and on reducing the duration and severity of COVID-19-associated symptoms because participants are symptomatic upon entry to this study. In addition to symptoms, this study is also evaluating COVID-19-related hospitalization or death from any cause. Previous studies with mAbs directed against the SARS-CoV-2 spike (S) protein that have received an EUA from the US FDA showed efficacy in reducing SARS CoV-2 shedding on NP swabs and time to symptom resolution.²²⁻²⁴ Efficacy assessments (including participant reported COVID-19 symptoms and severity, and COVID-19 related medical visits) will be collected through Day 28. The symptom endpoint includes those recommended by FDA and relies on targeted symptoms that have been associated with COVID-19, and which are expected to be dynamic and improve with effective anti-SARS-CoV-2 therapy. NP/nasal swabs will be collected at specified timepoints to assess viral load over time.

This study uses a randomized, double-blind, placebo-controlled design, which is a well-accepted approach for evaluating efficacy in a clinical research setting. Randomization will be stratified by geographic region, by vaccination status and by COVID-19 symptom onset (≤ 3 days vs >3 to 5 days). An early safety analysis will be conducted following enrollment of approximately 100 participants. Placebo was selected as the comparator since as of this date there is no globally approved SoC treatment for this patient population.

Results from a protocol-specified 45% interim analysis of this study showed that the novel primary endpoint of self-reported, sustained alleviation of all symptoms for 4 consecutive days, as compared with placebo, was not met. In addition, the 45% interim analysis of the secondary endpoint of COVID-19-related hospitalization or death from any cause through Day 28 showed 0.6% of those who received PF-07321332/ritonavir were hospitalized following randomization (2 of 333 hospitalized with no deaths), compared with 2.4% of participants who received placebo and were hospitalized (8 of 329 hospitalized with no deaths). These secondary endpoint data demonstrate that treatment with PF-07321332/ritonavir may provide significant clinical benefit to patients at low risk of progression to severe COVID-19 as measured by the endpoint of hospitalization or death.

Furthermore, results from Study C4671005 showed PF-07321332/ritonavir treatment significantly reduced the risk of hospitalization or death from any cause by 89% compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progression to severe disease when they were treated within 3 days of symptom onset. In a secondary endpoint, PF-07321332/ritonavir treatment also reduced the risk of hospitalization or death from any cause by 88% compared with placebo in participants treated within 5 days of symptom onset. Therefore, data from Study C4671002 will be analyzed irrespective of whether participants begin treatment within 3 or 5 days of symptom onset.

4.2.1. Diversity of Study Population

Reasonable attempts will be made to enroll participants to ensure the study population is representative of the patient population that will be treated with PF-07321332/ritonavir in clinical practice.

4.2.2. Choice of Contraception/Barrier Requirements

Studies to evaluate the developmental toxicity of PF-07321332 have not been conducted. Therefore, the use of a highly effective method of contraception is required (see [Appendix 4](#)).

CCI [REDACTED]

4.3. Justification for Dose

A dosing regimen of 300 mg PF-07321332 coadministered with 100 mg ritonavir q12h administered orally for 5 days will be evaluated in this study. Dose selection for this study included consideration of all relevant available preclinical and clinical data, including repeat-dose toxicology studies, clinical safety, and PK data from the Phase 1 study (C4671001), and *in vitro* pharmacology studies with PF-07321332.

A preliminary population PK model was developed from the Phase 1 (C4671001) PK data. Following the first dose of 300 mg of PF-07321332 coadministered with 100 mg ritonavir q12h, median C_{trough} of unbound (free) PF-07321332 are predicted to be approximately 289 ng/mL (equivalent to 933 ng/mL total), ie, approximately 3-fold higher than the *in vitro* EC_{90} of 90.4 ng/mL determined in dNHBE cells (equivalent to 181 nM, f_u , human=0.310). At this dose, for a hypothetical intersubject variability of 60%, more than 95% of the participants are predicted to maintain free PF-07321332 concentrations above the *in vitro* EC_{90} over the 12- hour dosing interval.

The selected duration is based on the effectiveness demonstrated following 5 day administration of other antiviral agents used in the treatment of acute respiratory infections, such as remdesivir for SARS-CoV-2 and oseltamivir for influenza.

Preliminary safety data from Study C4671001, collected up to 07 April 2021 and 14 April 2021, showed an acceptable safety profile for single doses of PF-07321332 ranging from 150 mg to 1500 mg dosed alone and of 250 mg and 750 mg dosed with ritonavir (100 mg administered at -12h, 0h, 12h) and for 10 day repeated doses ranging from 75 mg BID to 500 mg BID with 100 mg ritonavir BID.

In Study C4671005, a dosing regimen of 300 mg PF-07321332 coadministered with 100 mg ritonavir q12h administered orally for 5 days was efficacious in reducing the incidence of COVID-19-related hospitalization or death from any cause in nonhospitalized symptomatic adult participants with COVID-19 who were at increased risk of progression to severe disease. PF-07321332 was safe and well tolerated.

The proposed dosing regimen of 300 mg PF-07321332 coadministered with 100 mg ritonavir q12h administered orally for 5 days is thus expected to be safe and efficacious.

4.4. End of Study Definition

The end of the study is defined as the date of the last visit of the last participant in the study shown in the [SoA](#) for the last participant in the trial globally.

A participant is considered to have completed the study if he/she has completed all periods of the study, including the last visit as shown in the [SoA](#).

5. STUDY POPULATION

This study can fulfill its objectives only if appropriate participants are enrolled including participants across diverse and representative racial and ethnic backgrounds. Use of a pre-screener for study recruitment purposes will include collection of information, that reflects the enrolment of a diverse participant population including, where permitted under local regulations, age, sex, and race, and ethnicity. The following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate. All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a particular participant is suitable for this protocol.

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.

5.1. Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

Age and Sex:

1. Participants ≥ 18 years of age (or the minimum country-specific age of consent if >18) at the time of the Screening Visit.
 - WOCBP may be enrolled.
 - All fertile participants must agree to use a highly effective method of contraception. Refer to [Appendix 4](#) for reproductive criteria for male (Section [10.4.1](#)) and female (Section [10.4.2](#)) participants.

Type of Participant and Disease Characteristics:

2. Confirmed SARS-CoV-2 infection as determined by RT-PCR in any specimen collected within 5 days prior to randomization.

Note: RT-PCR is the preferred method; however, with evolving approaches to confirmation of SARS-CoV-2 infection, other molecular or antigen tests that detect viral RNA or protein are allowed. The test result must be available to confirm eligibility.

Participants may be enrolled based on positive results of a rapid SARS-CoV-2 antigen test performed at screening.

3. Initial onset of signs/symptoms attributable to COVID-19 within 5 days prior to the day of randomization and at least 1 of the specified signs/symptoms attributable to COVID-19 present on the day of randomization (see [Appendix 9](#) for criteria).
4. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

Informed Consent:

5. Capable of giving signed informed consent as described in [Appendix 1](#), which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

5.2. Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions:

1. Has at least 1 characteristic or underlying medical condition (self-report is acceptable) associated with an increased risk of developing severe illness from COVID-19, including:
 - ≥ 65 years of age;
 - $BMI \geq 30$ kg/m²;
 - Current smoker (cigarette smoking within the past 30 days) and history of at least 100 lifetime cigarettes;
 - Chronic lung disease (if asthma, requires daily prescribed therapy);
 - Known diagnosis of hypertension;
 - CVD, defined as history of any of the following: myocardial infarction, stroke, TIA, HF, angina with prescribed nitroglycerin, CABG, PCI, carotid endarterectomy, and aortic bypass;
 - Type 1 or Type 2 diabetes mellitus;
 - CKD;
 - Sickle cell disease;
 - Neurodevelopmental disorders (eg, cerebral palsy, Down's syndrome) or other conditions that confer medical complexity (eg, genetic or metabolic syndromes and severe congenital anomalies);
 - Active cancer other than localized skin cancer, including those requiring treatment (including palliative treatment), as long as the treatment is not among the prohibited medications that must be administered/continued during the trial period;

- Medical-related technological dependence (eg, CPAP [not related to COVID-19]).
2. Immunosuppressive disease (eg, bone marrow or organ transplantation or primary immune deficiencies) OR prolonged use of immune-weakening medications:
 - Has received corticosteroids equivalent to prednisone ≥ 20 mg daily for at least 14 consecutive days within 30 days prior to study entry;
 - Has received treatment with biologics (eg, infliximab, ustekinumab, etc.), immunomodulators (eg, methotrexate, 6MP, azathioprine, etc), or cancer chemotherapy within 90 days prior to study entry’;
 - HIV infection with CD4+ cell count $< 200/\text{mm}^3$.
 3. History of hospitalization for the medical treatment of COVID-19.
 4. Current need for hospitalization or anticipated need for hospitalization within 48 hours after randomization in the clinical opinion of the site investigator (see Section 8.1.2).
 5. Prior to current disease episode, any confirmed SARS-CoV-2 infection, as determined by a molecular test (antigen or nucleic acid) from any specimen collection.
 6. Known medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic or active hepatitis B or C infection, primary biliary cirrhosis, Child-Pugh Class B or C or acute liver failure.
 7. Receiving dialysis or have known renal impairment.
 8. Known HIV infection with viral load > 400 copies/mL or taking prohibited medications for HIV treatment (from known medical history within past 6 months of the screening visit) (Appendix 8).
 9. Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.
 10. Any comorbidity requiring hospitalization and/or surgery within 7 days prior to study entry, or that is considered life threatening within 30 days prior to study entry, as determined by the investigator.
 11. History of hypersensitivity or other contraindication to any of the components of the study intervention, as determined by the investigator.
 12. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study.

Prior/Concomitant Therapy:

13. Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance and for which elevated plasma concentrations may be associated

with serious and/or life-threatening events during treatment and for 4 days after the last dose of PF-07321332/ritonavir (see [Appendix 8](#)).

14. Concomitant use of any medications or substances that are strong inducers of CYP3A4 are prohibited within 28 days prior to first dose of PF-07321332/ritonavir and during study treatment (see [Appendix 8](#)).
15. Has received or is expected to receive monoclonal antibody treatment, antiviral treatment (eg, molnupiravir), or convalescent COVID-19 plasma.
16. Has received any SARS-CoV-2 vaccination within 12 months of screening.

Note: Participants entering the study must not receive any dose of a SARS-CoV-2 vaccine prior to Day 34.

Prior/Concurrent Clinical Study Experience:

17. Is unwilling to abstain from participating in another interventional clinical study with an investigational compound or device, including those for COVID-19 therapeutics, through the long-term follow-up visit. Previous administration with any investigational drug or vaccine within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
18. Known prior participation in this trial or other trial involving PF-07321332.

Diagnostic Assessments:

19. Known history of any of the following abnormalities in clinical laboratory tests (within past 6 months of the screening visit):
 - AST or ALT level ≥ 2.5 X ULN;
 - Total bilirubin ≥ 2 X ULN (≥ 3 X ULN for Gilbert's syndrome);
 - eGFR < 45 mL/min/1.73 m² within 6 months of the screening visit, using the serum creatinine-based CKD-EPI formula;²⁸
 - Absolute neutrophil count < 1000 /mm³.

Note: If the investigator suspects the participant may have any of the above laboratory values, confirmatory tests should be performed at screening to confirm eligibility before the first dose of study intervention. See [Appendix 2](#) for more details.

20. Oxygen saturation of $< 92\%$ on room air obtained at rest within 24 hours prior to randomization.

NOTE: For a potential participant who regularly receives chronic supplementary oxygen for an underlying lung condition, oxygen saturation should be measured while on their standard home oxygen supplementation.

Other Exclusions:

21. Females who are pregnant or breastfeeding.
22. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

5.3. Lifestyle Considerations

5.3.1. Contraception

The investigator or his or her designee, in consultation with the participant, will confirm that the participant has selected an appropriate method of contraception for the individual participant and his or her partner(s) from the permitted list of contraception methods (see Section 10.4.4) and will confirm that the participant has been instructed in its consistent and correct use. At time points indicated in the SoA, the investigator or designee will inform the participant of the need to use highly effective contraception consistently and correctly and document the conversation and the participant's affirmation in the participant's chart (participants need to affirm their consistent and correct use of at least 1 of the selected methods of contraception) considering that their risk for pregnancy may have changed since the last visit. In addition, the investigator or designee will instruct the participant to call immediately if the selected contraception method is discontinued or if pregnancy is known or suspected in the participant or partner.

5.4. Screen Failures

Screen failures are defined as participants who consent to participate in the clinical study but are not subsequently randomly assigned to study intervention. A minimal set of screen failure information is required to ensure transparent reporting of screen failure participants to meet the CONSORT publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any SAE.

Individuals who do not meet the criteria for participation in this study (screen failure) may not be rescreened.

5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Administration of Study Intervention

Not applicable.

6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY

Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, medical device(s), or study procedure(s) intended to be administered to a study participant according to the study protocol.

For the purposes of this protocol, study intervention refers to PF-07321332 150 mg tablets and matching placebo and ritonavir 100 mg capsules and matching placebo.

6.1. Study Intervention(s) Administered

Study Interventions(s)				
Intervention Name	PF-07321332	Placebo for PF-07321332	Ritonavir	Placebo for Ritonavir
ARM Name (group of patients receiving a specific treatment (or no treatment))	PF-07321332/ritonavir	Placebo	PF-07321332/ritonavir	Placebo
Type	drug	placebo	drug	placebo
Dose Formulation	tablet	tablet	capsule	capsule
Unit Dose Strength(s)	150 mg	0 mg	100 mg	0 mg
Dosage Level(s)	300 mg q12h for 5 days	0 mg q12h for 5 days	100 mg q12h for 5 days	0 mg q12h for 5 days
Route of Administration	oral	oral	oral	oral
Use	experimental	placebo	experimental	placebo
IMP or NIMP	IMP	IMP	IMP	IMP
Sourcing	Provided centrally by the sponsor Refer to the IP manual.	Provided centrally by the sponsor Refer to the IP manual.	Provided centrally by the sponsor Refer to the IP manual.	Provided centrally by the sponsor Refer to the IP manual.
Packaging and Labeling	Study intervention will be provided in blister wallets. Each wallet will be labeled as required per country requirement. Products will be provided with blinded labels.	Study intervention will be provided in blister wallets. Each wallet will be labeled as required per	Study intervention will be provided in HDPE bottles. Each bottle will be labeled as required per country requirement.	Study intervention will be provided in HDPE bottles. Each bottle will be labeled as required

Study Interventions(s)				
		country requirement.		per country requirement.
Current/Former Name(s) or Alias(es)	PF-07321332	N/A	ritonavir	N/A

Study Arm(s)		
Arm Title	PF-07321332/ritonavir	Placebo
Arm Type	experimental	placebo
Arm Description	Participants will receive PF-07321332/ritonavir 300 mg/100 mg every 12 hours for 5 days.	Participants will receive 0 mg every 12 hours for 5 days
Associated Intervention Labels	PF-07321332/ritonavir	Placebo

6.1.1. Administration

PF-07321332 150 mg tablets or placebo for PF-07321332, will be administered for 5 days with ritonavir 100 mg or placebo for ritonavir capsules. Participants will be dispensed 1 blister wallet of PF-07321332 150 mg or placebo for PF-07321332 tablets and 1 bottle of ritonavir or placebo for ritonavir capsules. Participants will be given clear dosing instruction to take:

- 2 tablets of PF-07321332 150 mg or placebo for PF-07321332 q12h
- 1 capsule of ritonavir 100 mg or placebo for ritonavir q12h

Participants should take the first dose of study intervention on Day 1, preferably during the in-person visit; that is, participants should take 2 tablets of PF-07321332 150 mg or placebo and 1 capsule of ritonavir 100 mg or placebo or the 2 tablets of placebo for PF-07321332 at the same time and no more than 10 minutes apart. To allow the participant to select a convenient 12 hour dosing schedule, timing of dosing for the second dose may be adjusted slightly, but should be taken at least 4 hours but no later than 12 hours after the first dose. The remaining doses should be taken every 12 hours (± 30 minutes). Participants will swallow the study intervention whole and will not manipulate or chew the study intervention prior to swallowing. Participants may take the study intervention with or without food. Taking study intervention with food may improve tolerability. Refer to the IP Manual for additional dosing and administration instructions.

If a dose is delayed, it should be taken as soon as possible, but no later than 4 hours before the next scheduled dose. Participants should not double up the next dose of study drug in

order to “make up” what had been missed. Dosing should be stopped at the end of the treatment period (10 doses total). Any remaining tablets and/or capsules at the end of 5 days (or 6 days if only one dose was administered on Day 1) should be returned.

6.2. Preparation, Handling, Storage, and Accountability

1. The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study interventions received and any discrepancies are reported and resolved before use of the study intervention.
2. Only participants enrolled in the study may receive study intervention and only authorized site staff may supply or administer study intervention. All study interventions must be stored in a secure, environmentally controlled, and monitored (manual or automated recording) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff. At a minimum, daily minimum and maximum temperatures for all site storage locations must be documented and available upon request. Data for nonworking days must indicate the minimum and maximum temperatures since previously documented for all site storage locations upon return to business. Study intervention may be shipped by courier to study participants if permitted by local regulations and in accordance with storage and transportation requirements for study intervention. Pfizer does not permit the shipment of study intervention by mail. The tracking record of shipments and the chain of custody of study intervention must be kept in the participant’s source documents/medical records. For investigational sites using ground transportation to deliver study intervention to participants, stability data reveal that if the total duration of transit is less than 24 hours, temperature monitoring is not required.
3. Any excursions from the study intervention label storage conditions should be reported to Pfizer upon discovery along with any actions taken. The site should actively pursue options for returning the study intervention to the storage conditions described in the labeling, as soon as possible. Once an excursion is identified, the study intervention must be quarantined and not used until Pfizer provides permission to use the study intervention. Specific details regarding the definition of an excursion and information the site should report for each excursion will be provided to the site in the IP manual.
4. Any storage conditions stated in the SRSD will be superseded by the storage conditions stated on the label.
5. Study interventions should be stored in their original containers.
6. Site staff will instruct participants on the proper storage requirements for take-home study intervention.
7. The investigator, institution, or the head of the medical institution (where applicable) is responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records), such as the

IPAL or sponsor-approved equivalent. All study interventions will be accounted for using a study intervention accountability form/record. All study intervention that is taken home by the participant, both used and unused, must be returned to the investigator by the participant. Returned study intervention must not be redispensed to the participants.

8. Further guidance and information for the final disposition of unused study interventions are provided in the IP manual. All destruction must be adequately documented. If destruction is authorized to take place at the investigator site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by Pfizer.

Upon identification of a product complaint, notify the sponsor within 1 business day of discovery as described in the IP manual.

6.2.1. Preparation and Dispensing

A qualified staff member will dispense the study intervention using the IRT system via unique container numbers in the bottles and blister cards provided, in quantities appropriate according to the [SoA](#). A second staff member will verify the dispensing. The participant should be instructed to maintain the product in the bottle and blister cards, as appropriate provided throughout the course of dosing and return the bottle and blister cards, as appropriate to the site at the next study visit.

Study intervention and placebo will be dispensed by qualified blinded site personnel according to the IP manual. The study intervention will be administered in a blinded fashion to the participants.

6.3. Measures to Minimize Bias: Randomization and Blinding

6.3.1. Allocation to Study Intervention

Allocation of participants to treatment groups will proceed through the use of an IRT system (IWR). The site personnel (study coordinator or specified designee) will be required to enter or select information including but not limited to the user's ID and password, the protocol number, and the participant number. The site personnel will then be provided with a treatment assignment, randomization number, and DU or container number when study intervention is being supplied via the IRT system. The IRT system will provide a confirmation report containing the participant number, randomization number, and DU or container number assigned. The confirmation report must be stored in the site's files.

Study intervention will be dispensed at the study visits summarized in the [SoA](#).

Returned study intervention must not be redispensed to the study participants.

The study-specific IRT reference manual and IP manual will provide the contact information and further details on the use of the IRT system.

6.3.2. Blinding of the Sponsor

The majority of sponsor staff will be blinded to study intervention allocation. There will be an unblinded team supporting the interactions with, and the analyses for, the E-DMC while the study is ongoing. The team will consist of a clinician, statistician and programmer(s) and will be separate from the blinded members of the study team.

- An unblinded submissions team will be responsible for preparing unblinded analyses and documents to support regulatory activities that may be required while the study is ongoing.

The study will be unblinded after all participants complete the Day 34 visit (or ET prior to Day 34 visit), and analyses through Day 34, including the primary efficacy endpoint analyses, will be conducted.

Details of the unblinded sponsor staff supporting the E-DMC and the timing of unblinding will be outlined in the Unblinding Plan.

6.3.3. Breaking the Blind

The IRT will be programmed with blind-breaking instructions. In case of an emergency, the investigator has the sole responsibility for determining if unblinding of a participant's treatment assignment is warranted. Participant safety must always be the first consideration in making such a determination. If the investigator decides that unblinding is warranted, the investigator should make every effort to contact the sponsor prior to unblinding a participant's treatment assignment unless this could delay further management of the participant. If a participant's treatment assignment is unblinded, the sponsor must be notified within 24 hours after breaking the blind. The date and reason that the blind was broken must be recorded in the source documentation and CRF.

The study-specific IRT reference manual and IP manual will provide the contact information and further details on the use of the IRT system.

6.4. Study Intervention Compliance

Participants will be issued an electronic study intervention diary (ie, participant-completed study intervention log) and will be educated to record the date and time of their study intervention dosing, preferably at the time of first dose.

Compliance with study intervention will be assessed by delegated site personnel through the accounting of unused study intervention returned by the participant at the study visits, review of the electronic study intervention diary, and discussion with the participant.

Study intervention administration, including any deviation(s) from the prescribed dosage regimen, should be recorded in the CRF.

A record of the number of study intervention tablets/capsules dispensed to and taken by each participant must be maintained and reconciled with study intervention and compliance records. Intervention start and stop dates will also be recorded in the CRF.

The following noncompliance cases will be considered medication errors (see Section 8.3.10):

- Participants interrupting study intervention for 2 consecutive doses;
- Participants taking either PF-07321332 or ritonavir alone for 2 consecutive doses;
- Participants who have an overall study intervention compliance of <80% or >115%.

In addition to the above-listed medication errors, any deviation from protocol specified dosing (eg, missed single dose or partial dose) should be recorded as a protocol deviation and the investigator or designee is to counsel the participant and ensure steps are taken to improve compliance.

6.5. Dose Modification

Dose modification for PF-07321332/ritonavir is not allowed.

6.6. Continued Access to Study Intervention After the End of the Study

No intervention will be provided to study participants at the end of their study participation.

6.7. Treatment of Overdose

For this study, any dose of PF-07321332 greater than 900 mg or ritonavir greater than 300 mg within a 24-hour time period will be considered an overdose.

There is no specific treatment for an overdose.

In the event of an overdose, the investigator should:

1. Contact the medical monitor within 24 hours.
2. Closely monitor the participant for any AEs/SAEs and laboratory abnormalities for at least 5 half-lives or 28 calendar days after the overdose of study intervention (whichever is longer).
3. Document the quantity of the excess dose as well as the duration of the overdose in the CRF.
4. Overdose is reportable to Pfizer Safety **only when associated with an SAE**.
5. Obtain a blood sample for PK analysis within 1 day from the date of the last dose of study intervention if requested by the medical monitor (determined on a case-by-case basis).

Decisions regarding dose interruptions or modifications will be made by the investigator in consultation with the medical monitor based on the clinical evaluation of the participant.

6.8. Concomitant Therapy

Hormonal contraceptives that meet the requirements of this study are allowed to be used in participants who are WOCBP (see [Appendix 4](#)).

Permitted During the Study

All participants may receive SoC therapy for COVID-19, in addition to study intervention, unless listed as prohibited medication (see [Appendix 8](#)) or as defined in Section 5.2. SoC therapy is defined as any therapy that is approved and used as indicated by the local regulatory authorities (including approvals for emergency use, compassionate use, or through similar regulatory guidance), or any therapy as recommended by a relevant national (or a reputable international) scientific body (eg, WHO, ECDC, CDC, NIH). Sites should consult with the sponsor if a new SoC option becomes available after study initiation. Investigator should ensure that any recommended SoC therapy is not a strong inducer of CYP3A4 or highly dependent on CYP3A4 for clearance.

Prohibited During the Study

Participants should not receive monoclonal antibody treatment, antiviral treatment (eg, molnupiravir), or convalescent COVID-19 plasma treatment for COVID-19 during the study period. COVID-19 vaccinations are permitted after the Day 34 visit.

PF-07321332 and ritonavir are both primarily metabolized by CYP3A4. Therefore, concomitant use of any medications or substances that are strong inducers of CYP3A4 are prohibited within 28 days prior to dosing of study intervention and during study treatment.

Additionally, PF-07321332 and ritonavir are inhibitors of CYP3A4. Therefore, medications highly dependent on CYP3A4 for clearance and for which elevated plasma concentrations may be associated with serious and/or life-threatening events are not permitted during dosing of PF-07321332/ritonavir and for 4 days after the last dose of PF-07321332/ritonavir. Because ritonavir 100 mg every 12 hours is being used to boost the exposure of PF-07321332, no additional DDIs are expected other than those associated with ritonavir 100 mg q12h based on in vitro assessments of PF-07321332.

A nonexhaustive list of prohibited and precautionary medications is provided in [Appendix 8](#). If a medication is not listed, it should not automatically be assumed it is safe to coadminister. Appropriately qualified site staff will review all concomitant medications before the first dose of study intervention is administered to determine if they are strong inducers of CYP3A4 or highly dependent on CYP3A4 for clearance, and thus prohibited.

6.8.1. Rescue Medicine

Standard medical supportive care may be provided to manage AEs.

7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL

7.1. Discontinuation of Study Intervention

It may be necessary for a participant to permanently discontinue study intervention. Reasons for permanent discontinuation of study intervention include the following.

- AE (including Grade 3 severity or greater and considered by the investigator to be related to study intervention);
- SAE considered by the investigator to be related to the study intervention;
- Requirement for prohibited concomitant medication;
- Death;
- Pregnancy;
- Study terminated by sponsor;
- Withdrawal by participant or legally authorized representative
- Hospitalization during the active treatment period;
- Miss more than 2 consecutive doses of study intervention.

Note that discontinuation of study intervention does not represent withdrawal from the study. If study intervention is permanently discontinued, the participant will remain in the study to be evaluated for all subsequent scheduled assessments. See the [SoA](#) for data to be collected at the time of discontinuation of study intervention and follow-up for any further evaluations that need to be completed.

In the event of discontinuation of study intervention, it must be documented on the appropriate CRF/in the medical records whether the participant is discontinuing further receipt of study intervention or also from study procedures, posttreatment study follow-up, and/or future collection of additional information.

7.1.1. Potential Cases of Decreased eGFR

If postscreening eGFR is $<45 \text{ ml/min/1.73 m}^2$ the participant will be instructed to discontinue any remaining study intervention doses as soon as study staff become aware of laboratory results.

7.2. Participant Discontinuation/Withdrawal From the Study

A participant may withdraw from the study at any time at his/her own request. Reasons for discontinuation from the study include the following:

- Refused further study procedures;
- Lost to follow-up;
- Death;
- Study terminated by sponsor.

At the time of discontinuing from the study, if possible, an early discontinuation visit should be conducted. See the [SoA](#) for assessments to be collected at the time of study discontinuation and follow-up and for any further evaluations that need to be completed.

The early discontinuation visit applies only to participants who are enrolled/randomized and then are prematurely withdrawn from the study. Participants should be questioned regarding their reason for withdrawal.

If a participant withdraws from the study, he/she may request destruction of any remaining samples taken and not tested, and the investigator must document any such requests in the site study records and notify the sponsor accordingly.

If the participant withdraws from the study and also withdraws consent (see Section 7.2.1) for disclosure of future information, no further evaluations should be performed and no additional data should be collected. The sponsor may retain and continue to use any data collected before such withdrawal of consent.

7.2.1. Withdrawal of Consent

Participants who request to discontinue receipt of study intervention will remain in the study and must continue to be followed for protocol-specified follow-up procedures. The only exception to this is when a participant specifically withdraws consent for any further contact with him or her or persons previously authorized by the participant to provide this information. Participants should notify the investigator in writing of the decision to withdraw consent from future follow-up, whenever possible. The withdrawal of consent should be explained in detail in the medical records by the investigator, as to whether the withdrawal is only from further receipt of study intervention or also from study procedures and/or posttreatment study follow-up, and entered on the appropriate CRF page. In the event that vital status (whether the participant is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately directed in accordance with local law.

7.3. Lost to Follow-Up

A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site.

The following actions must be taken if a participant fails to be available for a required study visit:

- The site must attempt to contact the participant and reschedule the missed visit as soon as possible. Counsel the participant on the importance of maintaining the assigned visit schedule, and ascertain whether the participant wishes to and/or should continue in the study;
- Before a participant is deemed lost to follow-up, the investigator or designee must make every effort to regain contact with the participant (where possible, 3 telephone calls and, if necessary, a certified letter to the participant's last known mailing address or local equivalent methods). These contact attempts should be documented in the participant's medical record;
- Should the participant continue to be unreachable, he/she will be considered to have withdrawn from the study.

8. STUDY ASSESSMENTS AND PROCEDURES

The investigator (or an appropriate delegate at the investigator site) must obtain a signed and dated ICD before performing any study-specific procedures.

Study procedures and their timing are summarized in the [SoA](#). Protocol waivers or exemptions are not allowed.

Safety issues should be discussed with the sponsor immediately upon occurrence or awareness to determine whether the participant should continue or discontinue study intervention.

Adherence to the study design requirements, including those specified in the [SoA](#), is essential and required for study conduct.

All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.

Procedures conducted as part of the participant's routine clinical management (eg, blood count) and obtained before signing of the ICD may be utilized for screening or baseline purposes provided the procedures met the protocol-specified criteria and were performed within the time frame defined in the [SoA](#).

In the event a participant is hospitalized, study assessments should be performed as feasible. Procedures not performed due to hospitalizations would not be considered protocol deviations.

Every effort should be made to ensure that protocol-required tests and procedures are completed as described. However, it is anticipated that from time to time there may be circumstances outside the control of the investigator that may make it unfeasible to perform the test. In these cases, the investigator must take all steps necessary to ensure the safety and well-being of the participant. When a protocol-required test cannot be performed, the investigator will document the reason for the missed test and any corrective and preventive actions that he or she has taken to ensure that required processes are adhered to as soon as possible. The study team must be informed of these incidents in a timely manner.

For samples being collected and shipped, detailed collection, processing, storage, and shipment instructions and contact information will be provided to the investigator site prior to initiation of the study.

The total blood sampling volume for individual participants in this study is approximately 150 mL. An additional optional blood sample of up to 4 mL will be collected for a subset of participants who agree to collect an optional PK sample. The actual collection times of blood sampling may change. Additional blood samples may be taken for safety assessments at times specified by Pfizer, provided the total volume taken during the study does not exceed 550 mL during any period of 56 consecutive days.

8.1. Efficacy Assessments

8.1.1. Participant Diary

Participants will be provided an electronic handheld device or will use their own device to record: daily COVID-19 signs and symptoms, study intervention and administration, and other PRO assessments in the study diary.

Participants will receive daily reminders to complete entries on their own as specified in the [SoA](#). The diary should be completed at approximately the same time every day. Staff will review the participant's study diary online as specified in the [SoA](#).

The diary allows recording of these assessments only within a fixed time window (eg, 24 hours), thus providing an accurate representation of the participant's experience at that time. The participant is able to make revisions to incorrect entries before pressing the save or submit button. In the event that a participant becomes aware of an error in data after the entry is saved, a change to the diary data may only be made by the investigator submitting a data clarification form. Data reported in the participant diary will be transferred electronically to a third-party vendor, where they will be available for review by investigators and the sponsor or delegate at all times via an internet-based portal.

8.1.2. COVID-19-Related Medical Visit Details

Details of participants' COVID-19-related medical visits (ie, hospitalization, practitioner's office, home healthcare services, telemedicine, urgent care, emergency room ≤ 24 hours,

extended care facility stay) will be collected during study visits, including level of care (ICU status) and dates of utilization, including admission and discharge, as applicable.

Hospitalization is defined as >24 hours of acute care, in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19 during the COVID-19 pandemic. This includes specialized acute medical care unit within an assisted living facility or nursing home. This does not include hospitalization for the purposes of public health and/or clinical trial execution.

8.1.3. Daily Signs and Symptoms of COVID-19

On Day 1, participants will complete the study diary before receiving study intervention. Participant assessment of COVID-19-related symptoms should be recorded at approximately the same time each day as specified in the [SoA](#) and described in Section [8.1.1](#).

COVID-19-related symptoms will be evaluated in accordance with FDA guidelines ([Appendix 9](#)).²⁹ Participants will record a daily severity rating of their symptom severity over the past 24 hours based on a 4-point scale in which 0 is reported if no symptoms were present; 1 if mild; 2 if moderate; and 3 if severe.

Vomiting and diarrhea will each be rated on a 4-point frequency scale where 0 is reported for no occurrence, 1 for 1 to 2 times, 2 for 3 to 4 times, and 3 for 5 or greater.

Sense of smell and sense of taste will each be rated on a 3-point Likert scale where 0 is reported if the sense of smell/taste was the same as usual, 1 if the sense of smell/taste was less than usual, and 2 for no sense of smell/taste.

Targeted COVID-19-associated symptoms are a subset of these symptoms ([Appendix 9](#)).

8.1.4. Oxygen Support Details

Type of oxygen support (eg, oxygen supplementation received at home, mechanical ventilation received in hospital) will be collected.

8.1.5. PRO Assessments

8.1.5.1. WPAI Questionnaire

COVID-19 impacts manual and office-based work, and results in missed work due to illness or quarantine and loss of productivity.³⁰ The Work Productivity and Activity Impairment Questionnaire: General Health (GH) is being implemented for COVID-19 (ie, WPAI-COVID-19) in order to evaluate change from baseline in work burdens. The WPAI-GH has demonstrated validity, reliability and sufficient predictive value to measure the impact of disease on absenteeism, presenteeism, and overall productivity in a manner that can also be monetized.³¹

The WPAI-COVID-19 consists of 6 questions that refer to the following assessments for work productivity: 1 = currently employed, 2 = hours missed due to health problems, 3 =

hours missed other reasons, 4 = hours actually worked, 5 = degree health affected productivity while working (using a 0 to 10 VAS), and 6 = degree health affected productivity in regular unpaid activities. The recall period for questions 2 through 6 is 7 days. Four main outcomes will be generated from the WPAI-COVID-19 and reported as: 1) percent work time missed due to COVID-19 for those who are currently employed, 2) percent impairment while working due to COVID-19 for those who are currently employed and actually worked in the past 7 days, 3) percent overall work impairment due to COVID-19 for those who are currently employed, and 4) percent activity impairment due to COVID-19 for all respondents.³¹ The WPAI-COVID-19 should be completed as specified in the [SoA](#).

8.1.5.2. EQ-5D-5L Scale

The EQ-5D is a validated, standardized, generic instrument that is a preference-based health related quality of life questionnaire in cost effectiveness and HTA.³²⁻³⁴ Recently, a version was developed called EQ-5D-5L with 5 response levels on each dimension compared to the 3 response levels in the EuroQol Quality of Life 5-Dimension 3-Level Scale (EQ-5D-3L).³²⁻³⁸

Measurement properties of the EQ-5D-5L demonstrated to be a valid version of the 3 level questionnaire that improved measurements by adding discriminatory power, reducing the ceiling, and establishing convergent and known groups validity.^{32,34,36,37} Both the EuroQol EQ-5D-3L and EQ-5D-5L versions are well established instruments used to measure health states and utilities in various diseases areas and assess mobility, self-care, usual activities, pain/discomfort, anxiety/depression and health status using a VAS.^{35,39} The EQ-5D-5L should be completed as described in the [SoA](#).

8.1.5.3. Global Impression Questions

Three questions will be included in the ePRO to assess patient-reported global impression items a) return to usual health; b) return to usual activities; and c) overall COVID-19-related symptoms:²⁹

8.1.6. Exit Interview

Qualitative exit interviews with a select group of US English-speaking participants (up to 50) at selected sites will be conducted by telephone, as indicated in the [SoA](#). Interviews will be conducted by trained moderators, that are not part of study site staff, and are anticipated to be approximately 60 minutes in duration. Participant understanding of daily diary signs and symptoms questions and global impression questions will be evaluated based on transcripts and interviewer field notes.

8.2. Safety Assessments

Planned time points for all safety assessments are provided in the [SoA](#). Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.

8.2.1. Medical History

Medical history in addition to COVID-19 disease history and demographics will be collected at screening. Smoking status will be collected. Complete medication history of all

prescription or nonprescription drugs (including vaccinations), and dietary and herbal supplements taken within 30 days prior to the planned first dose will be collected.

8.2.2. Height and Weight

Height and weight will also be measured and recorded at screening. Height may be self reported.

8.2.3. Targeted Physical Examinations

A targeted physical examination will include, at a minimum, cardiopulmonary assessments. Investigators should pay special attention to any previously identified or new AE/targeted condition that the participant has experienced.

Physical examination findings collected during the study will be considered source data and will not be required to be reported, unless otherwise noted. Any untoward physical examination findings that are identified during the active collection period and meet the definition of an AE or SAE ([Appendix 3](#)) must be reported according to the processes in Sections [8.3.1](#) to [8.3.3](#).

8.2.4. Vital Signs

Temperature, pulse rate, respiratory rate, oxygen saturation level, and blood pressure will be assessed as specified in the [SoA](#).

Blood pressure and pulse rate measurements will be assessed with the participant in the supine or seated position with their feet on the floor when possible with a completely automated device. It is recommended that the same position should be used for a participant throughout the study duration. Manual techniques will be used only if an automated device is not available.

Blood pressure and pulse rate measurements should be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (eg, television, cell phones).

Vital signs are to be taken before blood collection for laboratory tests.

Each participant will also be supplied with a pulse oximeter to be used based on the instruction and medical judgment of the site investigator.

8.2.5. Clinical Safety Laboratory Assessments

See [Appendix 2](#) for the list of clinical safety laboratory tests to be performed and the [SoA](#) for the timing and frequency. All protocol-required laboratory assessments, as defined in [Appendix 2](#), must be conducted in accordance with the laboratory manual and the [SoA](#). Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.

Laboratory safety parameters will be graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events⁴⁰, version 2.1. The investigator must review

the laboratory report, document this review, and record any clinically relevant changes occurring during the study in the AE section of the CRF. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

All laboratory tests with values considered clinically significantly abnormal during participation in the study or within 28 days after the last dose of study intervention should be repeated until the values return to normal or baseline or are no longer considered clinically significant by the investigator or medical monitor.

If such values do not return to normal/baseline within a period of time judged reasonable by the investigator, the etiology should be identified and the sponsor notified.

See [Appendix 6](#) for suggested actions and follow-up assessments in the event of potential drug-induced liver injury.

8.2.6. Pregnancy Testing

Pregnancy tests may be urine or serum tests, but must have a sensitivity of at least 25 mIU/mL. Pregnancy tests will be performed in WOCBP at the times listed in the [SoA](#). Following a negative pregnancy test result at screening, appropriate contraception must be commenced. Pregnancy tests will also be done whenever 1 menstrual cycle is missed during the active treatment period (or when potential pregnancy is otherwise suspected). Pregnancy tests may also be repeated if requested by IRBs/ ECs or if required by local regulations. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded if the serum pregnancy result is positive.

If a participant requiring pregnancy testing cannot visit a local laboratory, a home urine pregnancy testing kit with a sensitivity of at least 25 mIU/mL may be used by the participant to perform the test at home, if compliant with local regulatory requirements. The pregnancy test outcome should be documented in the participant's source documents/medical records. If the pregnancy test is positive, the EDP should be reported (Section [8.3.5.1](#)). Confirm that the participant is adhering to the contraception method(s) required in the protocol.

8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting

The definitions of an AE and an SAE can be found in [Appendix 3](#).

AEs may arise from symptoms or other complaints reported to the investigator by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative), or they may arise from clinical findings of the Investigator or other healthcare providers (clinical signs, test results, etc.).

The investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE and remain responsible to pursue and obtain adequate information both to determine the outcome and to assess whether the

event meets the criteria for classification as an SAE or caused the participant to discontinue the study intervention (see Section 7.1).

During the active collection period as described in Section 8.3.1, each participant will be questioned about the occurrence of AEs in a nonleading manner.

In addition, the investigator may be requested by Pfizer Safety to obtain specific follow-up information in an expedited fashion.

8.3.1. Time Period and Frequency for Collecting AE and SAE Information

The time period for actively eliciting and collecting AEs and SAEs (“active collection period”) for each participant begins from the time the participant provides informed consent, which is obtained before the participant’s participation in the study (ie, before undergoing any study-related procedure and/or receiving study intervention), through and including a minimum of 28 calendar days, except as indicated below, after the last administration of the study intervention.

Follow-up by the investigator continues throughout and after the active collection period and until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the investigator.

For participants who are screen failures, the active collection period ends when screen failure status is determined.

If the participant withdraws from the study and also withdraws consent for the collection of future information, the active collection period ends when consent is withdrawn.

If a participant permanently discontinues or temporarily discontinues study intervention because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE reported using the CT SAE Report Form.

After the defined active collection period, participants are contacted by phone for a vital status check at Week 12 and Week 24 (long-term follow-up period). Any SAE identified during this follow-up period and determined to be related to PF-07321332/ritonavir is reported to Pfizer Safety on the CT SAE Report Form immediately upon awareness and under no circumstance should this exceed 24 hours, as indicated in [Appendix 3](#). Investigators are not otherwise obligated to report AEs after the defined active collection period.

Investigators are not obligated to actively seek information on AEs or SAEs after the participant has concluded study participation. However, if the investigator learns of any SAE, including a death, at any time after a participant has completed the study, and he/she considers the event to be reasonably related to the study intervention, the investigator must promptly report the SAE to Pfizer using the CT SAE Report Form.

8.3.1.1. Reporting SAEs to Pfizer Safety

All SAEs occurring in a participant during the active collection period as described in Section 8.3.1 are reported to Pfizer Safety on the CT SAE Report Form immediately upon awareness and under no circumstance should this exceed 24 hours, as indicated in [Appendix 3](#). The investigator will submit any updated SAE data to the sponsor within 24 hours of it being available.

8.3.1.2. Recording Nonserious AEs and SAEs on the CRF

All nonserious AEs and SAEs occurring in a participant during the active collection period, which begins after obtaining informed consent as described in Section 8.3.1, will be recorded on the AE section of the CRF.

The investigator is to record on the CRF all directly observed and all spontaneously reported AEs and SAEs reported by the participant.

8.3.2. Method of Detecting AEs and SAEs

The method of recording, evaluating, and assessing causality of AEs and SAEs and the procedures for completing and transmitting SAE reports are provided in [Appendix 3](#).

Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrences.

8.3.3. Follow-Up of AEs and SAEs

After the initial AE or SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts. For each event, the investigator must pursue and obtain adequate information until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3).

In general, follow-up information will include a description of the event in sufficient detail to allow for a complete medical assessment of the case and independent determination of possible causality. Any information relevant to the event, such as concomitant medications and illnesses, must be provided. In the case of a participant death, a summary of available autopsy findings must be submitted as soon as possible to Pfizer Safety.

Further information on follow-up procedures is given in [Appendix 3](#).

8.3.4. Regulatory Reporting Requirements for SAEs

Prompt notification by the investigator to the sponsor of an SAE is essential so that legal obligations and ethical responsibilities toward the safety of participants and the safety of a study intervention under clinical investigation are met.

The sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The

sponsor will comply with country-specific regulatory requirements relating to safety reporting to the regulatory authority, IRBs/ECs, and investigators.

Investigator safety reports must be prepared for SUSARs according to local regulatory requirements and sponsor policy and forwarded to investigators as necessary.

An investigator who receives SUSARs or other specific safety information (eg, summary or listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the study and will notify the IRB/EC, if appropriate according to local requirements.

8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and Occupational Exposure

Environmental exposure, occurs when a person not enrolled in the study as a participant receives unplanned direct contact with or exposure to the study intervention. Such exposure may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental exposure include healthcare providers, family members, and others who may be exposed. An environmental exposure may include exposure during pregnancy, exposure during breastfeeding, and occupational exposure.

Any such exposure to the study intervention under study are reportable to Pfizer Safety within 24 hours of investigator awareness.

8.3.5.1. Exposure During Pregnancy

An EDP occurs if:

- A female participant is found to be pregnant while receiving or after discontinuing study intervention.
- A male participant who is receiving or has discontinued study intervention exposes a female partner prior to or around the time of conception.
- A female is found to be pregnant while being exposed or having been exposed to study intervention due to environmental exposure. Below are examples of environmental EDP:
 - A female family member or healthcare provider reports that she is pregnant after having been exposed to the study intervention by ingestion.
 - A male family member or healthcare provider who has been exposed to the study intervention by ingestion then exposes his female partner prior to or around the time of conception.

The investigator must report EDP to Pfizer Safety within 24 hours of the investigator's awareness, irrespective of whether an SAE has occurred. The initial information submitted should include the anticipated date of delivery (see below for information related to termination of pregnancy).

- If EDP occurs in a participant or a participant's partner, the investigator must report this information to Pfizer Safety on the CT SAE Report Form and an EDP Supplemental Form, regardless of whether an SAE has occurred. Details of the pregnancy will be collected after the start of study intervention and until a minimum of 28 calendar days after the last administration of study intervention,
- If EDP occurs in the setting of environmental exposure, the investigator must report information to Pfizer Safety using the CT SAE Report Form and EDP Supplemental Form. Since the exposure information does not pertain to the participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form is maintained in the investigator site file.

Follow-up is conducted to obtain general information on the pregnancy and its outcome for all EDP reports with an unknown outcome. The investigator will follow the pregnancy until completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a follow-up to the initial EDP Supplemental Form. In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth. In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by gross visual inspection (unless preprocedure test findings are conclusive for a congenital anomaly and the findings are reported).

Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly in a live-born baby, a terminated fetus, an intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures for reporting SAEs. Additional information about pregnancy outcomes that are reported to Pfizer Safety as SAEs follows:

- Spontaneous abortion including miscarriage and missed abortion;
- Neonatal deaths that occur within 1 month of birth should be reported, without regard to causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs when the investigator assesses the infant death as related or possibly related to exposure to the study intervention.

Additional information regarding the EDP may be requested by the sponsor. Further follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on preterm infants to identify developmental delays). In the case of paternal exposure, the investigator will provide the participant with the Pregnant Partner Release of Information Form to deliver to his partner. The investigator must document in the source documents that the participant was given the Pregnant Partner Release of Information Form to provide to his partner.

8.3.5.2. Exposure During Breastfeeding

An exposure during breastfeeding occurs if:

- A female participant is found to be breastfeeding while receiving or after discontinuing study intervention.
- A female is found to be breastfeeding while being exposed or having been exposed to study intervention (ie, environmental exposure). An example of environmental exposure during breastfeeding is a female family member or healthcare provider who reports that she is breastfeeding after having been exposed to the study intervention by ingestion.

The investigator must report exposure during breastfeeding to Pfizer Safety within 24 hours of the investigator's awareness, irrespective of whether an SAE has occurred. The information must be reported using the CT SAE Report Form. When exposure during breastfeeding occurs in the setting of environmental exposure, the exposure information does not pertain to the participant enrolled in the study, so the information is not recorded on a CRF. However, a copy of the completed CT SAE Report Form is maintained in the investigator site file.

An exposure during breastfeeding report is not created when a Pfizer drug specifically approved for use in breastfeeding women (eg, vitamins) is administered in accord with authorized use. However, if the infant experiences an SAE associated with such a drug, the SAE is reported together with the exposure during breastfeeding.

8.3.5.3. Occupational Exposure

The investigator must report any instance of occupational exposure to Pfizer Safety within 24 hours of the investigator's awareness using the CT SAE Report Form, regardless of whether there is an associated SAE. Since the information about the occupational exposure does not pertain to a participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form must be maintained in the investigator site file.

8.3.6. Cardiovascular and Death Events

Not applicable.

8.3.7. Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs or SAEs

Not applicable.

8.3.8. Adverse Events of Special Interest

Adverse events of special interest (AESIs) are examined as part of routine safety data review procedures throughout the clinical trial and as part of signal detection processes.

AESIs include hemodynamic events, inflammatory events, and thyroid-related events.

All AESIs must be reported as an AE or SAE following the procedures described in Section 8.3.1 through 8.3.4. An AESI is to be recorded as an AE or SAE on the CRF. In addition, an AESI that is also an SAE must be reported using the CT SAE Report Form.

8.3.8.1. Lack of Efficacy

The investigator must report signs, symptoms, and/or clinical sequelae resulting from lack of efficacy. Lack of efficacy or failure of expected pharmacological action is reportable to Pfizer Safety **only if associated with an SAE**.

8.3.9. Medical Device Deficiencies

Not applicable.

8.3.10. Medication Errors

Medication errors may result from the administration or consumption of the study intervention by the wrong participant, or at the wrong time, or at the wrong dosage strength.

Exposures to the study intervention under study may occur in clinical trial settings, such as medication errors.

Safety Event	Recorded on the CRF	Reported on the CT SAE Report Form to Pfizer Safety Within 24 Hours of Awareness
Medication errors	All (regardless of whether associated with an AE)	Only if associated with an SAE

Medication errors include:

- Medication errors involving participant exposure to the study intervention;
- Potential medication errors or uses outside of what is foreseen in the protocol that do or do not involve the study participant;
- The administration of expired study intervention;
- The administration of an incorrect study intervention;
- The administration of an incorrect dosage;
- The administration of study intervention that has undergone temperature excursion from the specified storage range, unless it is determined by the sponsor that the study intervention under question is acceptable for use;
- The administration of study intervention consistent with the medication error descriptions in Section 6.4.

Such medication errors occurring to a study participant are to be captured on the medication error page of the CRF, which is a specific version of the AE page.

In the event of a medication dosing error, the sponsor should be notified within 24 hours.

Whether or not the medication error is accompanied by an AE, as determined by the investigator, the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the CRF.

Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report Form **only when associated with an SAE**.

8.4. Pharmacokinetics

Blood samples of approximately 4 mL, to provide a minimum of 1.5 mL plasma, will be collected for measurement of plasma concentrations of PF-07321332 as specified in the [SoA](#). In a subset of participants, additional optional PK samples may be collected via home health visit, in-clinic visits, or self-collected whole blood microsample (Tasso device) to measure concentrations of PF-07321332. Instructions for the collection and handling of biological samples will be provided in the laboratory manual or by the sponsor. The actual date and time (24-hour clock time) of each sample will be recorded.

The actual times may change, but the number of samples will remain the same. All efforts will be made to obtain the samples at the exact nominal time relative to dosing. Collection of samples obtained ≤ 1 hour outside the scheduled nominal sampling time windows will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and the CRF. This protocol deviation does not apply to samples that are specified to be collected “at any time”.

Samples will be used to evaluate the PK of PF-07321332. Samples collected for analyses of PF-07321332 concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method, or for research related to the study intervention(s) and COVID-19. Samples may also be used to evaluate the concentration of ritonavir.

Genetic analyses will not be performed on these plasma samples unless consent for this was included in the informed consent. Participant confidentiality will be maintained.

Samples collected for measurement of plasma concentrations of study intervention will be analyzed using a validated analytical method in compliance with applicable SOPs. Potential metabolites may be analyzed with either validated or exploratory methods.

The PK samples must be processed and shipped as indicated in the instructions provided to the investigator site to maintain sample integrity. Any deviations from the PK sample handling procedure (eg, sample collection and processing steps, interim storage or shipping conditions), including any actions taken, must be documented and reported to the sponsor.

On a case-by-case basis, the sponsor may make a determination as to whether sample integrity has been compromised.

Drug concentration information that would unblind the study will not be reported to investigator sites or blinded personnel until the study has been unblinded.

Any changes in the timing or addition of time points for any planned study assessments must be documented and approved by the relevant study team member and then archived in the sponsor and site study files, but will not constitute a protocol amendment. The IRB/EC will be informed of any safety issues that require alteration of the safety monitoring scheme or amendment of the ICD.

8.5. Genetics

8.5.1. Specified Genetics

Genetics (specified analyses) are not evaluated in this study.

CCI [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

8.6. Biomarkers

Collection of samples for biomarker research is also part of this study.

The following samples for biomarker research are required and will be collected from all participants in this study as specified in the [SoA](#):

- NP/nasal swab will be collected to measure SARS CoV-2 viral load by RT-PCR.
- Residual NP/nasal viral load samples may be used for SARS CoV-2 viral sequencing.
- Residual NP/nasal viral load samples may be used for SARS CoV-2 infectivity assays and phenotypic analyses.

CCI [REDACTED]

8.6.1. Specified Gene Expression (RNA) Research

Specified gene expression (RNA) research is not included in this study.

CCI [REDACTED]

8.6.3. Specified Metabolomic Research

Specified metabolomic research is not included in this study.

8.6.4. Viral Load Assessments

An NP/nasal swab will be collected per the [SoA](#), and may be analyzed to measure SARS-CoV-2 RNA by RT-PCR. Residual viral load samples may be utilized for viral sequencing to assess for signs of viral evolution and evaluation of potential genetic viral variants (eg, 3CL gene) or immune responses, SARS CoV-2 infectivity assays, and additional molecular analysis.

Residuals of all samples may be banked for future research. Storage and shipping instructions will be in accordance with the laboratory manual.

CCI [REDACTED]

8.7. Immunogenicity Assessments

Immunogenicity assessments are not included in this study.

8.8. Health Economics

Health economics/medical resource utilization and health economics parameters will be evaluated in this study (Section [8.1.2.](#) and Section [8.1.3.](#)).

9. STATISTICAL CONSIDERATIONS

Detailed methodology for summary and statistical analyses of the data collected in this study are outlined here and further detailed in a SAP, which will be maintained by the sponsor. The

SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.

9.1. Statistical Hypotheses

The primary hypothesis to be tested is whether or not there is a difference in median time (days) to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo. The statistical hypothesis is as follows:

- The null hypothesis (H_0) is that there is no difference in median time to sustained alleviation of targeted symptoms of COVID-19 between PF-07321332/ritonavir and placebo;
- The alternative hypothesis (H_1) is that there is a difference in median time to sustained alleviation of targeted symptoms of COVID-19 between PF-07321332/ritonavir and placebo.

Because the prespecified 45% interim analysis of the primary endpoint was not met, the following secondary endpoints will be analyzed to provide a point estimate and 95% CI to measure associated variability. The analysis will be performed with a nominal alpha:

- 1) Proportion of participants with COVID-19-related hospitalization or death from any cause through Day 28.
- 2) Number of COVID-19-related medical visits through Day 28.

In support of the COVID-19 related medical visits endpoint, the number of days in hospital and ICU stay in patients with COVID-19-related hospitalization through Day 28 will be summarized.

Other secondary endpoints, which will be identified in the SAP, will be subsequently tested following the Hochberg procedure.⁴¹

Imputation of missing data within other specific efficacy variables and endpoints will be computed according to the rules specified in the SAP.

9.1.1. Estimands

9.1.1.1. Primary Estimand/Co-Primary Estimands

The primary estimand is the difference in median time (days) to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease at baseline and were treated ≤ 5 days after COVID-19 symptom onset. This will be estimated irrespective of adherence to randomized treatment. Because the study did not meet the primary endpoint based on the interim analysis at 45%, all hypothesis assessments are done with a nominal alpha.

9.1.1.2. Secondary Estimands

The estimands associated with the secondary objectives are as follows:

- The difference in proportions of patients experiencing COVID-19 related hospitalization or death from any cause through Day 28 in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease and were treated ≤ 5 days after COVID-19 symptom onset. This will be estimated without regard to adherence to randomized treatment.
- The difference in the estimated rate of the number of COVID-19-related medical visits through Day 28 in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease and were treated ≤ 5 days after COVID-19 symptom onset. This will be estimated without regard to adherence to randomized treatment.
- The difference in the estimated rate of number of days in hospital and ICU stay in patients with COVID-19 related hospitalization through Day 28 in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease and were treated ≤ 5 days after COVID-19 symptom onset. This will be estimated without regard to adherence to randomized treatment.

Estimands for the other outcome measures are not presented.

9.2. Analysis Sets

For purposes of analysis, the following analysis sets are defined:

Participant Analysis Set	Description
Full Analysis Set (FAS)	All participants randomly assigned to study intervention regardless of whether or not study intervention was administered.
Safety Analysis Set (SAS)	All participants randomly assigned to study intervention and who take at least 1 dose of study intervention. Participants will be analyzed according to the study intervention they received. A randomized but not treated participant will be excluded from the safety analyses.
Modified Intent -To-Treat (mITT)	All participants randomly assigned to study intervention who take at least 1 dose of study intervention and with at least 1 postbaseline visit through Day 28 who were treated ≤ 3 days after COVID-19 symptom onset. Participants will be analyzed according to the study intervention to which they were randomized.
Modified Intent -To-Treat 1 (mITT1)	All participants randomly assigned to study intervention, who take at least 1 dose of study intervention. Participants will be analyzed according to the study intervention to which they were randomized.
Per-Protocol (PP)	All participants in the mITT1 set without major protocol violations considered to impact the interpretation of the primary efficacy endpoint. Protocol deviations will be reviewed to generate the list of participants with significant deviations to be excluded from the PP analysis set. The PP exclusion criteria will be finalized prior to breaking the blind.

Both the mITT1 and PP analysis sets will be used in the analyses of the primary efficacy endpoint, with the mITT1 being primary. For proportion of COVID-19-related hospitalization or death from any cause endpoint, mITT1 will be used. For all other efficacy analysis, the mITT1 analysis set will be used, as defined in the SAP. The Safety Analysis Set will be used in the analyses of the safety data.

9.3. Statistical Analyses

The SAP will be developed and finalized before any analyses are performed and will describe the analyses and procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary and secondary endpoints.

9.3.1. General Considerations

Descriptive statistics for all efficacy endpoints by treatment group and visit will be provided.

The number of participants screened will be reported. The number of participants randomized to the double-blind treatment phase, completing the study drug administration, completing the study, and discontinued the study will be summarized from the FAS analysis set for each treatment group.

Baseline demographic and other characteristics will be tabulated for the FAS analysis set and summarized by treatment group. Quantitative variables will be described by standard descriptive statistics (mean, standard deviation, minimum, and maximum), and qualitative variables will be summarized by frequency tables with number and proportion in each category (with the corresponding sample sizes).

For continuous endpoints, MMRM analysis of covariance model will be used to analyze change from baseline over time. Estimated mean differences between treatments and their respective 95% CI and p-values will be calculated.

Binary endpoints will be summarized with the number and percent of participants satisfying the endpoint. Comparisons between groups will be presented as odds ratios with 95% confidence intervals based on logistic regression analysis with terms for treatment.

For categorical endpoints, proportion of participant for each category will be summarized for each group.

For count endpoints, the total number of the events and average number of events will be summarized for each group.

Time-to-event endpoints will be summarized with Kaplan-Meier curves. Log-rank test will be used to compare the median time-to-event between the treatment group. Rate ratios or hazard ratios and the associated 95% 2-sided CIs will be estimated by Cox proportional hazards models, including treatment and the strata as covariate.

9.3.2. Primary Endpoint(s)/Estimand(s) Analysis

The primary efficacy analysis will be conducted using the mITT1 population.

The primary endpoint, time to sustained alleviation of all targeted COVID-19 signs/symptoms through Day 28, is defined as time (days) from start of study intervention or placebo (Day 1) until sustained alleviation of all targeted COVID-19 associated signs/symptoms.

Sustained alleviation of all targeted COVID-19 signs/symptoms is defined as the event occurring on the first of 4 consecutive days when all symptoms scored as moderate or severe at study entry are scored as mild or absent AND all symptoms scored mild or absent at study entry are scored as absent. Missing severity at baseline will be treated as mild.

CCI



Participants who are hospitalized/dead due to COVID-19 will be considered to have 1 or more targeted symptoms not absent for the duration of the hospitalization.

The time to sustained symptom alleviation for the purpose of this study is defined as:

- For a participant with sustained symptom alleviation (event), time-to-event will be calculated as (First Event Date) – (First Dose Date) +1.
- For a participant that either completes Day 28 of the study or discontinues from the study before Day 28 without sustained symptom alleviation/resolution (censored), censoring date will be at the last date on which symptom alleviation/resolution is assessed, and time will be calculated as (Censoring Date) – (First Dose Date) +1 or Day 25 whichever occurs first
- The primary estimand is the difference in median time (days) to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease at baseline and were treated ≤ 3 days after COVID-19 symptom onset. This will be estimated irrespective of adherence to randomized treatment.

Time to sustained alleviation of all targeted COVID-19 signs/symptoms will be summarized with Kaplan-Meier curves. Log-rank test will be used to compare the difference in time (days) to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between treatment groups.

9.3.2.1. Supplemental Analyses

- The primary efficacy analyses will also be conducted using the PP population as supplemental analysis;
- The primary endpoint will also be analyzed in which participants who discontinued the study before Day 28 without event will be censored at Day 25.
- To support the analysis of primary endpoint, Cox proportion hazard models with terms including treatment and treatment strata as factor will be used to estimate the hazard ratio (the ratio of alleviation of all targeted signs and symptoms) and its 95% CI. Analyses will be fitted to proportion of participants who achieved sustained alleviation of all targeted COVID-19 signs/symptoms (proportion of events) and will include treatment and effect based on investigator site as independent variables (p-values will be reported from main model). Additional analyses may be performed

adjusting for baseline covariates (such as age, gender, vaccination status, etc) as additive terms to the primary model, if necessary.

9.3.3. Secondary Endpoint(s)/Estimand(s) Analysis

Proportion of participants with COVID-19 related hospitalization or death from any cause through Day 28

The estimand for proportion of participants experiencing COVID 19 related hospitalization or death from any cause through Day 28 is the difference in proportions of patients experiencing COVID-19-related hospitalization or death from any cause through Day 28 in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe disease and were treated ≤ 5 days after COVID-19 symptom onset. This will be estimated irrespective of adherence to randomized treatment.

The statistical methodology for proportion of participants with COVID-19 related hospitalization or death from any cause through Day 28 will be as follows:

The cumulative proportion of participants hospitalized for the treatment of COVID-19 or death during the first 28 days of the study will be estimated for each treatment group using the Kaplan-Meier method to include all participants and summarized graphically for each treatment group. The estimand is the difference of the proportions in the 2 groups. The 95% CI will be presented together with the associated Wald Test results. For the 95% CI, the corresponding estimate of the standard error is computed using Greenwood's formula.⁴² The Greenwood's formula to estimate the variance of the difference of proportions at Day 28 is $[\text{Var}(S_{\text{PF}}(28)) + \text{Var}(S_{\text{Placebo}}(28))]$. Instead of dealing with $S(t_i)$ the log-log approach to CI will be used. The 95% CI will be computed for the estimate of $L(t) = \log(\log(S(t)))$, the log hazard function.

The CI will be in the right range when transformed back to $S(t) = \exp(-\exp(L(t)))$. Antilogging this CI will give a 95% confidence interval for the difference itself.

For participants with missing data due to lost to follow up, for COVID-19-related hospitalization or death from any cause, a sensitivity analysis will implement the following event imputation methodology for those with missing data:

- If the participant's last observed data is prior to Day 21, then impute as an event with event day as day of last observed data +1.
- If the participant's last observed data is on or after Day 21, then no imputation for an event will be done and participant remains censored at day of last observed data.

Number of COVID-19-related medical visits through Day 28

The estimand for the number of COVID-19-related medical visits through Day 28 is the difference in estimated rate of number of COVID-19 related medical visits through Day 28 in nonhospitalized adult patients with COVID-19 who are at low risk of progression to severe

disease and were treated ≤ 5 days after COVID-19 symptom onset. This will be estimated without regard to adherence to randomized treatment.

The statistical methodology for this endpoint will be as follows:

The number of COVID-19 related medical visits will be analyzed with a negative-binomial regression model, using the log-total number of days of data collection as the participant offset variable. The resulting analysis will provide the estimated difference in rate of medical visits between treatment groups and the associated 95% CI.

Number of days in hospital and ICU stay in participants with COVID-19-related hospitalization through Day 28

Summary statistics for this endpoint will be provided in support of the number of COVID-19-related medical visits through Day 28.

Details on the definitions and analyses of the following secondary endpoints will be described in the SAP.

- Time (days) to sustained resolution of all targeted COVID-19 signs/symptoms through Day 28.
- Proportion of participants with severe signs/symptoms attributed to COVID-19 through Day 28.
- Duration of each targeted COVID-19 sign/symptom.
- Progression to a worsening status in 1 or more self-reported COVID-19 associated symptoms through Day 28.
- Proportion of participants with a resting peripheral oxygen saturation $\geq 95\%$ at Days 1 and 5.
- Proportion of participants with death (all cause) through Week 24.
- PF-07321332 PK in plasma and whole blood (if feasible).
- Viral titers measured via RT-PCR in nasal swabs over time.

CCI

9.3.5. Other Safety Analyses

Safety analyses will be carried out for the Safety population.

The safety assessments include AEs, laboratory assessments, physical examinations, vital signs and persistent symptoms of COVID-19.

No formal statistical analysis will be conducted on any of the other safety data listed above.

9.3.5.1. Laboratory Test Results

All clinical laboratory data will be subjected to clinical review, summarized by frequency of events and mean changes from baseline.

9.3.5.2. Physical Examination and Vital Signs

All physical examination and vitals will be descriptively summarized by treatment group.

9.3.5.3. Persistent Symptoms of COVID-19

The proportion of participants with persistent symptoms of COVID-19 will be summarized at Week 12 and Week 24 in participants who had at least 1 symptom present on the last day the symptom diary was completed (eg, Day 28).

CCI [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

9.3.6.1. PK Analyses

PK samples will be collected on Days 1 and 5, per [SoA](#). Additional PK sampling may be collected in a subset of participants via home health, site visit, or self-collected using Tasso, if feasible. Descriptive statistics and graphical summaries of PF-07321332 concentrations will be generated. Ritonavir concentrations may also be reported. PK data from this study may be combined with other studies and analyzed using population PK approaches. Results from any population PK analyses will be reported outside of the clinical study report.

9.4. Interim Analyses

There will be 3 interim analyses as follows:

First interim analysis (45% planned enrollment through Protocol Amendment 4): An interim analysis was conducted for efficacy, futility and sample size re-estimation, and reviewed by an independent E-DMC after a prespecified accrual of participants (ie, approximately 45% overall participants of the initial projected enrollment of 1140 participants completed Day 28

efficacy assessment in the mITT analysis set), according to the SAP and E-DMC charter. The sample size can be increased one time and the increase is limited to 30 to 35%. A well-established method described by Cui, Hung, and Wang (1999) (implemented in EAST 6.5) will be used to control the Type I error probability.^{43,44} Details will be pre-specified in the interim analysis plan and/or E-DMC charter.

The nominal significance level for the interim and final time to sustained alleviation of all targeted COVID-19 signs/symptoms analyses is determined by means of the Lan-DeMets procedure with an O'Brien-Fleming stopping boundary, with an overall 2-sided type I error rate of 5%.

O'Brien-Fleming approach will be used for decision making, ie, reject H_0 with 2-sided p-value ≤ 0.002 , or reject H_1 with 2-sided p-value > 0.924 at the interim analysis. At the final analysis, the p-value for rejecting H_0 will be ≤ 0.049 (2-sided) or reject H_1 with 2-sided p-value > 0.049 will be considered. The actual stopping boundaries will depend on the exact timing of the interim analysis.

Before any interim analysis is performed, the details of the objectives, decision criteria, dissemination plan, and method of maintaining the study blind as per Pfizer's SOPs will be documented and approved in an E-DMC charter. In addition, the analysis details will be documented and approved in the SAP.

The first interim analysis (45% planned enrollment through Protocol Amendment 4) summarized above was performed as described.

Second interim analysis (80% planned enrollment through Protocol Amendment 4): Upon review of the 45% analysis, the E-DMC requested the Sponsor to consider appropriate course of action for the ongoing trial to assess the clinical benefit. In order to respond properly to fulfill the E-DMC recommendation, the RRP decided that a second interim analysis should be conducted to address the E-DMC's request. This resulted in the analysis of 80% of enrolled participants through protocol amendment 4, without any adjustment to the alpha.

Third interim analysis (100% planned enrollment through Protocol Amendment 4): A third interim analysis was completed on enrolled participants who had risk factors for severe COVID-19 illness (ie, vaccinated against the SARS-CoV-2 virus) as well as participants who did not have risk factors for severe COVID-19 illness (ie, not vaccinated). Data from the study are required to support regulatory submissions thereby necessitating an interim analysis utilizing the 19 December 2021 dataset. This dataset had not been analyzed previously because the protocol was amended to increase the sample size and extend enrollment to assess the potential benefit of participants at low risk of progression to severe COVID-19 in the clinically relevant endpoint of hospitalization or death (Protocol Amendment 5, 21 January 2022). The participants who were vaccinated are considered the high risk population and the unvaccinated participants are considered standard risk in the statistical analysis.

There was no adjustment for alpha for this third interim analysis. Nominal p-values will be reported. This third interim analysis did not include any data from participants who entered the study under Protocol Amendment 5.

Before the third interim analysis was performed, the details of the objectives, dissemination plan, method of maintaining the study blind, and the analysis details as per Pfizer's SOPs will be documented and approved in the interim CSR analysis plan.

9.5. Sample Size Determination

The initial estimate of required sample size was based on the primary endpoint, the difference in time to sustained alleviation of all targeted COVID-19 associated signs/symptoms between participants who were treated ≤ 3 days after COVID-19 symptom onset, treated with PF-07321332/ritonavir compared to placebo. The sample size was calculated based on a 2-sample test-parallel design–log-rank test, assuming a 90% power, 2-sided test at $\alpha = 0.05$, approximate accrual rate of 30 participants per day, 2 days difference in the median days to sustained alleviation of all targeted COVID-19-associated symptoms (6 days for PF-07321332/ritonavir and 8 days for placebo ie, a 25% reduction in time to sustained alleviation of all targeted COVID-19 signs/symptoms) based on the Lilly-BLAZE-1¹ and assuming a 18% study discontinuation rate, the sample size of approximately 800 participants (approximately 515 events) will provide 90% power to detect that difference. Allowing for approximately 30% of participants with COVID-19 symptom onset > 3 days, a sample size of approximately 1140 participants were to be enrolled for this study.

After the second interim analysis (80% planned enrollment through Protocol Amendment 4), in order to improve estimation precision of the treatment effect in the clinically relevant key secondary endpoint of COVID-19-related hospitalization or death from any cause, the sample size was adjusted to approximately 1880 participants. This adjustment is expected to provide the required total number of 26 COVID-19-related hospitalizations or death from any cause, which will have approximately 90% conditional power (based on the second interim analysis data) such that the nominal 95% CI of the treatment group difference in the event rate does not include 0 when assuming that PF-07321332/ritonavir reduces the event rate by 70% or more relative to placebo.

The sample size increase of 740 participants is based on the assumption of a 1.5% event rate for the targeted enrollment countries. The number of participants is approximately 1880 (1140 enrolled participants plus the increase of 740 participants). Assuming a 5% premature study discontinuation rate, approximately 1980 participants will be enrolled in the study.

10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS

10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations

10.1.1. Regulatory and Ethical Considerations

This study will be conducted in accordance with the protocol and with the following:

- Consensus ethical principles derived from international guidelines, including the Declaration of Helsinki and CIOMS International Ethical Guidelines;
- Applicable ICH GCP guidelines;
- Applicable laws and regulations, including applicable privacy laws.

The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents (eg, advertisements) must be reviewed and approved by the sponsor, submitted to an IRB/EC by the investigator, and reviewed and approved by the IRB/EC before the study is initiated.

Any amendments to the protocol will require IRB/EC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.

Protocols and any substantial amendments to the protocol will require health authority approval prior to initiation except for changes necessary to eliminate an immediate hazard to study participants.

The investigator will be responsible for the following:

- Providing written summaries of the status of the study to the IRB/EC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/EC;
- Notifying the IRB/EC of SAEs or other significant safety findings as required by IRB/EC procedures;
- Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH GCP guidelines, the IRB/EC, European regulation 536/2014 for clinical studies (if applicable), European Medical Device Regulation 2017/745 for clinical device research (if applicable), and all other applicable local regulations.

10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP

In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable regulatory authority in any area of the world, or if the investigator is aware of any new information that might influence the evaluation of the benefits and risks of the study intervention, Pfizer should be informed immediately.

In addition, the investigator will inform Pfizer immediately of any urgent safety measures taken by the investigator to protect the study participants against any immediate hazard, and of any serious breaches of this protocol or of the ICH GCP guidelines that the investigator becomes aware of.

10.1.2. Financial Disclosure

Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial information as requested to allow the sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study.

10.1.3. Informed Consent Process

The investigator or his/her representative will explain the nature of the study, including the risks and benefits, to the participant or his/her legally authorized representative and answer all questions regarding the study. The participant or his/her legally authorized representative should be given sufficient time and opportunity to ask questions and to decide whether or not to participate in the trial.

Participants must be informed that their participation is voluntary. Participants or their legally authorized representative will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, privacy and data protection requirements, where applicable, and the IRB/EC or study center.

The investigator must ensure that each study participant or his or her legally authorized representative is fully informed about the nature and objectives of the study, the sharing of data related to the study, and possible risks associated with participation, including the risks associated with the processing of the participant's personal data.

The participant or his or her legally authorized representative must be informed that his/her personal study-related data will be used by the sponsor in accordance with local data protection law. The level of disclosure must also be explained to the participant or his or her legally authorized representative.

The participant or his or her legally authorized representative must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the sponsor, by appropriate IRB/EC members, and by inspectors from regulatory authorities.

The investigator further must ensure that each study participant or his or her legally authorized representative is fully informed about his or her right to access and correct his or her personal data and to withdraw consent for the processing of his or her personal data.

The medical record must include a statement that written informed consent was obtained before the participant was enrolled in the study and the date on which the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICD.

Participants or his or her legally authorized representative must be reconsented to the most current version of the ICD(s) during their participation in the study.

A copy of the ICD(s) must be provided to the participant or the participant's legally authorized representative.

10.1.4. Data Protection

All parties will comply with all applicable laws, including laws regarding the implementation of organizational and technical measures to ensure protection of participant data.

Participants' personal data will be stored at the study site in encrypted electronic form and will be password-protected to ensure that only authorized study staff have access. The study site will implement appropriate technical and organizational measures to ensure that the personal data can be recovered in the event of disaster. In the event of a potential personal data breach, the study site will be responsible for determining whether a personal data breach has in fact occurred and, if so, providing breach notifications as required by law.

To protect the rights and freedoms of participants with regard to the processing of personal data, participants will be assigned a single, participant-specific numerical code. Any participant records or data sets that are transferred to the sponsor will contain the numerical code; participant names will not be transferred. All other identifiable data transferred to the sponsor will be identified by this single, participant-specific code. The study site will maintain a confidential list of participants who participated in the study, linking each participant's numerical code to his or her actual identity and medical record ID. In case of data transfer, the sponsor will protect the confidentiality of participants' personal data consistent with the clinical study agreement and applicable privacy laws.

10.1.5. Committees Structure

10.1.5.1. Data Monitoring Committee

This study will use a E-DMC. The E-DMC is independent of the study team and includes only external members. The E-DMC charter describes the role of the E-DMC in more detail.

The E-DMC will be responsible for ongoing monitoring of the efficacy and safety of participants in the study according to the charter. The recommendations made by the E-DMC will be forwarded to the appropriate authorized Pfizer personnel for review and final decision. Pfizer will communicate such decisions, which may include summaries of aggregate analyses of safety data to regulatory authorities, investigators, as appropriate.

The E-DMC will review unblinded data to ensure the safety of participants throughout the duration of the study. In addition to up to weekly reviews of safety, the E-DMC will review the following:

- Sentinel cohort safety review: The E-DMC will review unblinded safety data after approximately the first 100 randomized participants have completed through Day 10. Whether enrollment is paused for this review will depend on the successful completion of

the Study C4671005 sentinel cohort (after approximately the first 60 randomized participants have completed through Day 10). If the Study C4671005 sentinel cohort safety review has successfully completed and no clinically significant safety signals have been identified prior to enrollment of the first 100 participants in this Study C4671002, the study will continue without pause. Otherwise, enrollment of Study C4671002 will be paused pending the E-DMC review of safety data. After review of the sentinel cohort in this Study C4671002, the frequency of safety reviews may be reduced subsequently based on E-DMC recommendations.

- Proof-of-concept assessment: Viral load data when 25% (approximately 200 participants in the primary analysis set with evaluable data) complete the Day 5 assessments. Enrollment will not be paused during review of these data, but may be paused or stopped following E-DMC review.
- First interim analysis (45% planned enrollment through Protocol Amendment 4): A planned interim analysis for efficacy, futility and sample size reestimation was conducted after approximately 45% of participants completed the Day 28 assessments in the mITT analysis set.
- Second interim analysis (80% planned enrollment through Protocol Amendment 4): At the request of the E-DMC, a second interim analysis was conducted on 80% of enrolled participants without any adjustment to the alpha.

The E-DMC will review all deaths that occur during the study. A pause in enrollment pending E-DMC review will occur if 2 participants experience a Grade 4 or higher AE that is deemed related to study intervention as determined by the investigator and if the sponsor agrees.

Details of the E-DMC are specified in the E-DMC Charter.

10.1.6. Dissemination of Clinical Study Data

Pfizer fulfills its commitment to publicly disclose clinical study results through posting the results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or www.pfizer.com, and other public registries in accordance with applicable local laws/regulations. In addition, Pfizer reports study results outside of the requirements of local laws/regulations pursuant to its SOPs.

In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and complete manner and are reported regardless of the outcome of the study or the country in which the study was conducted.

www.clinicaltrials.gov

Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer-sponsored interventional studies (conducted in patients) that evaluate the safety and/or efficacy of a product,

regardless of the geographical location in which the study is conducted. These results are submitted for posting in accordance with the format and timelines set forth by US law.

EudraCT

Pfizer posts clinical trial results on EudraCT for Pfizer-sponsored interventional studies in accordance with the format and timelines set forth by EU requirements.

www.pfizer.com

Pfizer posts public disclosure synopses (CSR synopses in which any data that could be used to identify individual participants have been removed) on www.pfizer.com for Pfizer-sponsored interventional studies at the same time the corresponding study results are posted to www.clinicaltrials.gov.

Documents within marketing authorization packages/submissions

Pfizer complies with the European Union Policy 0070, the proactive publication of clinical data to the EMA website. Clinical data, under Phase 1 of this policy, includes clinical overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this policy, includes the publishing of individual participant data. Policy 0070 applies to new marketing authorization applications submitted via the centralized procedure since 01 January 2015 and applications for line extensions and for new indications submitted via the centralized procedure since 01 July 2015.

Data sharing

Pfizer provides researchers secure access to patient-level data or full CSRs for the purposes of “bonafide scientific research” that contributes to the scientific understanding of the disease, target, or compound class. Pfizer will make data from these trials available 24 months after study completion. Patient-level data will be anonymized in accordance with applicable privacy laws and regulations. CSRs will have personally identifiable information redacted.

Data requests are considered from qualified researchers with the appropriate competencies to perform the proposed analyses. Research teams must include a biostatistician. Data will not be provided to applicants with significant conflicts of interest, including individuals requesting access for commercial/competitive or legal purposes.

10.1.7. Data Quality Assurance

All participant data relating to the study will be recorded on printed or electronic CRF unless transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is responsible for verifying that data entries are accurate and correct by physically or electronically signing the CRF.

Guidance on completion of CRFs will be provided in the CRF Completion Requirements document.

The investigator must ensure that the CRFs are securely stored at the study site in encrypted electronic form and are password protected to prevent access by unauthorized third parties.

QTLs are predefined parameters that are monitored during the study. Important deviations from the QTLs and any remedial actions taken will be summarized in the clinical study report.

The investigator must permit study-related monitoring, audits, IRB/EC review, and regulatory agency inspections and provide direct access to source data documents. This verification may also occur after study completion. It is important that the investigator(s) and their relevant personnel are available during the monitoring visits and possible audits or inspections and that sufficient time is devoted to the process.

Monitoring details describing strategy, including definition of study critical data items and processes (eg, risk-based initiatives in operations and quality such as risk management and mitigation strategies and analytical risk-based monitoring), methods, responsibilities, and requirements, including handling of noncompliance issues and monitoring techniques (central, virtual, or onsite monitoring), are provided in the data management plan and monitoring plan maintained and utilized by the sponsor or designee.

The sponsor or designee is responsible for the data management of this study, including quality checking of the data.

Records and documents, including signed ICDs, pertaining to the conduct of this study must be retained by the investigator for 15 years after study completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the sponsor. No records may be transferred to another location or party without written notification to the sponsor. The investigator must ensure that the records continue to be stored securely for as long as they are maintained.

When participant data are to be deleted, the investigator will ensure that all copies of such data are promptly and irrevocably deleted from all systems.

The investigator(s) will notify the sponsor or its agents immediately of any regulatory retain notification in relation to the study. Furthermore, the investigator will cooperate with the sponsor or its agents to prepare the investigator site for the inspection and will allow the sponsor or its agent, whenever feasible, to be present during the inspection. The investigator site and investigator will promptly resolve any discrepancies that are identified between the study data and the participant's medical records. The investigator will promptly provide copies of the inspection findings to the sponsor or its agent. Before response submission to the regulatory authorities, the investigator will provide the sponsor or its agents with an opportunity to review and comment on responses to any such findings.

10.1.8. Source Documents

Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. Source documents are filed at the investigator site.

Data reported on the CRF or entered in the eCRF that are from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

Definition of what constitutes source data and its origin can be found in the monitoring plan, which is maintained by the sponsor.

Description of the use of the computerized system is documented in the Data Management Plan, which is maintained by the sponsor.

The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.

Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP guidelines, and all applicable regulatory requirements.

10.1.9. Study and Site Start and Closure

The study start date is the date on which the clinical study will be open for recruitment of participants.

The first act of recruitment is the date of the first participant's first visit and will be the study start date.

The sponsor designee reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.

The investigator may initiate study-site closure at any time upon notification to the sponsor or designee/CRO if requested to do so by the responsible IRB/EC or if such termination is required to protect the health of study participants.

Reasons for the early closure of a study site by the sponsor may include but are not limited to:

- Failure of the investigator to comply with the protocol, the requirements of the IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP guidelines;

- Inadequate recruitment of participants by the investigator;
- Discontinuation of further study intervention development.

If the study is prematurely terminated or suspended, the sponsor shall promptly inform the investigators, the ECs/IRBs, the regulatory authorities, and any CRO(s) used in the study of the reason for termination or suspension, as specified by the applicable regulatory requirements. The investigator shall promptly inform the participant and should assure appropriate participant therapy and/or follow-up.

Study termination is also provided for in the clinical study agreement. If there is any conflict between the contract and this protocol, the contract will control as to termination rights.

10.1.10. Publication Policy

The results of this study may be published or presented at scientific meetings by the investigator after publication of the overall study results or 1 year after the end of the study (or study termination), whichever comes first.

The investigator agrees to refer to the primary publication in any subsequent publications, such as secondary manuscripts, and submits all manuscripts or abstracts to the sponsor 30 days before submission. This allows the sponsor to protect proprietary information and to provide comments, and the investigator will, on request, remove any previously undisclosed confidential information before disclosure, except for any study- or Pfizer intervention-related information necessary for the appropriate scientific presentation or understanding of the study results.

For all publications relating to the study, the investigator will comply with recognized ethical standards concerning publications and authorship, including those established by the International Committee of Medical Journal Editors.

The sponsor will comply with the requirements for publication of the overall study results covering all investigator sites. In accordance with standard editorial and ethical practice, the sponsor will support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement.

Authorship of publications for the overall study results will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.

If publication is addressed in the clinical study agreement, the publication policy set out in this section will not apply.

10.1.11. Sponsor's Qualified Medical Personnel

The contact information for the sponsor's appropriately qualified medical personnel for the study is documented in the study contact list located in the supporting study documentation/study portal or other electronic system.

To facilitate access to appropriately qualified medical personnel for study-related medical questions or problems, participants are provided with an Emergency Contact Card (ECC) at the time of informed consent. The ECC contains, at a minimum, (a) protocol and study intervention identifiers, (b) participant's study identification number, (c) site emergency phone number active 24 hours/day, 7 days per week, and (d) Pfizer Call Center number.

The ECC is intended to augment, not replace, the established communication pathways between the investigator, site staff, and study team. The ECC is to be used by healthcare professionals not involved in the research study only, as a means of reaching the investigator or site staff related to the care of a participant. The Pfizer Call Center number should only be used when the investigator and site staff cannot be reached. The Pfizer Call Center number is not intended for use by the participant directly; if a participant calls that number directly, he or she will be directed back to the investigator site.

10.2. Appendix 2: Clinical Laboratory Tests

The following safety laboratory tests will be performed at times defined in the [SoA](#) section of this protocol. Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by the clinical laboratory, or as derived from calculated values. These additional tests would not require additional collection of blood. Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.

Table 1 Protocol-Required Safety Laboratory Assessments

Hematology	Chemistry	Other	Additional Tests (Needed for Hy's Law)
Hemoglobin	BUN or urea	Ferritin	AST, ALT (repeat)
Hematocrit	Creatinine ^a	hsCRP	Total bilirubin (repeat)
RBC count	Glucose	Procalcitonin	Albumin
Platelet count	Calcium	LDH	Alkaline phosphatase
WBC count	Sodium	CK	(repeat)
Total neutrophils	Potassium	Haptoglobin	Direct bilirubin
(Abs)	Chloride		Indirect bilirubin
Eosinophils (Abs)	Total CO ₂ (bicarbonate)	<u>Thyroid function</u>	Creatine kinase
Monocytes (Abs)	AST, ALT	TSH	GGT
Basophils (Abs)	Total bilirubin	T4 (free)	PT/INR
Lymphocytes (Abs)	Alkaline phosphatase		Total bile acids
	Albumin	<u>Coagulation</u>	Acetaminophen drug
	Total protein	PT/aPTT	and/or protein adduct
		Fibrinogen	levels
		D-dimer	
		SARS-CoV-2 serology (IgM, IgG)	
		FSH ^b	
		Pregnancy test (β-hCG) ^c	

- a. eGFR will be calculated using the method developed by the CKD-EPI using serum creatinine. ²⁸
- b. FSH testing is performed locally for confirmation of postmenopausal status only.
- c. Local urine testing will be standard for the protocol unless serum testing is required by local regulation or IRB/EC. Serum or urine β-hCG for female participants of childbearing potential.

The investigator must review the laboratory report, document this review, and record any clinically relevant changes occurring during the study in the AE section of the CRF.

10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-Up, and Reporting

10.3.1. Definition of AE

AE Definition
<ul style="list-style-type: none">• An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.• Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.

Events <u>Meeting</u> the AE Definition
<ul style="list-style-type: none">• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (eg, ECG, radiological scans, vital sign measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator. Any abnormal laboratory test results that meet any of the conditions below must be recorded as an AE:<ul style="list-style-type: none">• Is associated with accompanying symptoms.• Requires additional diagnostic testing or medical/surgical intervention.• Leads to a change in study dosing (outside of any protocol-specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy.• Exacerbation of a chronic or intermittent preexisting condition, including either an increase in frequency and/or intensity of the condition.• New condition detected or diagnosed after study intervention administration, even though it may have been present before the start of the study.• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication. Overdose per se will not be reported as an AE or SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.

Events **NOT** Meeting the AE Definition

- Any clinically significant abnormal laboratory findings or other abnormal safety assessments that are associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
- The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant's condition.
- Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the procedure is the AE.
- Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).
- Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present or detected at the start of the study that do not worsen.

10.3.2. Definition of an SAE

An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed below:

a. Results in death

b. Is life-threatening

The term "life-threatening" in the definition of "serious" refers to an event in which the participant was at risk of death at the time of the event. It does not refer to an event that hypothetically might have caused death if it were more severe.

c. Requires inpatient hospitalization or prolongation of existing hospitalization

In general, hospitalization signifies that the participant has been admitted (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or outpatient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether "hospitalization" occurred or was necessary, the AE should be considered serious.

Hospitalization for elective treatment of a preexisting condition that did not worsen from baseline is not considered an AE.

<p>d. Results in persistent or significant disability/incapacity</p> <ul style="list-style-type: none">• The term disability means a substantial disruption of a person’s ability to conduct normal life functions.• This definition is not intended to include experiences of relatively minor medical significance, such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle), that may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
<p>e. Is a congenital anomaly/birth defect</p>
<p>f. Is a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, is considered serious.</p> <p>The event may be suspected from clinical symptoms or laboratory findings indicating an infection in a participant exposed to a Pfizer product. The terms “suspected transmission” and “transmission” are considered synonymous. These cases are considered unexpected and handled as serious expedited cases by pharmacovigilance personnel. Such cases are also considered for reporting as product defects, if appropriate.</p>
<p>g. Other situations:</p> <ul style="list-style-type: none">• Medical or scientific judgment should be exercised by the investigator in deciding whether SAE reporting is appropriate in other situations, such as significant medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious.• Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

10.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During the Active Collection Period

AE and SAE Recording/Reporting
<p>The table below summarizes the requirements for recording AEs on the CRF and for reporting SAEs on the CT SAE Report Form to Pfizer Safety throughout the active collection period. These requirements are delineated for 3 types of events: (1) SAEs; (2)</p>

nonserious AEs; and (3) exposure to the study intervention under study during pregnancy or breastfeeding, and occupational exposure.

It should be noted that the CT SAE Report Form for reporting of SAE information is not the same as the AE page of the CRF. When the same data are collected, the forms must be completed in a consistent manner. AEs should be recorded using concise medical terminology and the same AE term should be used on both the CRF and the CT SAE Report Form for reporting of SAE information.

Safety Event	Recorded on the CRF	Reported on the CT SAE Report Form to Pfizer Safety Within 24 Hours of Awareness
SAE	All	All
Nonserious AE	All	None
Exposure to the study intervention under study during pregnancy or breastfeeding,	All AEs or SAEs associated with exposure during pregnancy or breastfeeding Note: Instances of EDP or EDB not associated with an AE or SAE are not captured in the CRF.	All instances of EDP are reported (whether or not there is an associated SAE)* All instances of EDB are reported (whether or not there is an associated SAE). **
Environmental or occupational exposure to the product under study to a non-participant (not involving EDP or EDB).	None. Exposure to a study non-participant is not collected on the CRF.	The exposure (whether or not there is an associated AE or SAE) must be reported.***

* **EDP** (with or without an associated AE or SAE): any pregnancy information is reported to Pfizer Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is associated with an SAE, then the SAE is reported to Pfizer Safety using the CT SAE Report Form.

** **EDB** is reported to Pfizer Safety using the CT SAE Report Form which would also include details of any SAE that might be associated with the EDB.

*** **Environmental or Occupational exposure:** AEs or SAEs associated with occupational exposure are reported to Pfizer Safety using the CT SAE Report Form.

- When an AE or SAE occurs, it is the responsibility of the investigator to review all documentation (eg, hospital progress notes, laboratory reports, and diagnostic reports) related to the event.
- The investigator will then record all relevant AE or SAE information in the CRF.

- It is **not** acceptable for the investigator to send photocopies of the participant’s medical records to Pfizer Safety in lieu of completion of the CT SAE Report Form/AE or SAE CRF page.
- There may be instances when copies of medical records for certain cases are requested by Pfizer Safety. In this case, all participant identifiers, with the exception of the participant number, will be redacted on the copies of the medical records before submission to Pfizer Safety.
- The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE or SAE.

Assessment of Intensity

The investigator will make an assessment of intensity for each AE and SAE reported during the study and assign it to 1 of the following categories, which are based on the Division of AIDS (DAIDS)⁴⁰ Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1 (July 2017):

GRADE	Clinical Description of Severity
1	MILD adverse event
2	MODERATE adverse event
3	SEVERE adverse event
4	POTENTIALLY LIFE-THREATENING event
5	DEATH RELATED TO adverse event

An event is defined as “serious” when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, NOT when it is rated as severe.

Assessment of Causality

- The investigator is obligated to assess the relationship between study intervention and each occurrence of each AE or SAE. The investigator will use clinical judgment to determine the relationship.
- A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.
- Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention administration, will be considered and investigated.

- The investigator will also consult the IB and/or product information, for marketed products, in his/her assessment.
- For each AE or SAE, the investigator **must** document in the medical notes that he/she has reviewed the AE or SAE and has provided an assessment of causality.
- There may be situations in which an SAE has occurred and the investigator has minimal information to include in the initial report to the sponsor. However, **it is very important that the investigator always make an assessment of causality for every event before the initial transmission of the SAE data to the sponsor.**
- The investigator may change his/her opinion of causality in light of follow-up information and send an SAE follow-up report with the updated causality assessment.
- The causality assessment is one of the criteria used when determining regulatory reporting requirements.
- If the investigator does not know whether or not the study intervention caused the event, then the event will be handled as “related to study intervention” for reporting purposes, as defined by the sponsor. In addition, if the investigator determines that an SAE is associated with study procedures, the investigator must record this causal relationship in the source documents and CRF, and report such an assessment in the dedicated section of the CT SAE Report Form and in accordance with the SAE reporting requirements.

Follow-Up of AEs and SAEs

- The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations, as medically indicated or as requested by the sponsor, to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other healthcare providers.
- If a participant dies during participation in the study or during a recognized follow-up period, the investigator will provide Pfizer Safety with a copy of any postmortem findings, including histopathology.
- New or updated information will be recorded in the originally submitted documents.
- The investigator will submit any updated SAE data to the sponsor within 24 hours of receipt of the information.

10.3.4. Reporting of SAEs

SAE Reporting to Pfizer Safety via an Electronic Data Collection Tool

- The primary mechanism for reporting an SAE to Pfizer Safety will be the electronic data collection tool.
- If the electronic system is unavailable, then the site will use the paper SAE data collection tool (see next section) to report the event within 24 hours.
- The site will enter the SAE data into the electronic system as soon as the data become available.
- After the study is completed at a given site, the electronic data collection tool will be taken off-line to prevent the entry of new data or changes to existing data.
- If a site receives a report of a new SAE from a study participant or receives updated data on a previously reported SAE after the electronic data collection tool has been taken off-line, then the site can report this information on a paper SAE form (see next section) or to Pfizer Safety by telephone.

SAE Reporting to Pfizer Safety via CT SAE Report Form

- Facsimile transmission of the CT SAE Report Form is the preferred method to transmit this information to Pfizer Safety.
- In circumstances when the facsimile is not working, notification by telephone is acceptable with a copy of the CT SAE Report Form sent by overnight mail or courier service.
- Initial notification via telephone does not replace the need for the investigator to complete and sign the CT SAE Report Form pages within the designated reporting time frames.

10.4. Appendix 4: Contraceptive and Barrier Guidance

10.4.1. Male Participant Reproductive Inclusion Criteria

Male participants are eligible to participate if they agree to the following requirements during the intervention period and for at least 28 days after the last dose of study intervention, which corresponds to the time needed to eliminate reproductive safety risk of the study intervention(s):

- Refrain from donating sperm

PLUS either:

- Be abstinent from heterosexual intercourse with a female of childbearing potential as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.

OR

- Must agree to use contraception/barrier as detailed below:
 - Agree to use a male condom when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.
 - In addition to male condom use, a highly effective method of contraception may be considered in WOCBP partners of male participants (refer to the list of highly effective methods below in Section 10.4.4).

10.4.2. Female Participant Reproductive Inclusion Criteria

A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:

- Is not a WOCBP (see definitions below in Section 10.4.3).

OR

- Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), as described below, during the intervention period and for at least 28 days after the last dose of study intervention, which corresponds to the time needed to eliminate any reproductive safety risk of the study intervention(s). If a highly effective method that is user dependent is chosen, a second effective method of contraception, as described below, must also be used. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.

Because ritonavir may reduce the effect of estradiol-containing contraceptives when agents are coadministered, a barrier method or other nonhormonal method of contraception must also be used if the participant is using estradiol-containing contraceptives.

The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.

10.4.3. Woman of Childbearing Potential

A woman is considered fertile following menarche and until becoming postmenopausal unless permanently sterile (see below).

If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before the first dose of study intervention, additional evaluation should be considered.

Women in the following categories are not considered WOCBP:

1. Premenopausal female with 1 of the following:

- Documented hysterectomy;
- Documented bilateral salpingectomy;
- Documented bilateral oophorectomy.

For individuals with permanent infertility due to an alternate medical cause other than the above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.

Note: Documentation for any of the above categories can come from the site personnel's review of the participant's medical records, medical examination, or medical history interview. The method of documentation should be recorded in the participant's medical record for the study.

2. Postmenopausal female:

- A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. In addition:
 - A high FSH level in the postmenopausal range must be used to confirm a postmenopausal state in women under 50 years of age and not using hormonal contraception or HRT.
 - A female on HRT and whose menopausal status is in doubt will be required to use one of the non-estrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must

discontinue HRT to allow confirmation of postmenopausal status before study enrollment.

10.4.4. Contraception Methods

Contraceptive use by men or women should be consistent with local availability/regulations regarding the use of contraceptive methods for those participating in clinical trials.

1. Implantable progestogen-only hormone contraception associated with inhibition of ovulation.
2. Intrauterine device.
3. Intrauterine hormone releasing system.
4. Bilateral tubal occlusion (eg, bilateral tubal ligation).
5. Vasectomized partner:
 - A vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis cycle is approximately 90 days.
6. Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation:
 - Oral;
 - Intravaginal;
 - Transdermal.
7. Progestogen only hormone contraception associated with inhibition of ovulation:
 - Oral;
 - Injectable.
8. Sexual abstinence:
 - Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.

In addition, one of the following effective barrier methods must also be used when option 6 or 7 are chosen above:

- Male or female condom with or without spermicide;
- Cervical cap, diaphragm, or sponge with spermicide;
- A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double-barrier methods).

Because ritonavir may reduce the effect of estradiol-containing contraceptives when agents are co-administered, a barrier method or other nonhormonal method of contraception must also be used if the participant is using estradiol-containing contraceptives.

CCI [REDACTED]
[REDACTED]

| [REDACTED]

| [REDACTED]

| [REDACTED]

| [REDACTED]

| [REDACTED]

| [REDACTED]

| [REDACTED]

| [REDACTED]

[REDACTED]

10.6. Appendix 6: Liver Safety: Suggested Actions and Follow Up Assessments and Study Intervention Rechallenge Guidelines

Potential Cases of Drug Induced Liver Injury

Humans exposed to a drug who show no sign of liver injury (as determined by elevations in transaminases) are termed “tolerators,” while those who show transient liver injury but adapt are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a more serious potential outcome. These participants fail to adapt and therefore are “susceptible” to progressive and serious liver injury, commonly referred to as DILI. Participants who experience a transaminase elevation above $3 \times \text{ULN}$ should be monitored more frequently to determine if they are “adaptors” or are “susceptible.”

In the majority of DILI cases, elevations in AST and/or ALT precede TBili elevations ($>2 \times \text{ULN}$) by several days or weeks. The increase in TBili typically occurs while AST/ALT is/are still elevated above $3 \times \text{ULN}$ (ie, AST/ALT and TBili values will be elevated within the same laboratory sample). In rare instances, by the time TBili elevations are detected, AST/ALT values might have decreased. This occurrence is still regarded as a potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to TBili that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law criteria) cases and should always be considered important medical events, even before all other possible causes of liver injury have been excluded.

The threshold of laboratory abnormalities for a potential DILI case depends on the participant’s individual baseline values and underlying conditions. Participants who present with the following laboratory abnormalities should be evaluated further as potential DILI (Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:

- Participants with AST/ALT and TBili baseline values within the normal range who subsequently present with AST OR ALT values $>3 \times \text{ULN}$ AND a TBili value $>2 \times \text{ULN}$ with no evidence of hemolysis and an alkaline phosphatase value $<2 \times \text{ULN}$ or not available.
- For participants with baseline AST **OR** ALT **OR** TBili values above the ULN, the following threshold values are used in the definition mentioned above, as needed, depending on which values are above the ULN at baseline:
 - Preexisting AST or ALT baseline values above the normal range: AST or ALT values >2 times the baseline values AND $>3 \times \text{ULN}$; or $>8 \times \text{ULN}$ (whichever is smaller).
 - Preexisting values of TBili above the normal range: TBili level increased from baseline value by an amount of at least $1 \times \text{ULN}$ **or** if the value reaches $>3 \times \text{ULN}$ (whichever is smaller).

Rises in AST/ALT and TBili separated by more than a few weeks should be assessed individually based on clinical judgment; any case where uncertainty remains as to whether it represents a potential Hy's law case should be reviewed with the sponsor.

The participant should return to the investigator site and be evaluated as soon as possible, preferably within 48 hours from awareness of the abnormal results. This evaluation should include laboratory tests, detailed history, and physical assessment.

In addition to repeating measurements of AST and ALT and TBili for suspected Hy's law cases, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further testing, as needed, for further contemporaneous analyses at the time of the recognized initial abnormalities to determine etiology. A detailed history, including relevant information, such as review of ethanol, acetaminophen/paracetamol (either by itself or as a coformulated product in prescription or over-the-counter medications), recreational drug, or supplement (herbal) use and consumption, family history, sexual history, travel history, history of contact with a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and potential occupational exposure to chemicals, should be collected. Further testing for acute hepatitis A, B, C, D, and E infection, liver imaging (eg, biliary tract), and collection of serum samples for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted.

All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and TBili elevation defined above should be considered potential DILI (Hy's law) cases if no other reason for the LFT abnormalities has yet been found. **Such potential DILI (Hy's law) cases are to be reported as SAEs, irrespective of availability of all the results of the investigations performed to determine etiology of the LFT abnormalities.**

A potential DILI (Hy's law) case becomes a confirmed case only after all results of reasonable investigations have been received and have excluded an alternative etiology.

10.7. Appendix 7: ECG Findings of Potential Clinical Concern (No Longer Applicable)

10.8. Appendix 8: Prohibited Concomitant Medications That May Result in DDI

PF-07321332 and ritonavir are both primarily metabolized by CYP3A4. Therefore, concomitant use of any medications or substances that are strong inducers of CYP3A4, are prohibited within 28 days prior to dosing of study intervention and during study treatment.

Additionally, ritonavir and PF-07321332 are inhibitors of CYP3A4. Therefore, medications highly dependent on CYP3A4 for clearance and for which elevated plasma concentrations may be associated with serious and/or life-threatening events are not permitted during dosing of PF-07321332/ritonavir (at least 24 hours prior to the first dose of study intervention or as late as Day 1, prior to the first dose of study intervention – see below) and for 4 days after the last dose of PF-07321332/ritonavir. Ritonavir also appears to induce CYP3A, CYP1A2, CYP2C9, CYP2C19, and CYP2B6 as well as other enzymes, including glucuronosyl transferase. Since ritonavir 100 mg q12h is being used to boost the exposure of PF-07321332, no additional DDI is expected other than those associated with ritonavir 100 mg q12h based on in vitro assessments. Thus, the prohibited concomitant medications and those to be used with caution are primarily based on the ritonavir label.

A nonexhaustive list of prohibited and precautionary medications is provided below. If a medication is not listed, it should not automatically be assumed it is safe to co-administer. Appropriately qualified site staff will review all concomitant medications to determine if they are prohibited.

The Pfizer study team is to be notified of any prohibited medications taken during the study. After consulting with the sponsor, the investigator will make a judgement on the ongoing participation of any participant with prohibited medication use during the study.

This list of drugs prohibited for potential DDI concerns with the IMP may be revised during the course of the study with written notification from sponsor, to include or exclude specific drugs or drug categories for various reasons (eg, emerging DDI results for the IMP, availability of new information in literature on the DDI potential of other drugs).

This is not an all-inclusive list. Site staff should consult with the sponsor or designee with any questions regarding potential DDI.

Prohibited Medications that are Strong Inducers of CYP450 3A4^a		
Due to prolonged induction of CYP450 3A4 participants must not use these medications within 28 days prior to randomization and during dosing of PF-07321332/placebo and ritonavir/placebo.		
Drug Class	Specific Medication	Clinical Comments
Anti-cancer drugs	Apalutamide	Reduced concentrations of PF-07321332/ritonavir; may result in suboptimal concentrations.
Anticonvulsants	Phenytoin, Carbamazepine, Phenobarbital	
Antimycobacterials	Rifampin	
Herbal Products	St. John's Wort	
Prohibited Medications Dependent on CYP450 3A4 for Clearance or with other Notable Interactions^a		
These medications are prohibited for <i>at least 24 hours prior to the first dose</i> of PF-07321332/placebo and ritonavir/placebo, through 4 days after the last dose of PF-07321332/placebo and ritonavir/placebo. If a participant cannot temporarily interrupt the prohibited medication during this period, they should be considered ineligible.		
Drug Class	Specific Medication	Clinical Comments
Alpha 1-Adrenoreceptor Antagonist	Alfuzosin	Risk of hypotension, syncope
Analgesics	Piroxicam, Propoxyphene, Pethidine	Analgesic concentrations may increase.
Antianginal	Ranolazine	Risk of cardiac arrhythmias
Antiarrhythmics	Dronedarone, Amiodarone, Flecainide, Propafenone, Quinidine	Risk of cardiac arrhythmias
Anti-gout	Colchicine	Ritonavir 100 mg twice daily increased colchicine AUC 296% and C _{max} 184%. Potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment.
Antipsychotics	Clozapine, Lurasidone, Pimozide	Potential for increased levels of antipsychotics
Ergot Derivatives	Dihydroergotamine, Ergotamine, Methylergonovine	Risk of acute ergot toxicity (peripheral vasospasm and ischemia of the extremities)
Lipid lowering drugs (HMG CoA Reductase Inhibitors)	Lovastatin, Simvastatin	Risk of rhabdomyolysis
PDE-5 Inhibitors for pulmonary arterial hypertension treatment	Sildenafil (Revatio) when used for pulmonary arterial hypertension	Risk of visual disturbances, Co-administration may result in visual abnormalities, hypotension, prolonged erection, and syncope
Sedatives/Hypnotics	oral Midazolam, Triazolam	Risk of prolonged sedation, respiratory depression, or hypnotic concentrations

a. Note: If a drug is not listed, it should not automatically be assumed it is safe to co-administer

Prohibited Medications Dependent on CYP450 3A4 for Clearance or with other Notable Interactions^a		
These medications are prohibited <i>from the first dose</i> of PF-0321332/placebo and ritonavir/placebo, through 4 days after the last dose of PF-07321332/placebo and ritonavir/placebo. If a participant cannot temporarily interrupt the prohibited medication during this period, they should be considered ineligible.		
Drug Class	Specific Medication	Clinical Comments
Alpha 1-Adrenoreceptor Antagonist	Tamsulosin, Silodosin, Doxazosin (>2 mg daily), Terazosin (>5 mg daily)	Risk of hypotension, syncope
Analgesics	Methadone	Moderate to weak decreases in methadone concentrations have been observed.
Opioid Dependence Treatment	Fentanyl, Oxycodone	Analgesic concentrations may increase.
	Buprenorphine Lofexidine	Co-administration may increase concentrations of Buprenorphine and Lofexidine.
Anticancer drugs	Abemaciclib, Ceritinib, Dasatinib, Encorafenib, Ibrutinib, Ivosidenib, Neratinib, Nilotinib, Venetoclax, Vinblastine, Vincristine	Co-administration contraindicated due to potential loss of virologic response and possible resistance. Avoid co-administration of Encorafenib or Ivosidenib due to potential risk of serious adverse events such as QT interval prolongation. Avoid use of Neratinib, Venetoclax or Ibrutinib. Co-administration of Vincristine and Vinblastine may lead to significant hematologic or gastrointestinal side effects. For further information, refer to individual product label for anticancer drug.
Anticoagulants/ antiplatelet	Rivaroxaban, Warfarin	Possible increased risk of bleeding Possible decreased warfarin effects. Closely monitor INR if co-administration with Warfarin is necessary.

Prohibited Medications Dependent on CYP450 3A4 for Clearance or with other Notable Interactions^a		
These medications are prohibited <i>from the first dose</i> of PF-0321332/placebo and ritonavir/placebo, through 4 days after the last dose of PF-07321332/placebo and ritonavir/placebo. If a participant cannot temporarily interrupt the prohibited medication during this period, they should be considered ineligible.		
Drug Class	Specific Medication	Clinical Comments
Antidepressant	Bupropion	Monitor for an adequate clinical response to Bupropion.
	Trazodone	Adverse reactions of nausea, dizziness, hypotension, and syncope have been observed following co-administration of Trazodone and Ritonavir. A lower dose of Trazodone should be considered. Refer to Trazadone product label for further information.
Anti-infective (antibacterials)	Erythromycin	Co-administration may increase erythromycin concentrations.
	Clarithromycin	Co-administration may increase clarithromycin concentrations.
Antimycobacterials	Bedaquiline	Co-administration contraindicated due to potential loss of virologic response and possible resistance. Alternate antimycobacterial drugs such as rifabutin should be considered.
Antifungals	Isavuconazole Itraconazole Posaconazole Ketoconazole	Refer to Ketoconazole, Isavuconazonium Sulfate, and Itraconazole product labels for further information.
	Voriconazole	Co-administration of Ritonavir with Voriconazole may result in reduction in Voriconazole levels.
Antihistamines	Astemizole, Terfenadine	Risk of cardiac arrhythmias
Antipsychotics	Quetiapine	Co-administration may increase Quetiapine and increase risk of Quetiapine-related toxicity
	Risperidone, Perphenazine, Aripiprazole, Brexpiprazole, Cariprazine, Iloperidone, Thioridazine, Ziprasidone	Potential for increased levels of antipsychotics
Cardiac Medications (beta blockers)	Carvedilol, Metoprolol, Timolol	Co-administration may increase concentration of Carvedilol, Metoprolol, Timolol.

Prohibited Medications Dependent on CYP450 3A4 for Clearance or with other Notable Interactions^a		
<p>These medications are prohibited <i>from the first dose</i> of PF-0321332/placebo and ritonavir/placebo, through 4 days after the last dose of PF-07321332/placebo and ritonavir/placebo. If a participant cannot temporarily interrupt the prohibited medication during this period, they should be considered ineligible.</p>		
Drug Class	Specific Medication	Clinical Comments
Calcium channel blockers	Diltiazem, Verapamil, Nifedipine, Amlodipine (>5 mg daily), Felodipine, Nicardipine	Co-administration may increase concentrations of calcium channel blockers. The impact on the PR interval of co-administration of ritonavir with other drugs that prolong the PR interval (including calcium channel blockers) has not been evaluated. A dose decrease may be needed for these drugs when co-administered with PAXLOVID.
Cardiac glycosides	Digoxin	Caution should be exercised when co-administering PAXLOVID with digoxin, with appropriate monitoring of serum digoxin levels. Refer to the Digoxin product label for further information.
	Eplerenone	Co-administration increases eplerenone concentrations.
	Ivabradine	Co-administration increases ivabradine concentrations.
Corticosteroids (inhaled or intranasal) (systemic) (Local injections, including intra-articular, epidural, or intra-orbital)	Budesonide, Ciclesonide, Mometasone	Co-administration can increase concentration of Budesonide, Ciclesonide, and Mometasone and can result in adrenal insufficiency and Cushing's syndrome.
	Betamethasone Budesonide	Co-administration can increase concentration of Betamethasone, and Budesonide and can result in adrenal insufficiency and Cushing's syndrome.
	Betamethasone, Methylprednisolone, Prednisone, Triamcinolone	Co-administration can increase Betamethasone, Methylprednisolone, and Triamcinolone concentrations and can result in adrenal insufficiency and Cushing's syndrome.
Endothelin receptor antagonists	Bosentan	Bosentan should be discontinued at least 36 hours prior to the initiation of ritonavir.

Prohibited Medications Dependent on CYP450 3A4 for Clearance or with other Notable Interactions^a		
<p>These medications are prohibited <i>from the first dose</i> of PF-0321332/placebo and ritonavir/placebo, through 4 days after the last dose of PF-07321332/placebo and ritonavir/placebo. If a participant cannot temporarily interrupt the prohibited medication during this period, they should be considered ineligible.</p>		
Drug Class	Specific Medication	Clinical Comments
Hepatitis C direct acting antivirals (DAAs)	Elbasvir/Grazoprevir, Glecaprevir/Pibrentasvir	<p>Increased Grazoprevir concentrations can result in ALT elevations.</p> <p>It is not recommended to co-administer Ritonavir with Glecaprevir/Pibrentasvir.</p>
	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir	Refer to the Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir label for further information.
	Sofosbuvir/Velpatasvir/Voxilaprevir	<p>Refer to the Sofosbuvir/Velpatasvir/Voxilaprevir product label for further information.</p> <p>Patients on ritonavir-containing HCV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or HCV drug adverse events with concomitant use.</p>
HIV Antiretrovirals Protease Inhibitors	Lopinavir, Amprenavir, Indinavir, Nelfinavir, Atazanavir, Darunavir, Fosamprenavir, Saquinavir, Tipranavir.	Co-administration may increase HIV protease inhibitor concentrations.
	Ritonavir or cobicistat containing combination products	<p>Risk of increased rate of adverse reactions. Appropriate doses of additional Ritonavir in combination with ritonavir-containing combination products with respect to safety and efficacy have not been established.</p> <p>Co-administration will increase Elvitegravir concentrations.</p>
Integrase Inhibitors	Elvitegravir	
Hormonal contraceptive	Ethinyl Estradiol	An additional, non-hormonal method of contraception should be considered.

Prohibited Medications Dependent on CYP450 3A4 for Clearance or with other Notable Interactions^a		
These medications are prohibited <i>from the first dose</i> of PF-0321332/placebo and ritonavir/placebo, through 4 days after the last dose of PF-07321332/placebo and ritonavir/placebo. If a participant cannot temporarily interrupt the prohibited medication during this period, they should be considered ineligible.		
Drug Class	Specific Medication	Clinical Comments
Lipid lowering drugs (HMG-CoA Reductase Inhibitors)	Atorvastatin (>20 mg daily), Rosuvastatin (>10 mg daily) Lomitapide	Risk of rhabdomyolysis Co-administration may increase concentration of lomitapide
Hypoglycemics	Glipizide, Tolbutamide Repaglinide Saxagliptin (>2.5 mg daily)	Potentially decrease Glipizide and Tolbutamide concentrations. Potentially increase Repaglinide concentrations. Co-administration may increase Saxagliptin concentration.
Immunosuppressants	Cyclosporine, Tacrolimus, Sirolimus, Everolimus	Co-administration may increase immunosuppressant concentrations. Therapeutic concentration monitoring is recommended for immunosuppressants.
Long-Acting Beta-Adrenoceptor Agonist	Salmeterol	The combination may result in increased concentrations of Salmeterol and increased risk of cardiovascular adverse events, including QT prolongation, palpitations and sinus tachycardia.
Neuroleptics	Pimozide	Risk of cardiac arrhythmias
Sedatives/ Hypnotics	Midazolam (parenteral), Alprazolam, Bromazepam, Brotizolam, Clonazepam, Cloniprazepam, Delorazepam, Diazepam, Etizolam, Eszopiclone, Halazepam, Lormetazepam, Nitrazepam, Nordiazepam, Quazepam, Suvorexant, Temazepam, Zaleplon, Zolpidem Clorazepate, Estazolam, Flurazepam Zolpidem (>5 mg daily)	Risk of prolonged sedation, respiratory depression, or hypnotic concentrations Co-administration with Ritonavir may increase dose of Clorazepate, Estazolam, and Flurazepam. Co-administration may increase Zolpidem concentration.

a. Note: If a drug is not listed, it should not automatically be assumed it is safe to co-administer.

Precautionary Medications

Medications may be used with caution and require oversight by the investigator when co-administered with PF-07321332/ritonavir^a		
Drug Class	Specific Medication	Clinical Comments
Antidepressant	Citalopram, Escitalopram, Sertraline	No data available Co-administration may decrease Sertraline and Bupropion concentrations.
Antihypertensive Angiotensin receptor blockers:	Losartan, Valsartan	Co-administration with Ritonavir increases the level/effect of Losartan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Ritonavir increases the level/effect of Valsartan by decreasing hepatic clearance. To be used with caution.
Antiparasitic:	Atovaquone Quinine	Co-administration with Ritonavir may decrease the concentration of Atovaquone. Co-administration with Ritonavir may decrease concentration of Quinine.
Antipsychotic:	Haloperidol	Co-administration with Ritonavir increases the level/effect of Haloperidol by affecting hepatic/intestinal CYP3A4 metabolism. Haloperidol and Ritonavir both increase QTc interval. To be used with caution.
Bronchodilator:	Theophylline	Co-administration with ritonavir may decrease Theophylline concentration.
Corticosteroids	Fluticasone	Ritonavir twice daily increases Fluticasone AUC 350-fold.
HIV Antivirals Non-nucleoside reverse transcriptase inhibitors CCR5-antagonist Integrase inhibitors	Delavirdine Maraviroc Raltegravir	Co-administration may increase Ritonavir concentration. Co-administration may increase Maraviroc concentration. Raltegravir concentrations may be decreased.
Hypoglycemics	Canagliflozin	Co-administration may decrease Canagliflozin concentration.
Narcotic and Treatment for Opioid Dependence	Tramadol	Co-administration may increase concentration of Tramadol.

Medications may be used with caution and require oversight by the investigator when co-administered with PF-07321332/ritonavir^a		
Drug Class	Specific Medication	Clinical Comments
PDE-5 Inhibitors for treatment of erectile dysfunction	Sildenafil– ED (max dose 25 mg every 48 hours) Avanafil Tadalafil (max dose 10 mg every 72 hours) Vardenafil (max dose 2.5 mg every 72 hours)	Risk of visual disturbances, hypotension, prolonged erection, and syncope
Steroids (systemic)	Dexamethasone	Co-administration with Ritonavir may increase dose of Dexamethasone and Prednisone and may increase the risk for development of systemic corticosteroid effects including Cushing’s syndrome and adrenal suppression.
Stimulant	Methamphetamine	Co-administration with Ritonavir may increase concentration of Methamphetamine.

a. Note: If a drug is not listed, it should not automatically be assumed it is safe to co-administer

10.9. Appendix 9: Signs and Symptoms Attributable to COVID-19

Table 2. Signs and Symptoms Attributable to COVID-19

Daily Sign and Symptom Collection ²⁹	Entry Criterion#3 Targeted (used for study entry)	Daily Signs and Symptom Collection	Targeted Symptoms For Analysis
Cough	X	X	X
Shortness of breath or difficulty breathing	X	X	X
Fever (documented temperature >38°C [100.4°F]) or subjective fever (eg, feeling feverish)	X		
Feeling feverish		X	X
Chills or shivering	X	X	X
Fatigue (low energy or tiredness)	X	X	
Muscle or body aches	X	X	X
Diarrhea (loose or watery stools)	X	X	X
Nausea (feeling like you wanted to throw up)	X	X	X
Vomiting (throw up)	X	X	X
Headache	X	X	X
Sore throat	X	X	X
Stuffy or runny nose	X	X	X
Loss of smell		X	
Loss of taste		X	

10.10. Appendix 10: Country-Specific Requirements

10.10.1. France

Contrat Unique

1. GCP Training

Before enrolling any participants, the investigator and any subinvestigators will complete the Pfizer-provided Good Clinical Practice training course (“Pfizer GCP Training”) or training deemed equivalent by Pfizer. Any investigators who later join the study will do the same before performing study-related duties. For studies of applicable duration, the investigator and subinvestigators will complete Pfizer GCP Training or equivalent every 3 years during the term of the study, or more often if there are significant changes to the ICH GCP guidelines or course materials.

2. Study Intervention

No participants or third-party payers will be charged for study intervention.

3. Urgent Safety Measures

In addition, the investigator will inform Pfizer immediately of any urgent safety measures taken by the investigator to protect the study participants against any immediate hazard, and of any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.

4. Termination Rights

Pfizer retains the right to discontinue development of PF-07321332 at any time.

10.10.2. Japan

A Protocol Administrative Change Letter was issued on 22 July 2021 to provide Japan country specific guidance regarding Exclusion Criterion #8.

Exclusion Criterion #8: Known HIV infection with viral load >400 copies/ml or taking prohibited medications for HIV treatment (from known medical history within past 6 months of the screening visit).

If HIV infection is known by medical interview or examination results (if any), the investigators must consult with the patient’s HIV treatment specialist to confirm that the HIV RNA level has been monitored at an appropriate frequency and the HIV RNA level has been ≤400 copies/mL during the past 6 months before the screening visit in order to assess the study eligibility of that patient.

Rationale: There is a risk for patients with uncontrolled HIV to develop resistance to ritonavir which is being administered with PF-07321332. According to the HIV treatment guideline in Japan, even if there is an occasional increase in the amount of HIV RNA in the blood to about 20-500 copies/mL, the same treatment may be continued. The guideline recommends a resistance test when HIV RNA levels exceed 500 copies/mL.

10.11. Appendix 11: Protocol Amendment History

The Protocol Amendment Summary of Changes Table for the current amendment is located directly before the TOC. The protocol amendment summary of changes tables for past amendment(s) can be found below:

Amendment 1 (02-July-2021)

Overall Rationale for the Amendment: The protocol was amended to incorporate feedback from the FDA.

Section # and Name	Description of Change	Brief Rationale
1.1. Synopsis 1.3. Schedule of Activities 4.1. Overall Design 10.1.5.1. Data Monitoring Committee	Changed sentinel cohort safety review to allow for either the sentinel cohort from the C4671005 study or the data from the ACTIV-2b study to allow for continued enrollment into C4671002.	FDA allowed for continued enrollment (no pause) after completion of either the sentinel cohort from C4671005 or ACTIV-2b.
1.1. Synopsis 3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS 9.3.3. Secondary Endpoint(s)/Estimand(s) Analysis	Removed the following secondary endpoint: COVID-19 severity ranking based on symptom severity scores through Day 28.	FDA requested removal of this endpoint due to Agency guidance on Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment
1.1. Synopsis 3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS 9.3.3. Secondary Endpoint(s)/Estimand(s) Analysis	Changed endpoint to include, instead of exclude hospitalization: Number of COVID-19 related medical visits including hospitalization through Day 28.	FDA requested updating of this endpoint due to Agency guidance on Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment
1.1. Synopsis 4.1. Overall Design 4.2. Scientific Rationale for Study Design	Added that randomization will be stratified by geographic region, by vaccination status and by COVID-19 symptom onset (< 3 days vs. 3 to 5 days).	FDA recommendations on stratification were implemented.
1.2 Schema	Schema footnote was updated.	For clarification.

Section # and Name	Description of Change	Brief Rationale
1.3. Schedule of Activities	Flexible language added to PROs rollout.	Availability of some translations may be forthcoming, so allowances were made.
1.3 Schedule of Activities 5.1. Inclusion Criteria 5.2. Exclusion Criteria	Confirmed SARS-CoV-2 infection requirement updated from 72 hours to 5 days.	Timing window was updated in response to questions on feasibility.
1.3. Schedule of Activities 8.1.5.3. Global Impression Questions 9.3.6. Other Analyse(s)	Added in the Global impression questions from Days 1-28 after the sentinel cohort.	FDA recommendation on the inclusion of patient-reported global impression items were implemented.
5.2. Exclusion Criteria	Changed exclusion criteria to allow both partially and fully vaccinated participants with or without COVID-19 risk factors, with the exception of those with immunosuppressive disease.	FDA request to include fully vaccinated immunocompetent subjects, regardless of risk factors.
9.3.2. Primary Endpoint(s)/Estimand(s) Analysis	Updated definition of sustained alleviation by changing “any” to “all”.	FDA recommendations on update to the definition of sustained alleviation were implemented.
Throughout	Other typographical or administrative edits.	Updated to improve readability and consistency.

Amendment 2 (19-July-2021)

Overall Rationale for the Amendment: The protocol was amended to incorporate additional feedback from the FDA.

Section # and Name	Description of Change	Brief Rationale
1.1. Synopsis 1.3. Schedule of Activities 4.1. Overall Design 10.1.5.1. Data Monitoring Committee	Changed C4671002 sentinel cohort safety review to reference the sentinel cohort review from the C4671005 study to allow for continued enrollment into C4671002.	No longer participating in the ACTIV-2b study.
1.1. Synopsis	Statistical clarifications made to time to event analyses and sample size section and corrections were	The rationale for changing the statistical sections are as follows:

Section # and Name	Description of Change	Brief Rationale
<p>3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS</p> <p>9.1. Statistical Hypotheses</p> <p>9.1.1.1. Primary Estimand/Co-Primary Estimands</p> <p>9.1.1.2. Secondary Estimands</p> <p>9.3.1. General Considerations</p> <p>9.3.2. Primary Endpoint(s)/Estimand(s) Analysis</p> <p>9.3.2.1. Sensitivity Analyses</p> <p>9.4. Interim Analyses</p> <p>9.5. Sample Size Determination</p>	<p>made in the interim analysis and final analysis stopping rules.</p>	<p>a) To provide clarification in the primary endpoint analysis and to clarify how the sample size is estimated based on the primary analysis.</p> <p>b) To correct the interim analysis and final analysis stopping rules.</p>
<p>1.3. Schedule of Activities</p> <p>8.1.6 Exit Interview</p> <p>9.3.6 Other Analyse(s)</p>	<p>Exit interviews have been added to the protocol.</p>	<p>Added to confirm content validity of COVID-19 signs and symptoms daily diary, to describe participant's treatment experience and the importance and meaningfulness of any improvements reported.</p>
<p>5.1. Inclusion Criteria</p>	<p>Upper age limit of 59 years was removed from Inclusion criteria.</p>	<p>Participants aged greater than or equal to 60 years of age are at increased risk for COVID-19, but will be allowed if they are fully vaccinated, and fulfill other entry criteria.</p>
<p>5.2. Exclusion Criteria</p>	<p>Vaccination criteria was updated from partially to fully vaccinated and the risk factor of ≥ 60 years of age was added.</p>	<p>FDA request to include fully vaccinated immunocompetent participants, regardless of risk factors, and to exclude partial vaccination as it does not have the same protective effect as full vaccination.</p>
<p>6.3.2. Blinding of the Sponsor</p>	<p>Added Section to reference the Unblinding Plan.</p>	<p>To provide additional information and clarification in the process of unblinding.</p>

Section # and Name	Description of Change	Brief Rationale
8. STUDY ASSESSMENTS AND PROCEDURES	Updated total blood volume projection.	Final blood volumes from the central lab became available and were different than original estimates.
Throughout	Other typographical or administrative edits.	Updated to improve readability and consistency.

Amendment 3 (03-August-2021)

Overall Rationale for the Amendment:

The primary analysis set (mITT) has been refined to include just those participants who were randomized within 3 days of COVID-19 symptom onset. There is precedent for early treatment of acute respiratory illnesses being critical for successful antiviral intervention. This change allows for optimization of the primary analysis set by further reducing the symptom onset window from <5 days to ≤ 3 days.

Section # and Name	Description of Change	Brief Rationale
1.1. Synopsis 4.1. Overall Design 9.4. Interim Analyses 10.1.5.1. Data Monitoring Committee	Added the mITT analysis set detail to the interim analysis.	Added clarification to the analysis set for the interim analysis.
1.1. Synopsis 3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS 4.1. Overall Design 4.2. Scientific Rationale for Study Design 9.1. Statistical Hypotheses 9.1.1.1. Primary Estimand/Co-Primary Estimands 9.1.1.2. Secondary Estimands 9.2. Analysis Sets 9.3.2. Primary Endpoint(s)/Estimand(s) Analysis	Primary estimand changed to specify inclusion of participants who were randomized ≤ 3 days after symptom onset. Stratification was updated accordingly and so was sample size. Sample size increased from 800 to 1140. Added in a new mITT analysis set restricted to participants with COVID-19 symptom onset ≤ 3 days.	Due to uncertainty on the effect of time from symptom onset relative to initiation of treatment on the effectiveness of an antiviral, a change has been made to the primary analysis set. Primary analysis is now based upon the mITT, which includes those participants randomized within 3 days of symptom onset. Other changes are a consequence of the change in primary efficacy analysis. Sample size has been adjusted, and the key secondary endpoint analyses will include participants regardless of their symptom onset.

Section # and Name	Description of Change	Brief Rationale
9.3.2.1. Supplemental Analyses 9.3.3 Secondary Endpoint(s)/Estimand(s) Analysis 9.5. Sample Size Determination		
1.3. Schedule of Activities	Minor edits to footnotes.	To clarify use of brackets and procedure requirements associated with the location for expected visits.
5.2. Exclusion Criteria #16	Vaccination criteria was updated to clarify that participants without underlying medical conditions associated with an increased risk of developing severe illness from COVID-19 are not eligible if they have been vaccinated. It is only fully vaccinated participants with underlying medical conditions that are eligible.	Provide clarification around vaccination status in participants without underlying medical conditions associated with an increased risk of developing severe illness from COVID-19.
6.2. Preparation, Handling, Storage, and Accountability	Guidance added regarding shipping study intervention by courier and temperature monitoring for ground transportation.	Stability data demonstrate that if the total duration of transit is less than 24 hours, temperature monitoring is not required.
6.3.2. Blinding of the Sponsor	Modified language to specify that the study will be completely unblinded after the last data has been collected for the PCD.	At Day 34, all of the study endpoints (except mortality through Week 24) will be assessed, including the primary endpoint. There is limited data collected at the Week 12 and Week 24 visits and thus having an unblinded team completing the study poses little risk.
9.3.6. Other Analyse(s)	Updated Exit Interview analysis language.	Updated per the Exit Interview final proposal from vendor.
10.10.2. Japan	Added Japan country-specific guidance regarding Exclusion Criterion #8.	To incorporate country-specific changes into the global protocol.
10.11 Appendix 11	Modified with Amendment 2 changes.	Per Pfizer protocol template.
Throughout	Other administrative edits.	Updated to provide clarity.

Amendment 4 (23 November 2021)

Overall Rationale for the Amendment:

Approximately 60% of enrolled participants in C4671002 have risk factors for severe COVID-19 but have been vaccinated against COVID-19. The secondary endpoint of COVID-19 related hospitalization or death from any cause through Day 28 is therefore of

greater relevance, and the hierarchal order of the secondary endpoints has been revised accordingly.

Section # and Name	Description of Change	Brief Rationale
Section 1.1. Synopsis Section 3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS Section 9.1. Statistical Hypotheses Section 9.1.1.2. Secondary Estimands Section 9.3.3. Secondary Endpoint(s)/Estimand(s) Analysis	Secondary endpoints and estimands updated to reflect new hypothesis testing hierarchy	Secondary endpoint of COVID-19 related hospitalization or death from any cause through Day 28 is of greater relevance in the population enrolled and has been revised accordingly.
Section 1.2. Schema	Schema updated to remove the need for Day 3 in-person visits for ECG monitoring per PACL dated 31Aug21.	Updated to reflect changes from PACL.
Section 1.3. Schedule of Activities	Schedule of Activities updated to reflect updates PACL dated 13Aug21.	Updated to reflect changes from PACL.
Section 2.3.3. Overall Benefit/Risk Conclusion	Corrected to be consistent with Section 9.4.	Correct inconsistency.
Section 6.1.1. Administration	Co-administration of PF-07321332 and ritonavir should be at the same time, but no more than 10 minutes apart is acceptable.	Added language to specify what is considered to be an acceptable time for co-administration of PF-07321332 and ritonavir.
Section 6.3.2. Blinding of the Sponsor	Language was added to provide additional information about the study unblinding plan.	To provide additional information so that an unblinded submission team could be formed at the time of an interim analysis for preparing unblinded analyses and documents to support regulatory activities.
Section 8.2.5. Electrocardiograms Section 10.7. Appendix 7: ECG Findings of Potential Clinical Concern	Section removed, as ECGs are no longer required, per PACL dated 31Aug21.	Updated to reflect changes from PACL.
Section 9.2. Analysis Sets	Analysis set wording aligned with C4671005.	To promote consistency in wording of analysis sets across the C4671002 and C4671005 protocols.
Section 9.3.2.1. Supplemental Analyses	Added a supplemental analysis for censoring of the primary endpoint for discontinued participants.	Section updated per regulatory request to include an additional sensitivity analysis that considers all participants in the MITT

Section # and Name	Description of Change	Brief Rationale
		population with missing data for the primary endpoint by Day 28 as censored.
Section 9.3.6. Other Analyse(s)	Added wording for how the long-term COVID-19 symptoms will be analyzed.	Section updated, as there was no mention of the analysis of this data in prior protocol versions.
Section 10.8. Appendix 8: Prohibited Concomitant Medications That May Result in DDI	Corrections and updates to the list of precautionary and prohibited medications as in PACL dated 27Sep21.	Updated to reflect changes from PACL.
Throughout	Other administrative edits.	Updated to provide clarity.

Amendment 5 (21 January 2022)

Overall Rationale for the Amendment:

Results from a protocol-specified interim analysis of this study, which included 45% of the study's planned enrollment, showed that the novel primary endpoint of self-reported, sustained alleviation of all symptoms for 4 consecutive days, as compared with placebo, was not met. However, the key secondary endpoint of COVID-19-related hospitalization or death from any cause through Day 28 was also examined at the interim analysis, showing 0.6% of those who received PF-07321332/ritonavir were hospitalized following randomization (2 of 333 hospitalized with no deaths), compared to 2.4% of participants who received placebo and were hospitalized (8 of 329 hospitalized with no deaths).

Furthermore, results from Study C4671005 showed PF-07321332/ritonavir treatment significantly reduced the risk of hospitalization or death from any cause by 89% compared with placebo in nonhospitalized symptomatic adult participants with COVID-19 who were at increased risk of progression to severe disease when they were treated within 3 days of symptom onset. In a secondary endpoint, PF-07321332/ritonavir treatment also reduced the risk of hospitalization or death from any cause by 88% compared with placebo in participants treated within 5 days of symptom onset.

This protocol amendment, while acknowledging the lack of stringency of statistical type I error control, is primarily intended to extend study enrollment to assess potential benefit to participants at low risk of progression to severe COVID-19 in the clinically relevant endpoint of hospitalization or death. The rationale is based on the outcome from the interim analysis from this study and the final results of Study C4671005.

Section # and Name	Description of Change	Brief Rationale
Section 1.1. Synopsis	The secondary endpoint of incidence of COVID-19-associated hospitalizations or death from any cause will be analyzed to provide a point estimate and 95% CI to measure	Despite no demonstration of treatment benefit in the primary endpoint of alleviation of symptoms at the 45% IA, the potential benefit in the clinically relevant secondary endpoint of hospitalization or

Section # and Name	Description of Change	Brief Rationale
<p>Section 3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS</p> <p>Section 9.1. Statistical Hypotheses</p> <p>Section 9.1.1.2. Secondary Estimands</p> <p>Section 9.3.3. Secondary Endpoint(s)/Estimand(s) Analysis</p>	<p>associated variability. Other clinically relevant secondary endpoints (COVID-19 related medical visits) will also be analyzed.</p>	<p>death will be explored with this amendment. Other clinically relevant secondary endpoints (COVID-19 related medical visits) will also be analyzed.</p> <p>Based on outcomes in Study C4671005, in which PF-07321332/ritonavir treatment reduced the risk of hospitalization or death from any cause in participants treated within 3 or 5 days of symptom onset, results will be analyzed regardless of whether participants begin study treatment within 3 or 5 days of symptom onset, and estimands have been updated accordingly.</p>
Section 2.2.2. Clinical Overview	Results from Study C4671005 and interim analysis of C4671002 are presented.	Provide support for further evaluation of COVID-19-related hospitalizations and all cause death in the study population at low risk for progression to severe disease.
Section 2.3.2. Benefit Assessment	Results from Study C4671005 and the 45% interim analysis for Study C4671002 added.	To support the potential benefit of reductions in COVID-19 hospitalizations and all cause deaths for participants at standard risk of progression to severe disease.
Section 4.1. Overall Design	Updated sample size.	Per sample size re-estimation in Section 9.5.
Section 4.2. Scientific Rationale for Study Design	Added rationale for extending study enrollment based on Study C4671005 results and the interim analysis results for Study C4671002.	To allow a more complete assessment of the efficacy of PF-07321332/ritonavir in reducing the incidence of COVID-19-associated hospitalization or death from any cause in standard risk participants.
Section 4.3. Justification for Dose	Brief statement of C4671005 results added	To further support dose and length of treatment in this study.
Section 5.2. Exclusion Criteria	Exclusion Criteria #1 and #16 updated.	<p>#1: All participants with positive results of direct SARS-CoV-2 testing and who are at high risk for progression to severe COVID-19, including hospitalization or death are eligible to receive Paxlovid™ regardless of vaccination status, and so are excluded from this placebo-controlled study; age and BMI risk factors have been updated based on the Paxlovid Fact Sheet for Healthcare Providers.</p> <p>#16: Participants at low risk for serious complications who have received a SARS-CoV-2 vaccination ≥12 months prior to screening will be eligible, based on emerging data for the omicron variant showing substantially reduced vaccine efficacy against symptomatic SARS-CoV-2 infection and waning efficacy over time</p>

Section # and Name	Description of Change	Brief Rationale
		against severe disease requiring hospitalization.
Section 6.8. Concomitant Therapy	Added antiviral treatment for COVID-19 to prohibited medications during the study.	Based on the availability of authorized antiviral treatment for COVID-19.
Section 9.2. Analysis Sets	Analysis set wording aligned with C4671005.	To promote consistency in wording of analysis sets across the C4671002 and C4671005 protocols.
Section 9.4 Interim Analyses	Indicated no further interim analyses are planned.	No further interim analysis is needed given information provided from the previous 45% interim analysis and other data that have informed the new sample size estimate.
Section 9.5. Sample Size Determination	Increase in sample size	To power the study for an assessment of the efficacy of PF-07321332/ritonavir in reducing the incidence of COVID-19-associated hospitalization or death from any cause in standard risk participants.
Section 10.8: Appendix 8: Prohibited Concomitant Medications That May Result in DDI	Updated table.	To align with the Emergency Use Authorization Fact Sheet for Paxlovid™.
Throughout	Other administrative edits.	Updated to provide clarity.

10.12. Appendix 12: Abbreviations

The following is a list of abbreviations that may be used in the protocol.

Abbreviation	Term
3CL	3C-like protein
6MP	mercaptopurine
Abs	absolute
AE	adverse event
AESI	adverse events of special interest
ALT	alanine aminotransferase
aPTT	activated partial thromboplastin time
ARDS	acute respiratory distress syndrome
AST	aspartate aminotransferase
AUC	area under the concentration-time curve
AV	atrioventricular
β-hCG	beta-human chorionic gonadotropin
BID	twice a day
bpm	beats per minute
BMI	body mass index
BUN	blood urea nitrogen
CABG	coronary artery bypass graft
CCR5	chemokine receptor type 5
CD4	cluster of differentiation 4
CDC	United States Centers for Disease Control and Prevention
CFR	Code of Federal Regulations
CI	confidence interval
CIOMS	Council for International Organizations of Medical Sciences
CK	creatinine kinase
CKD	chronic kidney disease
CKD-EPI	chronic kidney disease epidemiology
C _{max}	the maximum concentration recorded
CO ₂	carbon dioxide (bicarbonate)
CONSORT	Consolidated Standards of Reporting Trials
COVID-19	coronavirus disease 2019
CPAP	Continuous positive airway pressure
CRF	case report form
CRO	contract research organization
CSR	clinical study report
CT	clinical trial
C _{trough}	predose concentration
CVD	cardiovascular disease
CYP	cytochrome P450
CYP3A4	cytochrome P450 3A4
DAA	direct acting antivirals

Abbreviation	Term
DAIDS	Division of AIDS
DDI	drug-drug interaction
DILI	drug-induced liver injury
DNA	deoxyribonucleic acid
dNHBE	differentiated normal human bronchial epithelial cells
DU	dispensable unit
EC	ethics committee
EC ₉₀	concentration required for 50% effect
ECC	emergency contact card
ECDC	European Centre for Disease Prevention and Control
ECG	electrocardiogram
eCRF	electronic case report form
ED	erectile dysfunction
EDB	exposure during breastfeeding
E-DMC	external data monitoring committee
EDP	exposure during pregnancy
eGFR	estimated glomerular filtration rate
EMA	European Medicines Agency
ePRO	electronic patient reported outcome
EQ-5D	EuroQol-5 Dimensions
EQ-5D-3L	EuroQol-5 Dimensions 3-Levels
EQ-5D-5L	EuroQol-5 Dimensions 5-Levels
ET	early termination
EU	European Union
EUA	Emergency Use Authorization
EudraCT	European Clinical Trials Database
FAS	full analysis set
FDA	Food and Drug Administration
FIH	first-in-human
FSH	follicle-stimulating hormone
FU	follow up
f _u	fraction of unbound drug in serum or plasma
GCP	Good Clinical Practice
GFR	glomerular filtration rate
GGT	gamma-glutamyl transferase
GH	good health
GLP	Good Laboratory Practice
HCP	health care professional; health care provider
HCV	hepatitis C virus
HCoV	human coronavirus
HDPE	high-density polyethylene
HF	heart failure
HIV	human immunodeficiency virus

Abbreviation	Term
HMG-CoA	3-hydroxy-3-methylglutaryl co-enzyme
HR	heart rate
HRT	hormone replacement therapy
hsCRP	high-sensitivity C-reactive protein
HTA	health technologies assessment
IA	interim analysis
IB	investigator's brochure
ICD	informed consent document
ICH	International Council for Harmonisation
ICU	intensive care unit
ID	identification
Ig	immunoglobulin
IMP	investigational medicinal product
IND	investigational new drug
INR	international normalized ratio
IP	investigational product
IP manual	investigational product manual
IPAL	Investigational Product Accountability Log
IRB	institutional review board
IRT	interactive response technology
ITT	intent-to-treat
IV	intravenous(ly)
IWR	interactive Web-based response
LDH	lactate dehydrogenase
LFT	liver function test
LT	long-term
mAb	monoclonal antibody
MAD	multiple ascending dose
mITT	modified intent-to-treat
MMRM	mixed-effect model repeated measure
MRC-5	human lung epithelial cells-5
mRNA	messenger ribonucleic acid
msec	millisecond
N/A	not applicable
NHP	non-human primate
NIAID	National Institute of Allergy and Infectious Diseases
NIH	National Institutes of Health
NIMP	noninvestigational medicinal product
NP	nasopharyngeal
PCD	primary completion date
PCI	percutaneous coronary intervention
PDE-5	Phosphodiesterase 5
PK	pharmacokinetic(s)

Abbreviation	Term
PP	per-protocol
PRO	patient reported outcomes
PT	prothrombin time
PTT	partial thromboplastin time
PVC	premature ventricular contraction/complex
q12h	every 12 hours
QTc	corrected QT
QTcF	corrected QT (Fridericia method)
QTL	quality tolerance limit
RBC	red blood cell
RNA	ribonucleic acid
RRP	Recommendation Review Panel
RT-PCR	reverse transcription polymerase chain reaction
SAD	single ascending dose
SAE	serious adverse event
SAP	statistical analysis plan
SARS-CoV2	severe acute respiratory syndrome coronavirus 2
SAS	safety analysis set
SCr	serum creatinine
SoA	schedule of activities
SoC	standard of care
SOC	System Organ Class
SOP	standard operating procedure
SRSD	single reference safety document
SUSAR	suspected unexpected serious adverse reaction
T4	thyroxine
TBili	total bilirubin
TEAE	treatment-emergent adverse event
TIA	transient ischemic attack
TOC	table of contents
TSH	thyroid-stimulating hormone
ULN	upper limit of normal
US	United States of America
USPI	United States Prescribing Information; United States Package Insert
VAS	visual analogue scale
WBC	white blood cell
WHO	World Health Organization
WOCBP	women of child bearing potential
WPAI	Work Productivity and Impairment

11. REFERENCES

1. Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial. *JAMA*. 2021;325(7):632-44.
2. World Health Organization. 2019-nCoV outbreak is an emergency of international concern. 31 Jan 2020. Available from: <https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/01/2019-ncov-outbreak-is-an-emergency-of-international-concern>. Accessed on: 22 March 2020.
3. World Health Organization. WHO Situation Report 51 Coronavirus disease 2019 (COVID-19). 11 March 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10. Accessed on: 22 March 2021.
4. . Johns Hopkins University, COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available from: <https://coronavirus.jhu.edu/map.html>. Accessed on: 07 March 2022.
5. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239-42.
6. Docherty AB, Harrison EM, Green CA, et al. Features of 20,133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ*. 2020;369:m1985.
7. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020;323(20):2052-59.
8. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 2020;368:m1091.
9. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet*. 2020;395(10239):1763-70.
10. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033-34.
11. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061-69.
12. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med*. 2020;382(19):1787-99.
13. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *N Engl J Med*. 2020;383(21):2041-52.
14. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. *Med (N Y)*. 2020;1(1):114-27 e3.
15. US Food and Drug Administration. FDA approves first treatment for COVID-19. May 2020. Available from: <https://www.fda.gov/news-events/press->

- announcements/fda-approves-first-treatment-covid-19?utm_medium=email&utm_source=govdelivery. Accessed on: 29 Jun 2021.
16. Veklury (remdesivir). US Prescribing Information (USPI); October 2020 2020, Foster City, CA, USA: Gilead Sciences, Inc. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf. Accessed on: 11 May 2022.
 17. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med*. 2020;383(19):1813-26.
 18. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. *JAMA*. 2020;324(11):1048-57.
 19. Consortium WHOST, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2021;384(6):497-511.
 20. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. *Antiviral Res*. 2018;153:85-94.
 21. Santos J, Brierley S, Gandhi MJ, et al. Repurposing therapeutics for potential treatment of SARS-CoV-2: A review. *Viruses*. 2020;12((7)(06)):705.
 22. Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. *Int J Infect Dis*. 2021;102:501-08.
 23. US Food and Drug Administration. (2021). Fact sheet for health care providers. Emergency use authorization (EUA) of bamlanivimab and etesevimab. Available from: <https://www.fda.gov/media/145802/download>. Accessed on: 04 June 2021.
 24. Chang, Mo G, Yuan X, et al. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection. *Am J Respir Crit Care Med*. 2020;201(9):1150-52.
 25. Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. *Science*. 2003;300(5626):1763-7.
 26. Pfizer. Investigator's Brochure PF-07321332. Data on file.
 27. NORVIR (ritonavir). US Prescription Information (USPI); Oct 2020, North Chicago, IL, USA: AbbVie Inc. Available from: <https://www.accessdata.fda.gov/spl/data/551acd76-c57f-3546-038d-c36559b90735/551acd76-c57f-3546-038d-c36559b90735.xml>. Accessed on: 29 Jun 2021.
 28. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604-12.
 29. US Food and Drug Administration. Guidance for Industry: Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment. May 2020. Available from: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs>. Accessed on: 30 Jun 2021.
 30. US Bureau of Labor Statistics. Effects of COVID-19 Pandemic on Productivity and Costs Statistics. Available from: <https://www.bls.gov/covid19/effects-of-covid-19-pandemic-on-productivity-and-costs-statistics.htm>. Accessed on: 08 Jun 2021.

31. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. *Pharmacoeconomics*. 1993;4(5):353-65.
32. Rabin R, Gudex C, Selai C, et al. From translation to version management: a history and review of methods for the cultural adaptation of the EuroQol five-dimensional questionnaire. *Value Health*. 2014;17(1):70-6.
33. van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. *Value Health*. 2012;15(5):708-15.
34. Ramos-Goni JM, Pinto-Prades JL, Oppe M, et al. Valuation and modeling of EQ-5D-5L health states using a hybrid approach. *Med Care*. 2017;55(7):e51-8.
35. Yang Y, Brazier J, Longworth L. EQ-5D in skin conditions: an assessment of validity and responsiveness. *Eur J Health Econ*. 2015;16(9):927-39.
36. Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life Res*. 2013;22(7):1717-27.
37. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*. 2011;20(10):1727-36.
38. Agborsangaya CB, Lahtinen M, Cooke T, et al. Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. *Health Qual Life Outcomes*. 2014;12:74.
39. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. *Health Policy*. 1990;16(3):199-208.
40. U.S. Department of Health and Human Services NIOH, National Institute of Allergy and Infectious Diseases, Division of AIDS, Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. July 2017. Available from: <https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf>. Accessed on: 10 Jun 2021.
41. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal statistical society: series B*. 1995;57(1):289-300.
42. Kalbfleisch JD, Prentice RL. In *The statistical analysis of failure time data*. Edited by.: John Wiley & Sons, Inc; 1980.
43. Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials. *Biometrics*. 1999;55(3):853-7.
44. US Food and Drug Administration. Guidance for Industry: adaptive design clinical trials for drugs and biologics. November 2019. Available from: <https://www.fda.gov/media/78495/download>. Accessed on: 16 Jun 2021.

Document Approval Record

Document Name: C4671002 Protocol Amendment 6

Document Title: C4671002 Protocol Amendment 6

Signed By:	Date(GMT)	Signing Capacity
PPD	09-Jun-2022 12:56:53	Final Approval
PPD	09-Jun-2022 13:12:47	Final Approval